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Glycans decorating cell surface and secreted proteins and lipids occupy the junction 
where critical host–host and host-pathogen interactions occur. In spite of the wide 
acceptance that glycans are centrally implicated in immunity, exactly how glycans and 
their variety and variability contribute to the overall immune response remains poorly 
defined.  
Glycans, frequently terminated by sialic acid residues, may be modified by external 
factors such as pathogens or upon specific physiological cellular events. The terminal, 
privileged positions of sialic acid-modified structures makes them key, fundamental 
determinants for a number of immune receptors with known involvement in cellular 
adhesiveness and cell trafficking, such as Selectins and Siglecs, with known relevant 
immune functions. At the time this thesis was initiated, it was established that sialic acids 
expressed at cell surface could modulate important mechanisms of the adaptive immune 
responses. Given the key role of dendritic cells (DCs) in the transition from innate to the 
adaptive immune responses, we anticipated that sialic acids could also modulate 
important mechanisms of human DCs.  DCs have a relevant role in antigen screening 
and uptake, migration to lymph nodes and antigen presentation to lymphocytes, 
ultimately triggering the adaptive immune response. Therefore, our primary hypothesis 
was that sialic acids may modulate DC functions, such as antigen uptake, maturation, 
homing to lymph nodes and antigen presentation to T cells. 
To test this hypothesis, we divided our work in four parts.  
1) Surface sialylated glycans expressed during differentiation from human monocytes to
DCs (moDCs) were analyzed. Our data showed that α2,3-sialylated O-glycans and α2,6- 
and α2,3-sialylated N-glycans expression increased during moDC differentiation. Three 
main sialyltransferases (STs) are committed with this new glycan configuration: ST6Gal-
1 correlates with the increased expression of α2,6-sialylated N-glycans; ST3Gal-1 
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contributes for the α2,3-sialylation of O-glycans, especially T antigens; and ST3Gal-4 
may contribute for the increased α2,3-sialylated N-glycans. Upon moDC maturation, 
ST6Gal-1 and ST3Gal-4 are downregulated and ST3Gal-1 is altered in a stimulus 
dependent manner.  
 
2) We subsequently analyzed the consequences of the modulation of cell surface sialic 
acids in DC functions. We observed that removing surface sialic acid by sialidase 
significantly decreased the capacity of moDCs to micropinocytose and receptor-
mediated endocytose. In contrast, treatment with a sialidase significantly improved the 
capacity of moDCs to phagocytose Escherichia coli. The improved phagocytosis 
mechanism required E. coli sialic acids, indicating a mechanism of host–pathogen 
interaction dependent on sialic acid moieties.  
Sialidase-treated moDCs have increased expression of MHC and co-stimulatory 
molecules, suggesting a more mature phenotype. Experiments using mouse bone 
marrow-derived DCs (BMDCs) from ST3Gal-1-/- and ST6Gal-1-/- strains indicated that 
endocytosis and maturation are influenced by changes in either α2,3 or α2,6-sialylated 
glycans. The analysis of α2,6-sialylated, N-glycosylated proteins, strongly suggested the 
potential involvement of β2 integrins, underlying these mechanisms. 
 
3) The effect of α2,6-sialylation in DC homing to lymph nodes was also analyzed. We 
observed that BMDCs deficient for ST6Gal-1 have an almost 50% reduction in DC 
homing, as assayed by in situ inflammation and adoptive transfer studies. A reduction in 
DC homing was also observed when wild type BMDCs were transferred into ST6Gal-1-/- 
recipient mice. Further investigations are necessary to identify the molecules involved in 
this process. 
4) Finally, we also analyzed the impact of sialylation on DCs ability to prime T cells. 
Sialidase-treated moDCs show increased gene expression of IL-12, TNF-α, IL-6 and IL-
10 cytokines, and activation of the transcription factor nuclear factor-κB. Sialidase-
33 
treated DCs induced a higher proliferative response of T cells with concomitant higher 
expression of interferon-γ, suggesting that the clearance of cell surface sialic acids 
contributes to the development of a T helper type 1 proinflammatory response.  
Together, our data strongly support sialic acid’s relevance in DC immune functions. 
Alterations of cell surface sialic acid content can alter the endocytosis/phagocytosis, 
maturation, migration/homing and the ability for T cell priming in human DCs. Moreover, 
sialic acid linkages created by ST6Gal-1 and ST3Gal-1 are functionally relevant. The 
engineering of cell surface sialylation, mediated by individual sialidases or 
sialyltransferases is a likely possibility to fine tune DC phagocytosis and immunological 




Os glicoconjugados que decoram a superfície celular e os lípidos e proteínas secretados 
ocupam o ponto de encontro onde normalmente ocorrem interacções críticas homólogas 
(hospedeiro-hospedeiro) e heterólogas (hospedeiro-patogénio). Apesar de ser 
largamente aceite que os glicanos são parte integrante do processo de imunidade, 
continua a não ser claro qual o papel que os glicanos, em toda a sua diversidade, tomam 
no quadro geral da imunidade. 
Os glicanos, que são frequentemente terminados por resíduos de ácido siálico, podem 
ser alterados por factores externos, tais como patogénios, ou por acontecimentos 
fisiológicos celulares específicos. Normalmente em posição terminal, as glico-estruturas 
que contêm ácido siálico assumem um papel fundamental numa quantidade substancial 
de receptores imunes envolvidos na adesividade e tráfico celular, tal como as Selectinas 
e as Siglecs, das quais se sabe apresentarem uma relevante função imune. 
À altura do início desta tese, era sabido que os ácidos siálicos expressos à superfície 
das células poderiam modular mecanismos importantes nas respostas imunes 
adaptativas. Considerando a posição de charneira que as células dendríticas (DCs) 
ocupam na transição da resposta imune inata para a adaptativa, antecipámos que os 
ácidos siálicos poderiam também modular mecanismos relevantes nas DCs humanas. 
As DCs têm uma função muito relevante na verificação e captura antigénica, migração 
para os gânglios linfáticos e apresentação antigénica aos linfócitos, uma sequência de 
funções que conduz, em ultima instância, à indução da resposta inata adaptativa. 
Considerando estas premissas, a nossa hipótese principal foi que os ácidos siálicos 
podem influenciar funções relevantes das DCs, tais como captura de antigénios, 




Para testar esta hipótese, dividimos o trabalho em quatro partes: 
1) Analisámos os glicanos sialilados de superfície, expressos durante a diferenciação 
de monócitos humanos em DCs (moDCs). Os nossos dados mostraram que a 
expressão dos glicanos com ligações em O (O-glicanos) e sialilados em α2,3, assim 
como glicanos com ligações em N (N-glicanos) sialilados em α2,6 e α2,3 aumentou 
durante o processo de diferenciação das moDCs. Contribuindo para esta nova 
configuração glicosídica, três sialiltransferases (STs) poderão estar envolvidas: a 
ST6Gal-1 correlaciona-se com a expressão aumentada de N-glicanos sialilados em 
α2,6; a ST3Gal-1 contribui para a sialilação em α2,3 de O-glicanos, em especial de 
antigénios T; e a ST3Gal-4 poderá ser responsável pelo aumento de N-glicanos 
sialilados em α2,3. Após estímulo e consequente maturação das moDCs, ambos os 
níveis de expressão génica de ST6Gal-1 e ST3Gal-4 são negativamente modificados 
sendo, também, que a expressão de ST3Gal-1 varia consoante o estímulo. 
 
2) Estudámos posteriormente as consequências da modulação dos ácidos siálicos de 
superfície nas funções das DCs. Observámos que a remoção dos ácidos siálicos de 
superfície diminui significativamente a capacidade de macropinocitose e endocitose 
mediada por receptores nas moDCs. Em contrapartida, o tratamento com sialidase 
aumentou significativamente a capacidade das moDCs para fagocitar Escherichia coli. 
Determinou-se também que este mecanismo requer a existência de ácido siálico 
presente nas E. coli indicando um mecanismo de interacção hospedeiro-patogénio 
dependente de ácido siálico em ambas as partes envolvidas. 
As moDCs tratadas com sialidase também apresentam um nível superior de expressão 
de moléculas de MHC e moléculas co-estimulatórias, sugerindo um fenótipo celular mais 
maduro. Recorrendo ao modelo de ratinho, utilizaram-se DCs derivadas de células da 
medula (BMDCs) de ratinhos deficientes em ST3Gal-1 e ST6Gal-1. Estes ensaios 
revelaram que quer a endocitose quer a maturação são influenciadas por modificações 
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nos glicanos sialilados em α2,3 ou α2,6. A detecção e quantificação de proteínas N-
glicosiladas e sialiladas em α2,6 apontou para um potencial envolvimento de integrinas 
β2 nestes mecanismos. 
3) O efeito da sialilação em α2,6 na migração das DCs para os gânglios linfáticos foi
também analisado. Observámos que BMDCs deficientes para ST6Gal-1 apresentam 
uma redução de cerca de 50% nos níveis de migração das DCs para os gânglios 
linfáticos, tal como aferido em ensaios de inflamação in situ e estudos de transferência 
adoptiva de células. Uma redução dos níveis deste tipo de migração foi também 
observada quando BMDCs nativas foram transferidas para ratinhos receptores 
deficientes em ST6Gal-1. São, contudo, necessários mais ensaios de forma a identificar 
as moléculas envolvidas neste processo. 
4) Por último, analisámos o impacto da sialilação na estimulação antigénica das DCs às
células T. Assim, concluiu-se que moDCs tratadas com sialidase apresentam um nível 
de expressão superior de IL-12, TNF-ɑ, IL-6 e IL-10, e activação do factor de transcrição 
nuclear kappa B (NF-κB). As DCs tratadas com sialidase induziram uma maior 
proliferação nas células T, com expressão correspondente de interferão-γ. Este dado 
sugere que a remoção de ácidos siálicos de superfície contribui para o desenvolvimento 
de uma resposta pro-inflamatória do tipo 1 por células T auxiliares (resposta Th1). 
Considerando estes dados no seu todo, concluímos que o ácido siálico tem um papel 
marcante nas funções imunes das DCs. Alterações à concentração de ácido siálico à 
superfície das células podem alterar a endocitose/fagocitose, maturação, migração para 
os tecidos e gânglios linfáticos e capacidade estimulatória para com as células T. 
Complementando estes dados, as ligações glicosídicas de ácidos siálicos criados por 
ST6Gal-1 e ST3Gal-1 são funcionalmente relevantes. A modulação programada da 
sialilação do glicocálice, mediada por sialidases individuais ou sialiltransferases é uma 
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possibilidade aceitável para a melhoria da fagocitose por DCs e da sua potência 
imunológica. Este facto tem um significado particular para imunoterapias baseadas em 











Dendritic cells (DCs) are key players of the immune system. As antigen-
presenting cells, they occupy the intersection between innate and adaptive immunity. By 
surveying the body microenvironment, they are strategically positioned to capture 
antigens and correctly classify collected antigen information, in a ‘self’ or ‘foreign’ 
category, and to respond accordingly. They carry antigen information from the infection 
site to the secondary lymphatic organs, presenting them to T cells, thus promoting an 
adaptive immune response against a specific antigen. The immune response against 
pathogens greatly depends on the function of DCs. Moreover, DCs also play an 
important role in anti-tumor immunity, in which specific cytotoxic T cells are primed by 
DCs to respond against tumor cells. 
In accordance with the wide variety of immune scenarios that DCs abridge, different 
DC subsets have been described. Such classification is made based in their origin, 
phenotypic profile, and physiological properties.  
Impaired DC functions may lead to several pathologies, such as increased 
susceptibility to infection and cancer or, oppositely, to a wide range of autoimmune 
diseases (Collin et al., 2011). Investigating the underlying mechanisms of DC-pathogen 
or DC-host and -tumor cell interactions may help us to better comprehend the immune 
response in physiological and pathological events and to identify new targets for 
therapeutic intervention.  
Glycosylation is the most frequent post-translational modification of all 
secreted and cell surface proteins, as well as of lipids. Specific glycan patterns, 
or signatures, are present on the surfaces of DCs.  These signatures are altered not 
only during differentiation but also in response to cytokine signals and antigen stimuli 
(Bax et al., 2007). Sialic acid is a sugar moiety that frequently terminates glycan 
structures. Due to its terminal position sialic acid is recognized or modulates ligand 
recognition by several immune receptors. Therefore sialic acid might modulate many 
immune processes such as host-pathogen recognition, cell migration, and antigen-
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presentation (Varki, 1997;2008). The addition of this sugar is mediated by the 
sialyltransferases, enzymes that are mainly located in the Golgi apparatus. 
Sialyltransferase expression is finely regulated during DC differentiation and maturation, 
concurring with the expression of specific sialylated structures. 
In diverse immune events, the sialylated glycans will be recognized by receptors, i.e. 
lectins, such as Siglecs. While promoting cell recognition by some lectins, the presence 
of specific sialic acids can also switch off recognition by other lectins specific for 
asialylated glycans, such as galectins. Thus, recognition of sialylated glycans may 
impact the DC immunobiological functions. The clarification of sialic acid’s influence in 
the DC immunobiology, thus, will potentially lead to a better understanding of the immune 
mechanisms mediated by DCs and may reveal novel therapeutic means to modulate 
immune responses. 
Therefore, the scope of this thesis is to study how glycans modulate DC-
mediated functions, with special attention to the sialic acid-mediated ones and 
how they modulate the different DC functions. This chapter includes an introduction 
of DCs’ function and glycan-recognition receptors, characterization of DCs’ sialome-
related factors, followed by a description of processes known to be modulated by sialic 
acid such as endocytosis, migration, priming of adaptive immune response and a very 
short approach on pathogen/tumoral recognition. 
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1.1  Immune system overview 
Living beings, evolutionarily, developed strategies to shield themselves against the 
negative effects of pathogens. One such strategy is the immune system, comprising 
specific sets of cells and molecules dedicated to protect our body against the harm 
caused by pathogens and toxins. Together, these specific immune components 
orchestrate a conceptual state commonly termed immunity.  
Immunity, as a concept, can be traced as far as the times of the first great Asian and 
Mediterranean empires upon the simple observation that following contraction of a 
certain diseases (such as smallpox or some variants of plague), its survivors would no 
longer be affected by that illness, even when in direct contact with other affected 
individuals. However, immunology as a science would only begin to develop from the 
industrial Revolution onwards with small but decisive steps taken by doctors and scientist 
such as Robert Koch, Louis Pasteur or Edward Jenner. Also decisive were the works of 
Elie Metchnikoff, Erin von Behring and Shibasaburo Kitasato, in the 19th century, whose 
observations led to the conclusion that the immune system comprises two different types 
of response: non pathogen-specific agents like macrophages (one of the first uncovered 
immune cells), existing prior to any infection, and specific pathogen recognizing 
molecules such as antibodies, present only after contact with a pathogen. These 
observations are at the root of the today widely accepted concept of innate and adaptive 
immune responses. Yet, one would need to wait for the 20th century to unveil the majority 
of the cellular participants of this immune play and its molecular components, and to 
establish one of main principles of the immune system: the relation between the innate 
and adaptive immune response. 
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1.1.1 The innate immune response 
 
The first line of immune system defense against biological aggression is the 
innate immune response. The main function of this phase is to provide an immediate 
response in order to contain the infection and to avoid the development of the pathology. 
During the innate immune response, antigenic information is collected and presented to 
lymphocytes, in order to stimulate a specific, enduring adaptive response (Janeway, 
1989).  
The innate phase response is characterized by a set of cellular and biochemical 
defense mechanisms, namely, 1) physical and chemical barriers, i.e. epithelial tissues 
and its secreted anti-pathogenic substances; 2) cells, i.e. phagocytes, granulocytes, and 
NK cells; 3) serum proteins, i.e. complement proteins, innate antibodies and 
inflammatory mediators; and 4) the coordinating/regulating, leukocyte-messaging 
molecules, i.e. cytokines and chemokines (Abbas et al., 2010). 
 
1.1.1.1 Bridging the adaptive immune response 
 
Another important function of the innate immune response is to elicit the longer 
duration and more effective adaptive immune response.  This function is mediated 
by phagocytic cells such as the Dendritic Cells (DCs) that capture the pathogens process 
them, and present them to T cells in secondary lymphoid organs. The co-localization of 
phagocytes and T cells in secondary lymphoid organs after antigen challenging was first 
shown by Sharp et al. (Sharp and Burwell, 1960), followed by evidence of clear 
interaction between these cell types (Schoenberg et al., 1964). Later, it became clear 
that the activation of T cells requires histocompatibility between the antigen-presenter 
and the T cell (Rosenthal and Shevach, 1973). Although the Major Histocompatibility 
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Complex (MHC) loci were uncovered in 1951 (Snell and Higgins, 1951), the premise that 
MHC-restricted antigen presentation was necessary for T cell activation was only 
confirmed in 1977 (Thomas and Shevach, 1977), thus emerging the concept of antigen 
presentation, currently accepted. Completing this concept, later observations concluded 
that different antigen presenting cells (APCs) express different levels of antigen 
presentation molecules (De Bruijn et al., 1992;Vidard et al., 1992;Robadey et al., 1996) 
and consequently, different stimulation abilities. Among APCs, it soon became clear that 
DCs are the most potent inducers of T cell activation (Steinman and Witmer, 
1978;Van Voorhis et al., 1982;Setum et al., 1993;Mellman et al., 1998). 
1.1.1.2 Dendritic cells 
DCs are part of the innate immune response and are essential to boost and/or 
regulate the adaptive immune response - therefore, DCs sit at the crossroads of both 
innate and adaptive immune responses.  
DCs capture antigens in an earlier phase, process them ‘on the go’ while 
migrating towards secondary lymphoid organs, such as lymph nodes, where they 
present the processed antigens to T cells via major histocompatibility complex 
(MHC), the processed antigens to T cells thus enacting an adaptive immune 
response (Steinman and Cohn, 1973;1974;Steinman et al., 1974;Steinman et al., 
1975;Steinman and Witmer, 1978;Steinman et al., 1979). DCs can also present antigens 
to B cells, although by non-classical (non-MHC) mechanisms (Palucka and Banchereau, 
2002;Qi et al., 2006;Harwood and Batista, 2010) (Fig. 1.1).  
Morphologically, DCs are relatively large cells with varying numbers of 
heterogeneously shaped pseudopods. Given these variety of shapes these cells were 




Fig. 1.1 – Basic hallmarks and functions of dendritic cells (DCs). In Crespo HJ et al. “Dendritic cells: a spot on sialic acid”, 
Frontiers in Immunology (4), 2013.  
 
1.1.1.2.1 DC subtypes and their hematopoietic differentiation 
Different DC subsets are widespread throughout the organism, inhabiting different 
organs and tissues such as the liver, spleen, thymus, gastrointestinal tract or skin, and 
many more, phenotypically adapted to the tissue they reside. DC cell surface present 
higher expression levels of MHC class II and co-stimulatory molecules, such as 
CD80 and CD86 (B7.1 and B7.2) and CD40, than other immune cells, such as 
49 
 
macrophages or B cells. This fact is highly relevant for their antigen-presenting function 
(van der Valk et al., 1984;Wood et al., 1985;Landry et al., 1988).  
DCs can also be phenotypically characterized by the expression of specific markers: 
B220, CD103 and CD8 in mouse, and the Dendritic Cell-Specific Intracellular adhesion 
molecule 3 (ICAM-3)-Grabbing Nonintegrin (DC-SIGN), CD123, CD1c/Blood Dendritic 
Cell Antigen-1 (BDCA-1), CD141/BDCA-2 and BDCA-3 and -4 in human (Dzionek et 
al., 2000;MacDonald et al., 2002;Wollenberg et al., 2002;Robbins et al., 2008;Haniffa et 
al., 2009;Bachem et al., 2010;Crozat et al., 2010;Jongbloed et al., 2010;Poulin et al., 
2010;Reizis et al., 2011;Haniffa et al., 2012;Langlet et al., 2012;Satpathy et al., 
2012;Lundberg et al., 2013;Plantinga et al., 2013). CD11b and CD11c are also DC 
markers widely used on mouse DC phenotyping that are also human DC markers, but 
not exclusively. 
In the absence of infection and inflammation, DCs are functionally divided in two major 
types: migratory and non-migratory, or lymphoid, tissue-resident DCs (reviewed in 
(Shortman and Naik, 2007;Collin et al., 2013)). A classic example of the former are 
dermal DCs and Langerhans cells that mainly reside in skin tissues. Upon contact with 
antigen, they mature and migrate to the draining lymph nodes (Silberberg et al., 
1974;Ross et al., 1994;Ebner et al., 1998). The non-migratory DCs (like spleen or 
thymus DCs) reside in secondary lymphoid organs, where they constantly screen 
blood or lymph for pathogens (Ardavin, 1997;Henri et al., 2001). Both the canonical 
myeloid and lymphoid hematopoietic progenitors contribute to the steady-state DC pool. 
As a common trait, the expression of the Fms-like tyrosine kinase 3 (Flt-3) molecules 
is characteristic of DC precursors, regardless of the myeloid or lymphoid lineage 
and DCs development is driven by Flt3-ligand (Flt-3L) (Manz et al., 2001;D'Amico 
and Wu, 2003;Shigematsu et al., 2004;Shortman and Naik, 2007;Watowich and Liu, 
2010;Singh et al., 2012). Much interestingly, it was recently reported that steady-state 
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conventional DCs are marked by the exclusive expression of the DNGR-1 (Schraml et 
al., 2013) which could, thus, function as a true lineage DC marker.  
Opposed to the steady-state conventional DCs, some DCs are classified as 
inflammatory or infection-derived DCs. These populations include the plasmacytoid 
DC (pDC) population, a first line of defense against microbial invasion. Functionally 
specialized in the detection of viral infections, pDCs develop a fully differentiated DC 
phenotype after infection and secrete type I interferon (Grouard et al., 1997;O'Keeffe et 
al., 2002). Other inflammatory DCs of interest are the monocyte-derived DCs (moDCs) 
(Segura and Amigorena, 2013)). MoDCs are one of the most relevant, well-established 
human DC model, especially in inflammation/pathogenic studies (Romani et al., 1996). 
This comes as the result of two factors: its relative ease to obtain from monocytes present 
in peripheral blood (Chapuis et al., 1997;Caux and Dubois, 2001) and the presence of 
all canonical DC phenotypical and functional properties (maturation markers, 
endocytosis, allogeneic and/or syngeneic T-cell stimulation) (Akagawa, 1994;Romani et 
al., 1996;Palucka et al., 1998;Santin et al., 1999).  
In mouse, the main DC model is the Bone Marrow-derived Dendritic Cells 
(BMDCs), allowing the reproduction of the differentiation of different DC subsets, by 
using different cytokine cocktails (Inaba et al., 1992;Shurin et al., 1997;Zhang et al., 
1997;Yamaguchi, 1998;Lutz et al., 1999;Zhang et al., 1999;Brasel et al., 2000). 
In the work here presented, these will also be the two DC models of choice as they 
are the best models that generally represent the DC populations and common functions 
of all DC subtypes above referred. 
 
1.1.1.2.2 Endocytosis 
A fundamental function of DCs is to capture pathogens and then trigger the adaptive 
response against them, as previously stated. Thus DCs serve a critical frontline function 
in immunity: the continuous survey of the surroundings by constitutive uptake of 
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encountered antigens (Sallusto et al., 1995). The three principal means by which DCs 
capture antigens are: 1) receptor-mediated endocytosis, in which particles are 
endocytosed after a specific cell-surface receptor recognition; 2) macropinocytosis, or 
the non-selective endocytosis of solutes, a constitutive process and the major source of 
antigens for presentation by DCs (Norbury, 2006); and 3) phagocytosis, the uptake of 
large molecules or cells, including virus, bacteria, protein clusters, apoptotic and necrotic 
cells, which also involves specific membrane receptors (Fig. 1.2).  
The uptake of foreign antigens usually triggers activation signals that will lead DCs 
into a mature phenotype that maximizes the potential for antigen presentation and 
stimulation of the adaptive response immune cells. 
 
Fig. 1.2 – Types of endocytosis. 
 
Receptor-mediated endocytosis is also fundamental in the maintenance of the self-
tolerance mechanisms.  At steady-state, self-antigens are endocytosed and posteriorly 
presented by DCs, but the endocytosis of self-antigens does not usually induce 
significant maturation changes (Wilson et al., 2003).   
Defective maturation contributes to turn DCs tolerogenic and promoting 
regulatory T cell responses. Nevertheless, very small foreign and more common 




DC maturation is the sum of all the phenotypical and functional changes 
occurring upon encounter with immune stimuli (i.e., antigens, cytokines, etc.) and it 
is crucial to enable DCs to effectively activate T cells. It is characterized by rapid 
downregulation of the antigen-uptake process, acidification of lysossomal 
compartments, higher expression of MHC II molecules and of CD80 and CD86 co-
stimulatory molecules, de novo or up-regulated synthesis of DC-specific 
inflammatory cytokines (Thomas and Lipsky, 1994). All these maturation and 
migration-changes are necessary hallmarks to enable DCs to perform antigen 
presentation and boosting T and B cell responses (Sallusto and Lanzavecchia, 1994). It 
is also known that the molecular nature of uptaken antigens, as well as the cytokines to 
which DCs are exposed during the uptake process, are responsible for the modulation 
of the maturation process. This ultimately influences the differentiation of the DC-pulsed 




DC migration comprises the whole of the trafficking of DCs: their hematopoiesis on 
bone marrow, their entry in circulation via blood towards the peripheral tissues and, from 
here or directly from blood, to the secondary lymphoid organs (Fig. 1.3). 
The homing of conventional or inflammatory DCs loaded with antigens to T cell niches 
(normally, secondary lymphatic organs) is a crucial step for the setting of effective 
immune responses. This process is characterized by chemokine-mediated cell-
recruitment to the lymphoid target site and activation of the surrounding tissues 
(von Andrian and Mempel, 2003;Bonasio and von Andrian, 2006;Forster et al., 2012). 
Tissue activation helps to increase the cell adhesion to the endothelium, by inducing the 
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expression of several adhesion molecules, of which integrins and selectins and its 
ligands are the most relevant elements.  
Fig. 1.3 - Programmatic Outline of DC and DC-Precursor Trafficking Routes. DCs develop from precursors that originate 
from primary lymphoid tissues (PLT) such as the BM and the thymus. Precursors and committed DCs enter the circulation 
and seed peripheral tissues and secondary lymphoid organs (SLOs). From peripheral tissues, they can access afferent 
lymph upon receiving a mobilization signal and travel to the draining LN. Leukocytes leave LNs via the efferent lymph and 
are collected in the thoracic duct (TD), which eventually guides DCs and their precursors back into the circulation. In 
Alvarez D. et al., Mechanisms and Consequences of Dendritic Cell Migration, Immunity, 29, 2008. 
DCs also migrate to non-lymphoid tissues, although this form of migration process 
and causes are, still, not totally clear. A steady-state setting is an unfavorable 
environment for DCs or DC precursors to migrate to non-lymphoid peripheral tissues. 
Although the rolling and tethering of DCs are observable in both steady-state and 
inflammatory contexts, migration to non-lymphoid tissues requires many of the adhesion 
molecules (intracellular adhesion and vascular adhesion molecules (ICAMs and 
VCAMs), integrins) normally involved in migration and homing phases that are ordinarily 
induced by inflammatory mediators (Robert et al., 1999b;Merad et al., 2002;Pendl et al., 
2002;Merad et al., 2004). Elucidating the underlying mechanisms of DCs and/or their 
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precursors’ migration in the steady state (or inflammation-suppressed pathologies, like 
several neoplasias) could prove to be of extreme importance in DC-based therapies, 
where this DC attribute needs further improvement. 
 
1.1.1.2.5 Cytokine production 
DCs provide the lymph node-based naive T helper (Th) cells with two pathogen-related 
signals: the information about the structure of pathogen’s antigens and its pathogenicity. 
This comes as the result of the endocytosis and subsequent antigen-processing during 
homing towards the lymph nodes. Upon arrival in the lymph nodes, mature DCs can 
then present the tissue-derived pathogen information to provide T cells via three 
signals: an Ag-specific ‘signal 1’ – MHC:T cell receptor triggering;  a ‘signal 2’, resulting 
from co-stimulatory stimulus, transmitting information regarding pathogenic potential; 
and a ‘signal 3’, comprising cytokine production (Howard et al., 2002;Corthay, 2006). 
The latter provides a first, determinant impulse towards one of the Th profiles, namely, T 
helper type 1 or 2 (Th1 or Th2) – responsible for the stimulation of a specific cellular and 
humoral response (respectively) –, T helper 17 (Th17) – stimulating anti-microbial 
mechanisms on epithelial and mucosal barrier tissues –, or regulatory (Treg) cells – 
inducing, as the name suggests, immune tolerance towards elicited antigens (Cools et 
al., 2007). 
 
In very general terms, IL-12 and IL-4 cytokines are the most relevant cytokines 
involved in T cell priming, with IL-12-producing DCs priming Th1 responses, and the 
non-IL-12-producing DCs priming Th2 responses (Maldonado-Lopez et al., 1999). The 
main drivers onto Th1 are inflammatory, monocyte-derived CD11c+ DCs (Macatonia 
et al., 1995;Rissoan et al., 1999), and CD11c- cDCs into Th2 (Rissoan et al., 1999). 
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The Th1-skewing cytokine IL-12 is the best explored, most relevant pro-
inflammatory third signal in DCs (Trinchieri, 1995), with IFN-γ, IL-4, IL-10, PGE2 and 
IFN-α activities intimately mediated by this cytokine (Gately et al., 1998;O'Garra, 
1998;Wu et al., 1998). Its main inducers are lipopolysaccharide (LPS), artificially 
synthesized poly(I)poly(C) or CD40L (Macatonia et al., 1995;Cella et al., 1996;Cella et 
al., 1999). 
Modulation of IL-12 expression also can be achieved by the action of chemokines, 
either positively, such as in the lymphoid-resident DCs in the mouse model (Aliberti et 
al., 2000), or negatively, as in the case of human DCs (Braun et al., 2000). DC contact 
with most pathogens induces IL-12 production. In contrast, maturation stimuli such as 
TNF-α, IL-1, cholera toxin, FasL, fungal hyphae or nematode products seem to have no 
impact in this cytokine secretion (Braun et al., 1999;d'Ostiani et al., 2000;Gagliardi et al., 
2000;Rescigno et al., 2000;Whelan et al., 2000). IL-12 production can be potently 
induced by CD40L, which is expressed at high levels on activated memory T cells (Cella 
et al., 1996;Heufler et al., 1996). In terms of activation kinetics, DCs only respond within 
8 to 16 hours after challenge with IL-12-inducing stimuli. This activation lag ensures a 
regulation of Th1 and Th2 polarization, avoiding unwanted responses (Langenkamp et 
al., 2000;Lanzavecchia and Sallusto, 2000;Tanaka et al., 2000).  
The Th2-skewing in DCs profile is characterized by secretion of low levels of IL-
1α/β, IL-6, IL-13 or OX40L, but, also importantly, by the absence of IL-12 (Rincon et 
al., 1997;Flynn et al., 1998;McKenzie et al., 1998;Rissoan et al., 1999), resulting from 
DC contact with low stimulatory antigens. Recently, it was shown a normally tolerated 
antigen became susceptible of a Th2 response after infection with a strong Th1-elliciting 
pathogen (Brimnes et al., 2003;Dahl et al., 2004), a fact that further stresses how 
complex and unclear the Th2 process still is. 
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DCs are also known to actively participate in the induction of Treg cells (Fairchild 
and Waldmann, 2000;Steinman et al., 2000). The induction of tolerance, more than the 
result of a dedicated, tolerogenic DC lineage or immature DCs, occurs after DC contact 
with micro-environmental factors (mostly antigens), inducing DCs to a tolerogenic-
skewing profile. Good examples of these tolerogenic factors, corroborating this 
hypothesis, are: 
- Non-immunogenic antigens present in respiratory and digestive tracts 
(Vermaelen et al., 2001) Antigens from specific pathogens - i.e. Plasmodium 
spp. antigens;  
- Some self-antigens, such as insulin (Chen et al., 2003);  
- Altered “self” peptides (Wildbaum et al., 2002) or self-antigens resulting 
from regular cell turnover (Huang et al., 2000). 
Tolerance induction may also originate in pro-inflammatory DCs, as well as specialized 
subsets/tissue-resident of DCs. For example:  
- Activation of DCs that secrete IL-10 (an immunoregulatory cytokine), but not IL-
12, can direct naïve T cells to a Treg subtype (Akbari et al., 2001;McGuirk et al., 
2002), as in the case of APCs from the liver (Khanna et al., 2000) and Peyer’s 
patches (Iwasaki and Kelsall, 1999) secreting high levels of IL-10, selectively 
inducing Treg or Th2 cells, respectively; 
- In vitro culture of mouse bone marrow progenitor cells in the presence of GM-
CSF, TNF-α and IL-10 induces the differentiation of a distinct subset of dendritic 
cells, CD11clow CD45RB+ DCs, similar to a tolerogenic subset 
naturally/physiologically present in the spleen and lymph nodes of normal mice 
(Wakkach et al., 2003). These DCs were shown to secrete high levels of IL-10 
after activation. Functional studies also showed that CD11clow CD45RB+ DCs 
specifically induce the differentiation of regulatory Treg cells in vitro. 
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- The murine CD103+ cDCs, present in hepatic, skin, kidney, intestinal and lung 
tissue (Johansson-Lindbom et al., 2005;del Rio et al., 2007;Jaensson et al., 
2008;Monteleone et al., 2008;Ginhoux et al., 2009;Schulz et al., 2009;Desch et 
al., 2011;Scott et al., 2011;Murakami et al., 2013;Yu et al., 2013) were proven to  
be relevant Treg inducers via a TGF-β and retinoic acid (RA) mechanism 
(Coombes et al., 2007). This mouse subset has recently been shown to be the 
functional homologue of the human CD141+ DCs (Jongbloed et al., 
2010;Haniffa et al., 2012;Kelly et al., 2013), with similar Treg induction 
mechanisms, namely and mainly, via TGF-β with RA also playing a part (Mucida 
et al., 2007; Nolting et al., 2009). 
As an exogenous factor, IL-10 is, thus, the key factor for the induction of 
tolerogenic DC in vitro and in vivo, but other cytokines and factors produced in the 
peripheral tissues, such as PGE2, TGF-β, RA or endocrine factors should also be taken 
considered on the generation of tolerogenic DCs (Wilbanks et al., 1992;Hosoi et al., 
1993).  
 
More recently, a newly defined lineage of T cells called T helper 17 (Th17) cells, 
was identified with protection functions against some bacterial and fungal 
infections (Korn et al., 2009) and with a relevant role in autoimmune disorders, such as 
multiple sclerosis (Correale and Farez, 2012).  
Th17 cells may be induced by DCs as the result of a combination of IL-6, low 
concentration of TGF-β, IL-23, or IL-21 (Acosta-Rodriguez et al., 2007;Korn et al., 
2007;Nurieva et al., 2007;Zhou et al., 2007;Volpe et al., 2008;Yang et al., 2008a;Hu et 
al., 2011), with IL-1 also known to enhance this process mediated by the transcription 
factor RORγt and the signal transducer and activator of transcription 3 (STAT3) (Bettelli 
et al., 2006;Mangan et al., 2006;Veldhoen et al., 2006;Manel et al., 2008;Yang et al., 
2008b;Ivanov et al., 2009). 
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However, IL-6 action may be a lineage dependent factor for Th17 induction. Although 
both splenic DCs and intestinal lamina propria DCs induce differentiation of naive T cells 
into Th17 cells, splenic DCs do so independent of IL-6, whereas in the presence of LP 
and skin CD103+ DCs, IL-6 is required to induce Th17 lineage cells. This comes as a 
result of the necessity of IL-6 to counteract the anti-Th17 differentiation effect of RA and 
high concentrations of TGF-β, both known to be produced by skin and intestinal lamina 
propria (LP) CD103+ DCs (Coombes et al., 2007;Mucida et al., 2007;Manel et al., 
2008;Nolting et al., 2009) but not by spleen DCs (Hu et al., 2011). 
 
1.1.2 Pathogen recognition by dendritic cells 
 
Pathogen recognition by DCs depends on the identification of distinct microbial 
patterns, not present in mammalian cells, but shared by most of the pathogenic microbial, 
known as ‘pathogen-associated molecular patterns’ (PAMPs) (Schnare et al., 
2000;Netea et al., 2004). These patterns include bacterial and viral unmethylated CpG 
DNA, bacterial flagellin, peptides containing N-formylmethionine residues, 
lipoteichoic acids and double-stranded and single-stranded viral RNA. A 
substantial part of PAMPs are glycan-containing ones, such as lipopolysaccharide, 
N-acetylglucosamine, peptidoglycan, terminal fructose- and mannose-containing 
glycans, and glucan-containing cell walls from fungi. 
PAMPs are recognized by specific receptors named ‘pattern recognition receptors’ 
(PRRs), with functions aggregating endocytosis and intracellular signaling. Examples of 
PRRs expressed by DCs include Scavenger receptors, NOD-like receptors and C-
type lectins. However, among the most widely studied are the Toll-like receptors 
(TLR), a growing family of 12 evolutionary conserved PRRs consisting of type I integral 
membrane glycoprotein with relevant role in the microbial response. The outcome of TLR 
recognition is the induction of intracellular signaling and consequent expression of 
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antigen presentation molecules (MHC class II molecules), co-stimulatory molecules 
(CD80/86, CD40), inflammatory and/or antiviral cytokines (such as TNF-α, IL-12, IL-23, 
IFNα/β) and chemokines (i.e., IL-8, RANTES) (Takeda et al., 2003;Dzopalic et al., 2012), 
thus enacting a powerful response against pathogenic microbes. 
C-type lectins (CLRs) are another very relevant family of PRRs expressed by DCs
(Zelensky and Gready, 2005). As lectins, their main function is the recognition of 
glycan structures and, in an immunological context, they recognize pathogen-
associated glycans or glycosylated self-antigens. In DCs, some CLRs of note include the 
DC-Specific Intracellular adhesion molecule-3 Grabbing Non-integrin (DC-SIGN),
CD207/Langerin, the Selectin family (discussed below), the Macrophage 
Galactose/N-acetyl-galactosamine-specific Lectin (MGL1), Mannose Receptor 
(MR), DEC205, the Blood DC antigens 2 (BDCA 2), the Dendritic Cell 
Immunoreceptor (DCIR), the Dendritic Cell Immunoactivating receptor (DCAR) and 
Dectin-1/2/3. In contrast to TLRs, all of these CLRs functionally bind glycan structures 
expressed by mammalian cells (except for Dectin-1/2/3 that apparently only recognizes 
fungal and/or mycobacterial glycans), a fact that demonstrates its potential role in both 
host and pathogen recognition (van Kooyk and Rabinovich, 2008). CLRs can also 
recognize and internalize pathogens for presentation without inducing DCs’ maturation. 
In fact, the CLR-mediated antigen uptake doesn’t necessarily elicit a factual immune 
response, and may instead contribute to induce immunological tolerance (Figdor et al., 
2004). A downside of these phenomena is the potential immune escape of pathogens 
recognized via CLRs (van Kooyk et al., 2004;van Gisbergen et al., 2005;van Kooyk, 
2008;van Kooyk and Rabinovich, 2008). 
Like CLRs, the Sialic acid-binding immunoglobulin-like lectins (Siglecs) can also 
recognize pathogens’ glycoproteins and glycolipids thus also contributing to the host’s 
innate immune responses. Siglecs specifically recognize sialic acid-containing 
glycans and as mentioned below they also play a relevant role in self recognition (Lock 
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et al., 2004;Crocker, 2005;Crocker et al., 2007;Kawasaki et al., 2013). The biological and 
immunological relevance of CLR and Siglec receptors will be discussed in detail in later 
sections. 
DCs can also recognize and internalize microbes and its derivate particles by 
receptors that bind to opsonins in opsonized (“coated”) microbes. Opsonization of 
microbes can occur in two forms: by coating with complement proteins or by binding of 
antibodies to antigens expressed on their surface. DC recognition of opsonized microbes 
is thus mainly mediated by complement receptors and Fc receptors and assures the 
capture of pathogens that might otherwise evade recognition by other DC receptors 
(Sedlik et al., 2003;Ben Nasr et al., 2006). 
Summarizing, DCs can interact in different ways with microbes, as well as with the 
host antigens, through a panoply of receptors. This recognition initiates mechanisms that 
will induce or suppress a specific immune response. DC recognition is thus considered 
to be of great relevance for the development of a suitable, specific immune outcome, 
dictating the balance tolerance/reactivity of the developing host-pathogen response. 
 
1.1.3 Dendritic cells-based therapy 
 
The current knowledge of DC immunobiology allowed several biotechnological and 
pharmaceutical companies to develop DC-based immunotherapies. Applications for DC-
based therapy include a plethora of pathologies ranging from infectious and 
hypersensitivity diseases to malignancies. 
The development of moDC cell culture protocols (Romani et al., 1994;Jonuleit et al., 
1997) allowing its relatively easy obtention, as well as its pro-inflammatory properties, 
makes them the preferred DC subset for autologous therapy applications. One strategy 
is the ex vivo upload of moDCs with the antigen to turn them able to efficiently develop 
an efficient response against the antigen bearer (Caminschi and Shortman, 2012;Matos 
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et al., 2013;Mintern et al., 2013;Phanse et al., 2013;Yao et al., 2013). The best example 
of this strategy, with growing media attention, is the vaccination of cancer patients 
with DCs loaded with tumor antigens, the Provenge® (sipuleucel-T) vaccine from 
Dendreon pharmaceutical company, targeting prostate cancer, being the most prominent 
example.  
Other approaches include the use of specific antibodies targeting DC endocytic 
receptors that are used to force the upload of specific antigens towards that receptor. 
Antibodies are also used to block specific receptor-ligand interaction and consequent 
downstream signaling, counteracting, for instance, the negative immunomodulatory cues 
of the tumor microenvironment.  
DCs have also been studied as vectors for DNA vaccines encoding for antigens (Cao 
et al., 2013). Viral transduction of DCs not only targets antigens to these cells, but also 
induces intracellular pathways to modulate the immune response (Liechtenstein et al., 
2013).  
All these relatively recent drug-niche that exploits DC unique immune potential is proof 
of reconnaissance of DCs’ cornerstone role in the immune system. Nevertheless, DC-
based therapies still face several hindrances until their full application, most notably 
having a relatively low overall efficacy (Dougan and Dranoff, 2009;Draube et al., 2011). 
The low efficacy is mostly derived from the lack of full knowledge regarding DC biology, 
including the pathogenesis/tolerance balance and their migratory mechanisms. The 




1.2  Glycosylation as an immunomodulation target  
 
Glycosylation of cell surface and secreted proteins and lipids occupy the juncture 
where critical host-host and host-pathogen interactions occur. The role of glycan 
epitopes in cell-cell and cell-pathogen adhesive events is already well-established, and 
cell surface glycan structures change rapidly in response to stimulus and inflammatory 
cues. Glycosylation is the most frequent modification of proteins and lipids. The 
majority of glycans exist as membrane-bound or soluble glycoconjugates. One 
consequence of this fact is that all cells present at their surface a glycocalyx, that is, 
the full surface-complex of glycans and glycoconjugates. The two main classes of 
glycoconjugates are glycoproteins and glycolipids and their synthesis occurs mainly 
in (but not limited to) the lumen of the endoplasmic reticulum and in the Golgi apparatus. 
In glycoproteins, the sugar chain is classified as being N-linked or O-linked, depending 
if the glycosidic moiety is linked to an asparagine (Asn) residue in the protein moiety or 
to a serine/threonine (Ser/Thr) residue, respectively (Figure 1.4). 
The cell glycocalyx is the result of the expression of the set of enzymes responsible 
for the synthesis and/or transfer of monosaccharides or glycosylated structures, i.e., the 
glycosyltransferases. Also critical is the expression of enzymes responsible for the 
partial removal of glycans or even entire structures from glycosylated molecules, i.e., the 
glycosidases. These two sets of enzymes work in a finely controlled balance during the 
glycoconjugate synthesis at the Golgi apparatus. Both enzyme types can also be present 
in plasma membrane or soluble forms, with potentially relevant biological roles as we 
shall see in sections below (Banerjee, 2012;Hennet, 2012;Rosnoblet et al., 2013).  
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Fig. 1.4 - Common classes of animal glycans. In Varki A et al. (Ed.), “Essentials of Glycobiology”, Cold Spring Harbor 
Laboratory Press, 2nd Edition, 2009. 
Sialic acids are a large family of negatively charged, nine-carbon monosaccharides 
that are normally found at glycan terminal positions, and one of most common among 
vertebrates is N-acetylneuraminic acid (Neu5Ac). On the cell surface, sialic acid 
residues can be present in N- and O-glycans in glycoproteins, as well as in gangliosides, 
i.e., a glycolipid containing one or more residues of sialic acid.
The sialyltransferases are a family of twenty glycosyltransferases that catalyze the 
addition of sialic acids to terminal non-reducing position of the oligosaccharide, 
transferring the sialic acid from the activated sugar donor cytidine-monophosphate-
Neu5Ac (CMP-Neu5Ac) to different sugar acceptors (Table 1.1) (Varki et al., 2009). 
Sialyltransferases normally locate at the Golgi apparatus as integral membrane proteins 
adding sialic acids to glycoconjugates during their synthesis. However, some 
sialyltransferases are also expressed as soluble enzymes (Jones et al., 2010a) and 
sialyltransferase activity at the plasma membrane has also been reported in immune 
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cells (Cabral et al., 2010). Each sialyltransferase presents high selectivity towards its 
acceptor substrate. In vivo, competition between other sialyltransferases and 
glycosyltransferases’ common substrates is observed. As a result, the cell’s sialylation 
status is the dynamic sum of transferase activities, Golgi localization and concentration 
of activated sugar donors. Sialyltransferases depending on their specificities, can 
establish α2,3-, α2,6-, α2,8-linkages and can be organized in four families depending 
on linkage specificity and acceptor substrate (Fig. 1.5):  
- the ST3Gal family, catalyzing the addition of sialic acid to a terminal galactose 
of N- or O-linked glycans and glycolipids in an α2,3-linkage;  
- the ST6Gal family, α2,6-linking sialic acids to galactose residues of N-
glycans;  
- the ST8Sia family, the only known sialyltransferases promoting the linkage to 
another sialic acid residue in N- or O-glycans, in a α2,8-bond;  
- and, finally, the ST6GalNAc family, adding sialic acid to terminal N-
acetylgalactosamine (GalNAc) residues of glycoproteins and glycolipids, in an 
α2,6-linkage (Harduin-Lepers et al., 2001).  
 
The overall sialic acid content of a cell is also regulated by the removal of sialic acid 
residues, catalyzed by the sialidases. In humans, four known enzymes fit into this family, 
also known as the Neuraminidase family: Neu1, Neu2, Neu3 and Neu4. These 
sialidases are variedly distributed, with Neu1 located at the lysosomes and also 
expressed on the surface of diverse types of cells, Neu2 at the cytosol, Neu3 
integrated in the cell membrane and Neu4 being an intracellular protein (Varki et 
al., 2009). They are all exoglycosidases, i.e., they cleave terminal sialic acids, but have 
different substrate specificities: Neu1, Neu2 and Neu4 remove sialic acid residues 
from glycoproteins, Neu2 and Neu4 also cleaves sialic acids from glycolipids and 




Fig. 1.5 - Structural relationships within the human sialyltransferase family. Homology dendrogram is shown for 20 
members of the human sialyltransferase family. Sialoside products produced by each of the four major subfamilies are 
shown in symbol form. In Paulson JC and Rademacher C, “Glycan terminator”, Nature Structural & Molecular Biology 
16, 1121 - 1122 (2009) 
 
A list of human sialyltransferases and sialidases, their expression patterns in DCs, 




Table 1.1 - Human sialyltransferases and sialidases. Preferred substrates and glycan specificity and expression pattern 
in human dendritic cells are indicated. Data was based on (Bax et al., 2007;Videira et al., 2008;Stamatos et al., 
2010;Miyagi et al., 2012). 
 
Preferred saccharide 




Sialyltransferase    
ST3Gal-1 Galβ1,3GalNAc O-glycan Yes 
ST3Gal-2 Galβ1,3GalNAc O-glycan Yes (mature) 
ST3Gal-3 Galβ1,3(4)GlcNAc O-glycan, N-glycan Yes (mature)) 
ST3Gal-4 Galβ1,4(3)GlcNAc N-glycan, O-glycan Yes (mature) 
ST3Gal-5 Galβ1,4GlcCeramide Glycolipid Yes 
ST3Gal-6 Galβ1,4GlcNAc N-glycan Yes 
ST6Gal-1 Galβ1,4GlcNAc N-glycan Yes 





ST6GalNAc-2 Galβ1,3GalNAcα1, O-Ser/Thr O-glycans Yes 
ST6GalNAc-3 Siaα2,3Galβ1,3GalNAc O-glycan 
Yes 
(undetermined) 
ST6GalNAc-4 Siaα2,3Galβ1,3GalNAc O-glycan Yes 
ST6GalNAc-5 GM1b Glycolipid No 
ST6GalNAc-6 All α-series gangliosides Glycolipid Yes 
ST8Sia-1 Siaα2,3Galβ1,4Glc-Ceramide Glycolipid No 
ST8Sia-2 Siaα2,3Galβ1,4GlcNAc N-glycan on NCAM No 
ST8Sia-3 Siaα2,3Galβ1,4GlcNAc N-glycan on NCAM No 
ST8Sia-4 (Sialα2,8)nSiaα2,3Galβ1-R N-glycan on NCAM Yes 
ST8Sia-5 GM1b, GT1b, GD1a, GD3 Glycolipid No 
ST8Sia-6 Siaα2,3(6)Gal 
Sialic acid on O-
glycan 
Unknown 





























1.3 Sialylation and modulation of the immune response 
The terminal position occupied by sialic acids on membrane and extracellular glycans 
puts them on the frontline during leukocyte communication and overall immune 
response. Sialic acids, on an immune perspective, can function in two (seemingly 
contradictory) major ways: as biological masks and as recognizable cell 
patterns/markers (Varki and Gagneux, 2012).  
As a biological mask, sialic acid helps shield host cells from pathogen and/or 
host recognition (Kelm and Schauer, 1997). During acute phase inflammation a rise in 
soluble and circulatory forms of sialyltransferases occurs, leading to an increase in 
soluble and cell surface sialic acid content. Higher sialic acid is thus part of the acute 
phase response and it seems to protect cells against pathogens, and may help the 
immune system distinguishing ‘self’ from ‘non-self’ antigens (Jamieson et al., 
1993). ST6Gal-1 is an example of sialyltransferase whose soluble expression is 
upregulated during an acute phase response and its expression has been used by some 
authors as a serological clinical marker for inflammatory conditions (Kaplan et al., 
1983;Jamieson et al., 1987;Yasukawa et al., 2005).  
Non-sialylated glycans are recognized by specific lectins, and the addition of sialic 
acid to its terminal position may block lectin binding and associated functions. As an 
example, the presence of α2,6-linked sialic acids on N-glycans blocks recognition 
by galectins (Zhuo and Bellis, 2011). Galectins are a family of β-galactoside-binding 
lectins that regulate a broad range of cell behaviors, such as cell adhesion, migration, 
proliferation, differentiation, transformation, apoptosis, angiogenesis, and immune 
responses (Hughes, 2001;Leffler et al., 2004;Hsu et al., 2006;Nakahara and Raz, 
2006;Erbacher et al., 2009). 
However, sialic acid masking can also be used by pathogens as a mimicry tactic 
in order to evade the immune system. This is the case of some Trypanosoma spp. that 
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have mutated ST3Gal sialyltransferases acting as trans-sialidases, transferring the 
host’s sialic acid to coat themselves in order to evade host recognition (Paris et al., 
2005;Freire-de-Lima et al., 2012). 
 
1.3.1 Sialic acid-recognition in immune processes 
 
Sialic acids or sialylated glycans can be recognized by several cell surface 
receptors, such as the previously mentioned CLRs and Siglecs (Sperandio, 
2006;Crocker et al., 2007).  
Siglecs are sialic acid-recognizing proteins that, albeit structurally similar, are 
commonly organized in two categories: i) one comprises the CD22 family (including 
CD22 (or Siglec-2), sialoadhesin (or Siglec-1), myelin-associated glycoprotein (MAG or 
Siglec-4) and Siglec-15; and ii) the CD33-related family comprising CD33 (or Siglec 3), 
Siglec-5, -11, -14 and -16 in humans, all chiefly expressed in myeloid and lymphoid cells 
(Pillai et al., 2012;Varki and Gagneux, 2012). Siglecs recognize and bind ligands present 
not only in other cells (viz. in trans) but also on the same cell (in cis). Many Siglecs 
present one or two intracellular tyrosine-based inhibitory motifs (ITIMs) 
immunoreceptors, classically described as being involved in signaling to regulation-
inducing pathways, or intracellular tyrosine-based activation motifs (ITAMs), 
involved in the initiation of activation signaling pathways (Flaswinkel et al., 1995;Isakov, 
1997). Hence, Siglecs have a decisive role in regulating, either positively or negatively, 
immune responses such as inflammation or tissue damage by actively discriminating 
between self-associated molecular patterns (SAMPs) and PAMPs (Crocker et al., 
2007;Crocker and Redelinghuys, 2008;Liu et al., 2009;Varki and Gagneux, 2012). We 
will discuss the functional relevance of these receptor families in DC-related aspects, 
later on, in section 2.4.1.2. 
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Studies using mice deficient for selected α2,3- and α2,6-sialyltransferases have 
provided evidence confirming the importance of sialic acid in immune processes (Hennet 
et al., 1998;Priatel et al., 2000b;Moody et al., 2003). ST6Gal-1-/- mice have impaired 
humoral immune response, characterized by reduced levels of circulating and cell-
surface IgM, impaired B cell proliferation in response to various activation signals, 
and impaired antibody production following contact with antigens (Hennet et al., 
1998). CD22, one of the first described Siglecs (Powell et al., 1993), was later shown to 
recognize ST6Gal-1-mediated glycans, functionally regulating several B cell 
functions and survival mechanisms (Ghosh et al., 2006). Other ST6Gal-1 KO mice 
studies have also revealed that soluble forms of ST6Gal-1 have a relevant role in 
myelopoiesis during acute inflammation, namely, by limiting it, thus avoiding 
uncontrolled excessive neutrophilic and eosinophilic inflammatory responses 
(Nasirikenari et al., 2006;Jones et al., 2010a;Nasirikenari et al., 2010).  
 
These are only few examples on how sialic acids influence immune-relevant 
processes. Other examples include roles in host-pathogen interactions, regulation 
/modulation of the acute phase response and influence in the progression and 




1.4 Dendritic cells and glycosylation 
 
As previously mentioned, DCs play a role of great relevance in the immune system. 
The characterization of the DC’s ‘glycome’ – the whole set of glycosylation features 
(‘sialome’ included) –, its functional impact on the DCs immunobiology and, of course, 
on the immune system has been a work in progress. Glycosylation of DCs has 
consistently being proven to be a very relevant feature, similar to what occurs with other 
immune cells. The most recognized feature is probably DC adhesion where selectin 
ligands of glycosidic nature are deemed crucial in the migration process. But, 
nonetheless, it is also known that glycosylation has a relevant role in the remainder 
immune processes as well, especially in innate recognition and DC activation, where the 
boundary condition of the DC glycocalyx makes glycans key players in these processes. 
There are many questions still open, such as DC migration to specific sites, with 




1.4.1 Sialylation in dendritic cells 
 
The interest in studying the role of sialylation in DCs, resulted from the large focus on 
DC’s immunobiology and also from the growing scientific interest in glycobiology 
(including sialic acids). The role of sialylation has been mostly studied in moDCs 
(inflammatory DCs) for the reasons previously mentioned (see section 1.1.1.2.1).  
Jenner and coworkers stated that immature moDCs present a high sialylation 
content, namely α2,3- and α2,6-sialylated glycoproteins, when compared to its 
monocyte precursors. These results, also corroborated by our work, will be explained in 
further detail below (Jenner et al., 2006;Videira et al., 2008). Both sialyltransferases and 
sialidases undergo significant gene expression variation during differentiation from 
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monocyte to moDC (Jenner et al., 2006;Videira et al., 2008;Trottein et al., 2009;Stamatos 
et al., 2010), namely, a significant upregulation of the ST3Gal-1 and ST6Gal-1 genes 
occurs during moDCs’ differentiation. The up-regulation correlates with increases of 
measurable enzymatic activities attributable to these two enzymes and the increased 
degree of α2,3- and α2,6-sialylation (Videira et al., 2008) during myeloid lineage-
committed differentiation.  The data implicate these two sialyltransferases as the major 
regulators in the biosynthesis of α2,3- and α2,6-linked sialic acid-containing glycan 
structures specific for moDCs. Interestingly, the membrane sialidases, Neu1 and Neu3 
are also significantly upregulated during DC differentiation (Stamatos et al., 2010), 
probably acting in more specific cell glycans. 
 
moDCs maturation is also accompanied by an increase in α2,3-sialylation and, 
contrasting, a decrease of α2,6-sialylation that is likewise correlated with changes in 
the sialyltransferase and sialidase activities (Jenner et al., 2006;Bax et al., 2007;Videira 
et al., 2008). Moreover, the reported sialylation variations are stimulus-dependent 
processes (Videira et al., 2008). These observations are summarized on the present 
chapter’s Table 1.1, on section 1.2.  
While the functional impact of these observed sialic acid changes remains to be 
elucidated, there is already some indication supporting the biologic relevance, and it will 
be discussed later on. 
 
1.4.1.1 Sialic acid-recognizing dendritic cell receptors 
 
One of the most immediate aspects of sialic acid-containing glycans expressed by 
DCs is being the target of receptors. In this aspect, Siglecs are the largest and most 
relevant family.  
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Recognition of DCs’ sialylated glycans has some known functional implications: e.g., 
inhibitory T cell Siglecs recognizing high α2,6-sialic acid content of immature and 
tolerogenic DCs as part of a host-tolerance inducing mechanism (Jenner et al., 2006), 
or the observed increased binding of Siglecs-1, -2 and -7 correlating with the higher 
sialic acid content of mature DCs (Bax et al., 2007). This gathered evidence hints at an 
even more promising, relevant role of Siglec-mediated immunobiological processes 
involving DCs and other leukocytes, but still to be unraveled and requiring, thus, further 
studies. 
Besides being recognized by Siglecs through their expression of glycans, DCs also 
express Siglecs that enable them to also recognize sialylated structures on self or on 
neighboring cell surfaces. MoDCs and blood-circulating DCs (namely plasmacytoid, 
CD1a+ and CD141+ DCs (Hemont et al., 2013)) express Siglec-1, -2, -3, -5, -7, -9, -10, 
-14 and -15 (Lock et al., 2004;Bax et al., 2007;Crocker and Redelinghuys, 2008;Crocker 
et al., 2012), with plasmacytoid DCs having a more restricted pattern and apparently only 
expressing Siglec-5 (Lock et al., 2004). Siglecs, with the exception of Siglec-14 and -15, 
expressed by DCs present immunoreceptor tyrosine-based inhibition motifs (ITIMs) in 
their cytosolic portion and are therefore mainly involved in inhibiting activation signals 
and have an immunoregulatory function (Crocker, 2005;Crocker et al., 2007). 
The concentration of sialic acids on surfaces of human cells is very high; for example, 
Stamatos and colleagues estimated that DCs had 8.9 nmoles of sialic acid per 5x106 
cells, which correspond to nearly 1018 sialic acid molecules per cell (Stamatos et al., 
2010). Therefore, it is possible that the majority of Siglecs expressed at DC surface bind 
in cis, i.e., to sialic acids at their own cell surface. Due to short length of Siglecs 
compared with other cell surface proteins, the cis interaction normally has primacy 
over the trans interactions – the only exception being sialoadhesin (CD22), which has 
an extended structure, projecting their binding site away from plasma membrane and 
being therefore involved in trans interactions (Freeman et al., 1995).  
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Siglec interactions in cis can be released as a result of sialidase activity, expressed 
either extrinsically – for instance from pathogens –, or intrinsically – due to the activity 
of endogenous sialidases (Crocker, 2002;2005).  
Siglecs potentially play a largely relevant role in host-tolerance mechanisms. (Lock 
et al., 2004;Bax et al., 2007;Santos et al., 2008). Chen and co-workers reported Siglec-
10 as involved in helping to distinguish TLR-recognized, danger-associated molecular 
patterns (DAMPs) – generated during cell/tissue damage or even regular cell cycle – 
from PAMPs, thus controlling inflammation (Chen et al., 2009). There are known 
examples of T cell activation where DC Siglecs have a relevant role in inducing Th1 and 
Th2 responses, as is the case of DC Siglecs-1 and -7 trans recognition of α2,3-sialic 
acids and α2,8-polisialic acids, respectively, in mimicked GM1a and GD1a (Siglec-1 
recognized) and GD1c (Siglec-7 recognition) gangliosides included in Campylobacter 
jejuni’s lipopolysaccharides (Bax et al., 2011).  
CD33-related Siglecs can function as endocytic receptors that are important in 
the clearance of sialylated antigens. On the other hand, many pathogens are able to 
express appropriate sialic acids themselves (Jones et al., 2003;Avril et al., 2006;Carlin 
et al., 2007;Khatua et al., 2010). Pathogen’s sialic acids may interfere with DC functions, 
such as endocytosis (Lock et al., 2004;Biedermann et al., 2007) thus helping DCs to 
internalize and further present pathogen’s antigens. This, however, may also open an 
opportunity window for pathogens to modulate DCs’ immune functions (by binding to 
immunoregulating Siglecs) or even use DCs as vectors (i.e. “Trojan horses”) for infection 
of other immune system cells, e.g. the Human Immunodeficiency Virus (HIV) using 
Siglec-1 as a gateway-receptor for DC entry and posterior transmission to CD4+ T cells 
(Izquierdo-Useros et al., 2012). However, a safety mechanism may be present: Siglec-
15 can act as an activation receptor balancing the negative signaling triggered after 
recognition of sialylated pathogens (viz., enveloped viruses) through inhibitory Siglecs 
(Crocker and Redelinghuys, 2008). 
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1.4.1.2 Dendritic cell sialylation and endocytosis 
 
The sialic acid’s role on endocytosis has long been studied on the perspective of the 
pathogen. Adding to the already referred trans-sialidase bearing T. cruzi parasite, it is 
also known that several bacteria developed sialic acid-masking mechanisms in order to 
escape immune surveillance and/or response (Severi et al., 2007). As part of the work 
presented on this thesis, recent discoveries, however, hinted that sialic acid’s role in 
these immune processes surpasses its simple antigen status, with a functional impact 
on the innate immune phase cells as well, like DCs.  
 
1.4.1.3 Sialylation and dendritic cell migration 
 
DC migration includes both DC recruitment to non-lymphoid tissue and homing 
to lymphoid organs.  
DCs residing within tissues may respond to pro-inflammatory cytokines and 
pathogens hence triggering maturation. DCs then migrate to lymphoid tissues via 
afferent lymphatic vessels, wherein they activate antigen-responsive T cells. More rarely, 
immature and mature DCs may also enter the blood, and from there, disseminate to non-
lymphoid and lymphoid organs, thereafter returning to blood, thus undergoing cycles of 
recirculation. DCs have complex trafficking routes, allowing for their dynamic 
reassortment, making the most of their capacity to uptake antigens and to encounter T 
cells to present antigens and activate them. 
 
While, generally, the migratory processes are based upon mechanisms like adhesion 
and chemotaxis, some processes still show their own particularities. The extravasation 
of blood DCs to any tissue involves DC adhesion to endothelium and is dependent 
of selectin interactions with sialofucosylated glycans. The role of certain sialylated 
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glycans as selectin ligands is one of the most recognized functions of sialic acid in the 
context of leukocyte recruitment (Sperandio et al., 2009). 
Selectins are CLRs expressed by platelets, endothelium or leukocytes, hence taking 
their name: P-, E- or L-selectins, although endothelial cells also express P-selectins.  
All selectins recognize selectin ligands, with the sialic acid- and fucose-containing 
tetrasaccharide sialyl-Lewis X antigen (sLex) (Neu5Acα2,3Galβ1,4[Fucα1,3]GlcNAc-) 
being the most studied structure. Selectin ligands are expressed in most circulating 
immune cells and some endothelial cells during inflammation (Fig. 1.6). They 
mediate the rolling and tethering phase of cell transmigration over the endothelial cell 
surface (McEver, 2002).  
 
Fig. 1.6 - Selectin-dependent interactions. In Ley K. and Kansas G.S., “Selectins in T-cell recruitment to non-lymphoid 
tissues and sites of inflammation”, Nature Reviews Immunology, (4), 2004. 
 
sLex expression is well characterized in neutrophils and lymphocytes (Patel et al., 
1995;Sperandio, 2006) but only relatively approached in DC (Robert et al., 1999a;Pendl 
et al., 2002;Julien et al., 2007;Silva et al., 2011). Recently, it was found that moDCs also 
express functional selectin ligands, based on their observations of moDC tethering 
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and rolling over a P-, E- and L-selectin immobilized surface (Silva et al., 2011). They 
observed decreasing tethering affinities (by decreasing order) towards P-selectin, E-
selectin and L-selectin, with similar lower rolling velocity on P- and E-selectins and the 
largest rolling velocity observed over L-selectins. These findings were in line with other 
studies using blood DCs and CD34+-derived DCs (Robert et al., 1999a;Urzainqui et al., 
2007). Furthermore, the use of anti-sLex antibodies on the rolling studies resulted in a 
significant binding inhibition, definitely proving that sLex mediates the moDCs-selectin 
binding (Silva et al., 2011). 
In order to properly function as a selectin ligand, sLex must be expressed in carrier 
glycoproteins or glycolipids (Foxall et al., 1992;Marth and Grewal, 2008). The only 
described sLex carrier-protein described in moDCs is the P-selectin glycoprotein 
ligand-1 (PSGL-1) (Julien et al., 2007), a mucin-like glycoprotein, present in the microvilli 
of most leukocytes (Laszik et al., 1996;Kieffer et al., 2001) (Figure 2.7). In DCs, sLex-
decorating PSGL-1 is the sole ligand for P-selectin, with significant less affinity 
towards L-selectin and being indifferent for E-selectin binding (Silva et al., 2011). 
Nevertheless, sialic acids also participate in the chemokine receptor-mediated firm 
arrest, as well as in β1 integrins function (Semel et al., 2002;Frommhold et al., 
2008;Woodard-Grice et al., 2008). There is also evidence concerning the chemokine-
mediated migration to the lymph nodes. It was recently reported that ST8Sia-IV-
dependent polisialylation of neuropilin-2 seems to be relevant for CCL21-driven 
migration towards lymph nodes (Rey-Gallardo et al., 2011). Other report claims that 
ST3Gal-4 is not relevant for CCR7-dependent DC homing, in the mouse model 
(Frommhold et al., 2008). Nevertheless, the large body of evidence points to α2,3-
sialylation as the prominent sialylation form involved in DC migration. 
In the work for this thesis, we sought to contribute to this issue by studying DC homing 
in ST6Gal-1-deficient mice. As reported in section 4.3, the results suggest that DC 
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migration towards draining lymph nodes is significantly impaired, suggesting a previously 
unknown role for α2,6-sialylated N-glycans in DC homing.  
DC mobility is a crucial step still in need of better elucidation. Most of the clinically 
efficacy of DC immunotherapy relies on the migration ability of these cells. In ex vivo 
generated DC vaccines, it is estimated that only 1-2% of total administered DCs reach 
secondary lymphatic organs (Ridolfi et al., 2004). Therefore, the majority of ex vivo 
generated DCs are inefficient because they do not meet T cells. Thus, understanding 
DC migration should be regarded as important to find means to improve DC 
immunotherapy. 
 
1.4.1.4 Sialic acid in dendritic cell-T cell interactions. 
 
The ultimate function of DC immunobiology is the DC-T cell interaction, 
whereupon DCs present the uptaken, processed antigens to T cells, to initiate a specific, 
long-lasting immune response.  
DCs’ sialic acid-containing glycans have been shown to negatively influence T cell 
priming, most likely by interference on MHC-mediated antigen presentation and co-
stimulation (Boog et al., 1989;Dubsky et al., 2005). However, one should not discard a 
synergistic effect with enhanced protein-protein interaction due to the absence of the 
negatively charged sialic acid (Boog et al., 1989), leading to enhanced inter cellular 
interactions.  
Reinforcing these results, others have observed that endogenous sialidase activity 
also promotes cytokine production by moDCs, in what was attributable to the action of 
Neu3 upregulation during moDC differentiation (Stamatos et al., 2010). Interestingly, 
tolerogenic, immature moDCs present high sialic acid content (Jenner et al., 2006) and 
it has been hypothesized that, host tolerance induction by DCs could be a Siglec-
mediated process (Jenner et al., 2006). 
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The contribution to this issue, herein presented, is solid evidence that sialidase-
treated moDCs are able to prime T cells and to induce proliferation more efficiently 
than fully sialylated moDCs. This effect could be attributable to the increased 
maturation by sialidase-treated moDCs but the effect of the verified upregulation of a set 
of pro-inflammatory, Th1 profile-inducing cytokine expression (viz., IL-1α, -6, -12 and 
TNF-α) in sialidase-treated moDCs (with subsequent IFN-γ secretion) accounting for the 
observed increased priming is not excluded. 
Taken together, this evidence reminds that DC sialylation has implications in their 
interaction with T cells and it should be considered to fine tune DC-based therapy either 
pathology-treating or tolerance-inducing. 
 
1.4.2 Dendritic cell glycan-recognition of tumors 
 
Although not covered by the work within this thesis, the relevance of DCs functions in 
onco-immunology should be mentioned. 
Recognition of tumor antigens by DCs elicit a maturation response on DCs that is 
critical to the initiation of anti-tumor immune responses. 
The immune potency of such response depends on many factors, including, but not 
limited to, the antigen. Tumor cells are able to evade immune responses by creating a 
tolerance-inducing microenvironment, which includes the secretion of inhibitory factors 
and activation of immunosuppressant intracellular pathways in the immune cells which 
leads to defective maturation of DCs (Banchereau and Steinman, 1998b;Rabinovich et 
al., 2007;Condamine and Gabrilovich, 2011). Furthermore, matured DCs present flaws 
in their tumor antigen-presenting capacity and a faulty ability to prompt T cell responses, 
thus defective in generating effective anti-tumoral solutions (Rabinovich et al., 
2007;Benencia et al., 2012).  
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Aberrant glycosylation is a hallmark of cancer cells and the aberrantly glycosylated 
proteins are shed into the bodily (serum, urine, pleural effusions, etc). Altered 
glycosylation in tumor cells can result from a decrease or increase of expression of 
certain glycan structures, the appearance of truncated structures, or even novel 
structures. Upregulation and/or downregulation of specific glycosyltransferases are often 
regarded as drivers for these changes. Tumor-associated carbohydrate (TAC) structures 
allow tumor cells to invade and metastasize or to evade the immune system. For 
instance, sialyl-Tn antigen (STn) expression by cancer cells is associated with many 
malignant features such as invasiveness and cell differentiation (Pinho et al., 2007;Julien 
et al., 2012). Moreover, STn+-bearing MUC1 mucins inhibited DC maturation and 
modulate DCs towards IL-10high IL-12low antigen presenting cells (Monti et al., 2004). 
Recently, Carrascal et al. have shown that DCs pulsed with antigens derived from STn+ 
cancer cells induced T cells to anergy, displaying a FoxP3high IFN-γlow phenotype, in a 
mechanism likely to involve STn+ MUC1 and CD44 antigens (Carrascal et al., 2014).  
How TAC contributes to immune evasion depends on their recognition by DC 
receptors. The few available studies point, so far, to the CLRs, MGL-1, DC-SIGN and 
Siglecs receptors as being relevant in TAC recognition by DCs (van Gisbergen et 
al., 2005;Saeland et al., 2007). MGL-1 is highly expressed in immature, tolerogenic DCs 
and shown to interact with the tumor-associated Tn antigen-bearing forms of MUC1 
(Napoletano et al., 2007). The latter is also expressed by immature DCs and recognizes 
Lex and Lewis Y (Ley) glycoantigens in a carcinoembrionic antigen-context expressed in 
colorectal carcinoma (Fig. 1.7). Besides these receptors, the observed involvement of 
DCs’ Siglecs (such as Siglec-3 and -9) could help justifying the frequent tolerance-
induction mechanisms via recognition of sialylated antigens (e.g. sialyl T and sLea), 
usually overexpressed by tumor cells. These receptors could send inhibitory intracellular 
signals from their ITIM motifs thus preventing DCs from differentiating (by inducing 
apoptosis of their precursors) or maturating, keeping them in a tolerance-inducing state 
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with concomitant upregulated anti-inflammatory cytokine expression, downregulated 
pro-inflammatory cytokine expression and reduced antigen presenting capability 
(Rughetti et al., 2005;Ishida et al., 2008;Ohta et al., 2010). 
It is now evident that TAC and, in particular, sialic acid-containing TAC influences 
tumor progression. DCs become tolerogenic after recognition of TAC, favoring 
tumor progression and being generally associated with bad prognosis. The 
collected evidence regarding the glycan influence on anti-carcinogenic immune 
processes should be, therefore, seriously considered whenever DC-based 
immunotherapies against specific malignancies are available. 
 





1.5 Concluding remarks 
DCs are pivotal, key players of the immune system, influencing and defining the 
immune response and outcome upon antigen uptake and the induction of adaptive 
immune responses. DCs are important sentinels due to their special mechanisms for 
antigen capture and processing, and a unique capacity to migrate to defined sites in 
lymphoid organs, to meet T cells. They also undergo rapid maturation in response to a 
variety of stimuli that act in receptors such as PAMP binding in Toll-like receptor or 
cytokines in cytokine receptors. Due to their role in dictating adaptive immune responses, 
DCs are now being used as cell based vaccines to treat cancer patients. However, many 
of their mechanisms are still poorly understood and the efficacy of DC-based 
immunotherapeutic at the clinical setting is limited. 
The importance of glycosylation and, in particular, sialic acid in biological processes 
is being increasingly acknowledged. Being at the terminal position of many glycans, sialic 
acids are located in a privileged position and can be recognized by many receptors or 
may interfere with many ligand-receptor interactions. Thus, sialic acids can (potentially) 
play an essential role in modulating many of the DC functions. 
Understanding the DC-sialylation binomial can prove to be the definite element to 
achieve better forms of immunotherapy still to be clinically developed. Sialic acid 
modifications on DCs, through Glycoengineering may be very promising tool to fine tune 










Dendritic cells (DC) play a central role in the interface between innate and adaptive 
immune responses. Although the DC subset comprises several subtypes, all DC 
subtypes’ main, immunologically relevant functions can be summed up in three phases: 
1) antigen uptake at peripheral tissues and/or secondary lymphoid organs, 2) maturation
and homing to the regional draining lymphatic organs, and 3) antigen presentation/T cell 
priming. The elucidation of the mechanisms that modulate their function is important for 
understanding the immune response, identification of therapeutic targets and 
development of novel immunotherapies.  
Sialic acid moieties play a relevant role in modulation of immune functions, such as 
antigen recognition, cell adhesion and migration, among others functions, due to their 
terminal position at cell surface glycans.  
Considering the high sialic acid content of DCs, our primary hypothesis is that 
sialic acid has an impact in DC functions, such as antigen uptake, maturation, 
homing to lymph nodes and antigen presentation to T cells. As a matter of fact, sialic 
acid moieties have been shown to modulate important functions of lymphocytes (Hennet 
et al., 1998;Priatel et al., 2000a), but their role in DC functions were unknown. 
In this thesis, to test this hypothesis, the following specific objectives were 
established: 
1 – To characterize the sialylation phenotype of DCs in their immature and mature 
states. 
2 - To analyze the expression of sialyltransferases responsible for DC sialylation and 
enzymatically determine their activity, during the differentiation and maturation phases; 
3 – To investigate the influence of α2,3- and α2,6-sialylation of DCs in the tissue 
distributions of these cells in the mouse; 
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4 – To determine how does sialylation affect the antigen uptake, maturation, homing 
and capacity to stimulate T cells by DCs. 
5 – To contribute to the assessment of the underlying intracellular signalling 
processes affected by sialic acid modulation, and the involved sialylated receptors; 
Ultimately, this work aims to understand whether the engineering of cell surface 
sialylation, mediated by individual sialidases or sialyltransferases, is a possible tool to 










3.1 moDC and BMDCs differentiation and maturation 
3.1.1 Human monocytes’ separation 
Differentiation of monocytes to monocyte derived DCs (moDCs) is currently a widely 
used technique to obtain large numbers of DCs. Monocyte precursors are normally 
present in the average healthy adult, at a steady-state concentration of 200-800×103 
cells/mL (2-10% of blood mononuclear cells). In this study, we use blood leukocyte 
concentrates obtained from whole blood donations, to obtain an enough amount of 
monocytes and hence to obtain a reasonable amount of moDCs. 
Mononuclear cells were isolated by a Ficoll gradient centrifugation, from blood ‘buffy 
coats’ of healthy volunteers provided by the Portuguese Blood Institute. For this, blood 
from the buffy coats was diluted 2 parts blood to 3 parts of Phosphate Buffer Saline 
(PBS) (v/v), pH 7.4 and then centrifuged at 1200×g (2500 r.p.m. on a Heraeus Sepatech 
model Megafuge 1.0R centrifuge equipped with a BS4402/A basculant rotor) for 20 min 
in order to obtain a rough mononuclear leukocyte concentrate. After dilution in 30 mL 
phosphate buffer saline (PBS), the mononuclear cell concentrates were separated by 
Ficoll gradient (Biochrom AG), at a proportion of cell suspension to Ficoll solution of 5:3, 
centrifuging at 1200×g, for 20 min. After centrifugation, a clear white ring formed by 
peripheral blood mononuclear cells (PBMCs) was carefully removed and gently washed 
twice with PBS in order to remove debris and contaminating erythrocytes and platelets.  
PBMCs were then magnetically sorted using CD14 magnetic Microbeads (Miltenyi 
Biotech). PBMC cell number was determined and accordingly ressuspended in ice-cold 
Beads buffer (PBS pH 7.2, 0.5% bovine serum albumin (BSA), 2 mM 
ethylenediaminetetraacetic acid (EDTA)), at a volume fourfold the volume of CD14– 
magnetic Microbeads to Beads buffer, calculated according to the following formula: 





This PBMC + CD14 Microbeads suspension was left incubating for 15 minutes, at 
4°C, after which cells were washed by adding Beads buffer at a proportion of 1 mL per 
107 PBMCs and centrifuging 500×g for 5 minutes. The washed PBMC/CD14 Microbeads 
mixture was ressuspended in 500 μl ice-cold Beads buffer per 108 PBMCs. In parallel, 
the magnetic cell sorting column (LS columns, Miltenyi Biotech) to be used was prepared 
by washing with 3 mL Beads buffer. PBMC/CD14 Microbeads suspension was 
afterwards applied into the column already mounted in the magnet (accounting for CD14+ 
cell selection), following a 3 × 3 mL ice-cold Beads buffer wash removal of CD14– 
fraction. This fraction was discarded except when autologous lymphocytes were needed 
for the T-cell priming assay. Elution of CD14+ cells was then performed by removing the 
column from the magnet, filling it with 5 mL ice-cold Beads buffer and, with the help of 
the supplied plunger, flushing the cells out of the column. The hence separated CD14+ 
cells were then counted and prepared for culture. 
 
3.1.2 DC differentiation and maturation 
 
The CD14+ cells, after phenotypical confirmation by flow cytometry (see ‘Flow 
cytometry’ subsection below), were then cultured in complete culture medium, namely, 
RPMI 1640 supplemented with 2 mM L-glutamine, 1% nonessential amino acids, 1% 
pyruvate, 100 μg/mL penicillin/ streptomycin (Gibco BRL) and 50 μM 2-mercaptoetanol 
and 10% fetal calf serum (FCS) (Sigma-Aldrich Ltd.) for 6 days in the presence of 1,000 
U/mL human recombinant IL-4 and GM-CSF (R&D Systems) to give rise to immature 
moDC. 
The moDC maturation was induced at 6th day culture, by the addition of 5 μg/mL of 




3.1.3 Flow cytometry analysis of antibody- and lectin-cell staining of moDCs 
Staining with Fluorescein isothiocyanate (FITC), phycoerythrin (PE) or PE-Cy5-
conjugated human antibodies against CD14 (M5E2), anti-CD80 (L307.4), CD86 (Fun-1; 
IT2.2), HLA-DR (L243) (BD Pharmingen), anti-HLA-ABC (W6/32) (Dako Glostrup) and 
BDCA-1 (AD5-8E7) (Miltenyi Biotec) was used to monitor monocyte isolation, moDC 
differentiation and to assess maturation levels. 
As a standard procedure, 105 cells were washed, ressuspended in 100 μl serum free 
RPMI 1640 medium and incubated with 10 μl of the selected antibodies for 15 min at 
room temperature, in the dark. 
For the analysis of the moDC maturation phenotype after endocytosis, 2×105 cells 
were first incubated with 0.1 mg/mL of FITC-conjugated ovalbumin, in RPMI 1640 + 10% 
fetal calf serum, for 1h, at 4°C or 37°C. Following incubation, moDCs were treated or 
mock-treated with sialidase as described below (subsection Sialidase treatment). Half of 
the cells were reserved for RNA extraction and real-time polymerase chain reaction 
(PCR). The remaining cells were washed with FACSFlow® (Becton-Dickinson) stained 
with antibodies against maturation markers (HLA-DR, HLA-ABC and CD80/86) and 
analyzed by flow cytometry. 
On all procedures, after the staining step, cells were washed twice with, and 
ressuspended in, FACSFlow®. Acquisition and analysis proceeded in a FACSCalibur® 
flow cytometer (Becton-Dickinson Instruments) using CellQuest® software (Becton 
Dickinson) and/or INFINICYT® software (Cytognos). 
For the lectin staining, 105 cells were washed, ressuspended in serum free RPMI 
medium and incubated with 50 μg/mL of FITC-lectins (extracted from Maackia 
amurensis (MAA), Sambucus nigra (SNA) or Arachis hypogaea (PNA) species) (EY 
Labs) for 15 min, at room temperature in the dark. Cells were then washed twice, 






ST3Gal-1-/- and ST6Gal-1-/- mice were obtained from the Consortium For Functional 
Glycomics and originally developed by Priatel et al. (Priatel et al., 2000a) and Hennet et 
al. (Hennet et al., 1998), respectively. C57BL/6 (wild-type (WT)) mice (Jackson 
Laboratories) were purchased to Jackson Laboratories or authorized resellers. 
Mice were used at 10–12 weeks of age, with C57BL/6 animals used as controls. All 
handling of animals was previously approved by the Ethics Committee of the Medical 
Sciences Faculty of Lisbon and the Institutional Animal Care and Use Committee of 
Roswell Park Cancer Institute of Buffalo, NY, USA, under the supervision of officially 
recognized animal handlers. ST3Gal-1-/-, ST6Gal-1-/- and WT mice were euthanized by 
asphyxiation with CO2.  
 
3.1.5 Murine lymphoid tissue-resident and blood DCs extraction  
 
Lymphoid tissue-resident DCs were collected from mice in the following procedure: 
after lymph nodes removal, DCs were obtained by flushing said lymph nodes with culture 
medium and mechanically disrupting the lymphoid tissue on a 70 μm cell strainer with 
the help of a sterilized syringe plunger. In the extraction of adoptively transferred BMDCs 
(see below), the culture medium was supplemented with 2.5 mg/mL collagenase D from 
Clostridium histolyticum (Roche Diagnostics). 
Spleens were also removed, its contents flushed and finely minced. A 20 min, 37°C 
incubation with collagenase D at 1 mg/mL, followed by an erythrocyte lysis, using a Tris-
HCl 0.17 M, NH4Cl 0.16 M hypotonic solution, for 5 min at room temperature, were finally 
performed. 
The blood samples were collected by cardiac puncture into tubes containing an EDTA 
solution as anticoagulant. To this suspension, a hypotonic erythrocyte lysis solution was 
added in order to prepare the cell suspension for flow cytometry acquisition. 
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3.1.6 Bone marrow-derived DCs  
BMDCs were obtained mainly as described previously by Lutz et al. and Inaba et al. 
(Inaba et al., 1992;Lutz et al., 1999), with some modifications. Briefly, the bone marrow 
was flushed from the mice tibiae and femurs to a 10 mm Petri dish with the help of a 
syringe filled with complete cell culture medium (RPMI-Glutamax-I® supplemented with 
5% FBS (v/v), 50 μg/mL gentamicin sulphate (Cellgro), 50 μM 2-mercaptoethanol 
(Invitrogen)) and a 1/2G needle. The resulting bone marrow suspension was strained 
with 40 or 70 μm strainers (BD Falcon) and exposed to hypo-osmotic erythrocyte lysis 
buffer as described above. The bone marrow cells were then counted and cultured at 
5×105 cells/mL on 6-well plates, in complete culture medium supplemented with 10 
ng/mL murine GM-CSF (R&D Systems), for 6 days. The resulting DCs were then 
magnetically separated by anti-CD11c antibody-coated-magnetic beads (Miltenyi 
Biotech) and confirmed by anti-CD11c staining. The average separation purity was of, at 
least, 85%. 
3.1.7 Flow cytometry analysis of murine DC subsets  
Blood, lymph node and splenic cells were stained with allophycocyanin (APC)-
labelled anti-CD11c (HL3), peridinin chlorophyll protein (PerCP)-labelled anti-CD8a (53-
6.7) or FITC-labelled anti-B220 (RA3-6B2) in combination with anti-CD11b (NS-1), anti-
CD86 (GL1) or anti-I-Ab (murine MHC class II molecules) (AF6-120.1) PE-labelled mAbs 
(BD Biosciences). Samples were analyzed as described above. The DCs were 
considered CD11c- and I-Ab-positive cells. The cut-off point for positive staining was 
above the level of the control isotype mAbs. 
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3.2 Analysis of sialyltransferases (ST) activity 
 
3.2.1 Real-time PCR analysis of ST gene expression 
 
RNA was extracted from 1×106 cells using the RNeasy Mini Kit (Qiagen) and GenElute 
Mammalian Total RNA Purification kit (Sigma Aldrich), and genomic DNA was eliminated 
from the resulting extract with the RNase-Free DNase Set (Qiagen), as described by the 
manufacturer. The concentrations of the RNA samples were determined 
spectrophotometrically. 1 μg of total RNA was reverse transcribed with random primers, 
using the High Capacity cDNA Archive Kit (Applied Biosystems). PCR was performed in 
a 7500 Fast system (Applied Biosystems) using TaqManFast Universal PCR Master Mix, 
primers and Taqman probes provided by Applied Biosystems and following the 
manufacturer’s instructions. The reference sequences detected by each primer/probe 
set and the Assay ID provided by the manufacturer were the following: ST6Gal-1 
(NM173216.1 NM003032.2/Hs00174599_m1); ST6Gal-2 
(NM032528/Hs00293264_m1); ST3Gal-1 (NM173344 NM003033/Hs00161688_m1); 
ST3Gal-2 (NM006927.2/Hs00199480_m1); ST3Gal-3 (NM174969 NM174968 
NM006279 NM174972 NM174964 NM174971 NM174963/Hs00196718_m1); ST3Gal-4 
(NM006278/Hs00272170_m1); ST3Gal-5 (NM003896.2/Hs00187405_m1); ST3Gal-6 
(NM006100.2/Hs00196086_m1); ST6GalNAc-1 (NM018414.2/Hs00300842_m1); 
ST6GalNAc-2 (NM006456.1/Hs00197670_m1); ST6GalNAc-3 
(NM152996.1/Hs00541761_m1); ST6GalNAc-4 (NM175039.1 NM17 5040.1 
NM014403.3/Hs00205241_m1); ST6GalNAc-5 (NM030965.1/Hs00229612_m1); 
ST6GalNAc-6 (NM013443.3/Hs00203739_m1); CD1a (Hs00233332_m1); CD1b 
(Hs00233507_m1), CD1c (Hs00233509_m1); IL-6 (Hs00174131_m1); IL-12α 
(Hs00168405_m1); IL-1β (Hs00174097_m1); tumor necrosis factor-α (TNF-α; 
Hs00174128_m1); IL-10 (Hs00174086_m1); β-actin (4352935E); glyceraldehyde 3-
phosphate dehydrogenase (GAPDH; 4333764F). Each reaction was performed in 
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duplicate. Thermal cycling conditions were 95°C for 20 seconds followed by 40 cycles of 
95°C for 3 seconds and 60°C for 30 seconds. The messenger RNA (mRNA) expression 
was normalized using the geometric mean of β-actin and GAPDH household genes 
expression. The relative mRNA levels were expressed in ‰ of the β-actin/GAPDH 
expression and were calculated by the formula 2ΔCt×1000, and the relative expression for 
each gene was calculated by using the formula 2ΔΔCt, adapted according to the method 
described by Livak and Schmittgen (Livak and Schmittgen, 2001). ΔCt stands for the 
difference between the cycle threshold (Ct) of the amplification curve of the target gene 
and that of the β-actin/GAPDH. The efficiency of the amplification reaction for each 
primer-probe was above 95% (as determined by the manufacturer). 
3.2.2 Sialyltransferases enzymatic activity assays 
Total sialyltransferase (ST) activity was assayed in whole homogenates as previously 
described by Dall’Olio et al. (Dall'Olio et al., 1996) with minor modifications, using 
asialotransferrin as N-glycan sialylation acceptor and Galβ1,3GalNAcɑ1-O-benzyl 
(Sigma) as O-glycan sialylation acceptor. Cell pellets were homogenized in ice-cold 
water and the protein concentration assessed by Lowry method (Lowry et al., 1951). The 
assay mixture contained 50 mM sodium cacodylate buffer, pH 6.2, 0.1%Triton X-100, 4 
μM cytidine monophosphate (CMP)-[14C]Neu5Ac, 6 μM CMP-Neu5Ac, one acceptor 
substrate (8 mg/mL of glycoprotein or 2 mM of Galβ1,3GalNAcα1-O-benzyl) and 50 μg 
of the protein homogenate, in a final volume of 25 μl. The enzyme reaction was 
performed at 37°C for 2 h. Controls without exogenous acceptors were run in parallel 
and their incorporation was subtracted. Mice liver homogenates were used as positive 
controls. 
Two glyco-acceptors were used: glycoprotein and benzyl-glycoside. For the 
glycoprotein acceptor, the reaction was ended with the addition of 1% phosphotungstic 
acid in 0.5 M HCl (PTA). Acid insoluble material was collected by centrifugation. The 
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formed precipitates were washed twice with PTA and once with methanol, boiled in HCl 
1 M for 20 min and then transferred to liquid scintillation vials and processed for 
scintillation counting on a Perkin-Elmer Microbeta® scintillation analyzer (Perkin Elmer). 
As for the benzyl-glycoside reaction, it was stopped with the addition of 0.5 mL H2O and 
products were isolated by hydrophobic chromatography on C-18 SepPak cartridges 
(Millipore Corp.). After washing with H2O, the benzyl-glycoside was eluted with 
acetonitrile and counted by liquid scintillation. The activity was measured as the amount 
of radioactive sialic acid transferred from the donor to the acceptor substrate per hour 




3.3 Sialidase treatment 
 
Sialic acid removal of moDCs’ cell surface was performed by ressuspending moDCs 
in RPMI 1640 at a cell concentration of 5×106 moDCs/mL and incubating them with 200 
mU/mL of sialidase from Clostridium perfringens (Roche Diagnostics) in serum-free 
RPMI 1640 for 90 min at 37°C. In some experiments the bacterial surface was 
desialylated with 135 U/mL of a sialidase from Arthrobacter ureafaciens (Sigma Aldrich 
Ltd), according to the manufacturer’s instructions. 
In parallel to all sialidase treatments, identical samples were treated in the same 
conditions with heat-inactivated sialidase (mock treatment). At the end of the incubation, 




3.4 Endocytosis assay 
 
3.4.1 Endocytosis by moDCs 
 
Endocytosis assays were performed with monocytes obtained by CD14 antibody 
positive selection, as described above or immature moDCs cultured until 7th day. 3×105 
cells in RPMI 1640+10% FCS were incubated with 1 mg/mL of either Lucifer yellow CH 
potassium salt, FITC-dextran (DX, Mr=40,000) and FITC-ovalbumin (Molecular Probes), 
for 45 min, on ice/4°C or at 37°C. 50 μl of 0.1% Trypan blue solution was added at the 
end of the incubation to quench the surface attached fluorescence. Cells were then 
washed twice with PBS+1% FCS and analyzed by flow cytometry, as described. 
 
3.4.2 Endocytosis by BMDC 
 
The endocytosis assays with mouse BMDCs were performed by minor modifications 
of the above described moDCs endocytosis assay. Briefly, 3×105 BMDCs/mL were 
incubated, for 30 min, with FITC-conjugated ovalbumin at a final concentration of 0.05 
mg/mL, at 4°C or 37°C. After stopping the reaction, the cells were stained with PE-
labelled anti-MHC II (I-Ab) (AF6-1201) (BD Biosystems). To neutralize cell surface-
adsorbed fluorescently labelled ovalbumin, 300 μl 0.1% trypan blue solution was added 
and cells were washed twice before acquisition by flow cytometry. 
 
3.4.3 Bacterial strain and labelling 
 
For the phagocytosis assays, an Escherichia coli K12-derived strain was mainly used 
in this work. In some experiments, pathogenic E. coli isolates from blood cultures and 
hemocultures obtained from different patients either with urinary infection or septicemia 
and identified through a Vitek 2 system (Biomerieux) were used. In order to study moDCs 
and BMDCs phagocytosis, both strains were fluorescently labelled with 0.1 mg/mL of 
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FITC (Molecular Probes-Invitrogen), at 95° for 1h in 0.1 M sodium carbonate buffer (pH 
9.0). Bacteria were then incubated for 1h in PBS, with continuous shaking and stored at 
-20°. 
 
3.4.4 Phagocytosis assay 
 
Human moDCs/mature moDCs or murine BMDCs (5×105 cell/mL) were incubated 
with 5×106 FITC-bacteria, for 1h, at 37°C or 4°C. Incubation time was terminated by 
adding 0.1% trypan blue solution to quench surface-attached fluorescence. The 
phagocytosis was analyzed by flow cytometry and confocal microscopy. The internalized 
bacteria were estimated by flow cytometry, by measuring the mean fluorescence 
intensity (MFI) of the cells. The MFI values obtained at 4°C (representing basal, 
background fluorescence) were subtracted from the values obtained at 37ºC. In some 
experiments, phagocytosis was conducted with human moDCs incubated with 50 μg/mL 
of either SNA or MAA lectins, or, alternatively, in the presence of 10 μM cytidine 5′-
monophospho-N-acetylneuraminic acid (CMP-5-NeuAc) (Sigma Aldrich Ltd.). In the 
competitive binding assays, 10 mM free synthetic sialic acid (Sigma) was added 30 min 




3.5 T cell activation assay 
 
In order to test for T cell activation by moDCs, different parameters of autologous T 
cell priming assays already described in the literature (Bajana et al., 2007;Verkade et al., 
2007) were modified, tested and optimized. Immature human moDCs were generated 
(as described in the subsection Human monocyte to moDC differentiation) from 
monocytes isolated from PBMCs of healthy, consenting volunteers who had been 
vaccinated with tetanus toxoid (TT) within the previous 12 months so as to have optimal 
immunological memory. In these cases, the negative fractions (CD14– PBMCs) resulting 
from monocyte isolation were maintained in culture in complete culture medium 
(previously described) until the mixed lymphocyte cultures with autologous moDCs. On 
day 5, moDCs were pulsed with or without 5 μg/mL TT (Sigma Aldrich Ltd.) and, 18h 
later, moDCs were inactivated with 0.05 mg/mL mitomycin C (Sigma Aldrich Ltd.) for 30 
min and washed three times with 10 mL RPMI-1640 medium. The CD14– PBMCs were 
fluorescently labelled with 5.56 μg/mL carboxyfluorescein diacetate succinimidyl ester 
(CFSE) (Molecular Probes), for 15 min at 37°C, according to the manufacturer’s 
instructions. The labelled cells were then incubated with the autologous, TT-loaded 
moDCs (treated or mock-treated with sialidase), in the proportion of 8:1 or 4:1 (T cell : 
moDC ratio), in 96-well round-bottom plates, for 7 days. As a positive control for T cell 
proliferation, PBMCs were stimulated with 2 μg/mL phytohaemagglutinin (PHA) (Fluka) 
for 3 days.  
Evaluation of the T cell proliferation was performed using flow cytometry, after staining 
the samples with allophycocyanin-labelled (APC) anti-CD3 (clone 33-2A3) 
(Immunostep). The T cell activation level was obtained by one of two ways: the number 
of proliferating T cell, calculated as the percentage of CD3+ cells with relatively 
decreased CFSE fluorescence intensity vs. day 0 fluorescence intensity; or, alternatively, 
by determining interferon-γ (IFN-γ) gene expression after 48 hr of co-culture. 
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3.6 Mouse in vivo studies 
 
3.6.1 DC adoptive transfer 
 
The procedure commonly known as ‘adoptive transfer’ refers to the transfer of 
exogenously generated cells – in this case, BMDCs – into recipient organisms. Briefly, 
BMDCs generated and matured as previously described, were gently detached from the 
Petri dishes after addition of 10-15 mL pre-warmed Accutase (Sigma-Aldrich) at 37°C for 
10 min. The detached cells were washed, fluorescently labelled with PKH 67 (Sigma 
Aldrich) according to manufacturer’s instructions, in order to track down end-point 
migration towards draining lymph nodes, and checked for successful staining by flow 
cytometry. 1.0×107 cells were then ressuspended in 200 μl PBS and subcutaneously 
injected in the recipient mice hind legs footpads (5x106 PKH+ cells / 100 μL in each 
footpad). After 24h, the recipient mice were euthanized and the draining lymph nodes – 
namely, popliteal and inguinal lymph nodes – removed. In order to extract the included 
cells, a similar procedure to the one previously described in the Lymphoid tissue-resident 
DCs extraction subsection. The cells were then stained with fluorescently labelled 
antibodies for known murine DC markers: PE-anti-CD11b (M1/70), APC-anti-CD11c 
(N418), APC-anti-B220 (RA3-6B2) and PerCP-anti-I-Ab (M5/114.15.2) (Biolegend). 
 
3.6.2 Inflammatory DC migration 
 
To stimulate DCs to migrate towards draining lymph nodes, 2 mg Alexa Fluor 647-
labelled ovalbumin (Invitrogen) were added to 1 mL of an injectable solution of alum 
(10mg/mL aluminum hydroxide) (Thermo Scientific). 250 μL of this suspension were then 
subcutaneously injected in the scruff area of WT and ST6Gal-1-/- mice. 48h later, the 
mice were euthanized and the draining lymph nodes of the neck region, as well as 
mediastinal lymph nodes, were collected and processed, as described in the Lymphoid 
tissue-resident DC extraction section, in order to extract the therein contained cells. The 
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collected migratory DCs were, then, fluorescently labelled, as previously described in 
section 6.1. The migrating, ovalbumin-stimulated DCs were finally detected as, besides 
being positive for all DCs markers, they also were Alexa Fluor 647-positive. 
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3.7 Intracellular signalling pathways studies (MAPK western blot) 
To assess the activation of intracellular pathways potentially induced by sialic acid 
removal, moDCs lysates were submitted to SDS-PAGE and western blot assays. Briefly, 
a fraction of moDCs were cultured, as previously described, and collected. The LPS-
stimulated fraction was incubated with 5 μg/mL of LPS (Sigma-Aldrich Ltd.) for 1h, prior 
to collection. The remainder moDCs were gently harvested and submitted to sialidase 
treatment, as previously described (section Sialidase treatment). In parallel, a mock-
treatment with heat-inactivated sialidase was performed. In order to maintain the 
signalling pathways at the highest possible level, all reactions (sialidase treatment, mock 
treatment and LPS-stimulation) were stopped by putting the cell suspension on ice. The 
cells were then centrifuged at 4°C (or lower) and washed with ice-cold PBS, followed by 
lysis with lysis buffer (50 mM Tris buffer, pH 8.0 + 150 mM sodium chloride) 
supplemented with a cocktail of protease and phosphatase inhibitors, namely, cOmplete 
Protease Inhibitor tablets (Roche Applied Science), 1mM sodium orthovanadate (Sigma-
Aldrich) and 10 mM sodium fluoride (Sigma-Aldrich). The cells were then mechanically 
disrupted with the help of a mechanical homogenizer until fully lysed. After protein 
quantification by the Bradford method, 20 μg of sample protein in loading buffer were 
loaded per lane of a 12.5% SDS-PAGE gel. The developed gel was then transferred to 
a PVDF membrane (BioRad) on an ECL TE 77 PWR semi-dry transfer system (GE Life 
Sciences) for 1h, according to the manufacturer’s instructions. The protein-containing 
membrane was washed in TBS for 5 min and blocked with TBS-Tween 20 (TBS-T) 0.1% 
(v/v) + 5% BSA for 1 h, at room temperature. The blotting procedure followed by 
incubating the rabbit anti-human ERK 1/2 and phosphorylated-ERK (pERK) 1/2 
antibodies (Cell Signalling Technology, Inc., MA, U.S.A.) were diluted 1:2000 and 
1:1000, respectively, in TBS-T 0.1% (v/v) and incubated with the membrane overnight, 
at 4°C. After washing thrice with TBS-T 0.1% (v/v), the membrane was incubated with a 
1:2500 dilution of goat anti-rabbit Fc-horseradish peroxidase (HRP) conjugate antibody 
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(Sigma-Aldrich) in TBS-T 0.1% (v/v) + 5% BSA (w/v) for 1h, at room temperature, and 
finally washed as previously mentioned. The membrane was then developed by addition 
of Immobilon chemoluminescent substrate to the membrane for 5 min and digitally 
revealed in a ChemiDocTM XRS+ system (BioRad) with Image LabTM software, which also 
allowed the quantification of the blots’ intensities and densities. After blotting for the 
pERK 1/2 protein, the membranes were ‘stripped’ of antibodies by incubating them with 
a mild stripping buffer (15 g/l glycine + 1 g/l SDS + 1% (v/v) Tween-20, pH 2.2) twice for 
10 min and washing them, first, with PBS (twice) and lastly, with TBS-T 0.1% (v/v) (twice). 
The stripped membrane was, thus, prepared for the blotting assay with the anti-ERK 1/2 
antibody, as above described. 
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3.8 Microscopy studies 
3.8.1 Confocal laser scanning microscopy 
Human moDCs were allowed to adhere to concanavalin-A-coated cover glasses and 
then, paraformaldehyde-fixed and permeabilized with 0.1% Triton-X (Sigma). The cell 
cytoskeleton was stained with phalloidine-Alexa Fluor 633 (Molecular Probes-
Invitrogen). Images were acquired with a TCS SP2 AOBS confocal microscope (Leica 
Microsystem GmbH) with ×40 oil immersion optics and 488 nm and 633 nm laser lines 
for FITC and Alexa Fluor 633 excitation, respectively. The obtained micrographs were 
assembled and analyzed with the Leica Confocal software LCS LITE 2.6 (Leica 
Microsystems). 
3.8.2 Nuclear factor-κB translocation 
Human moDCs were adhered to cover-slip glasses, fixed and then permeabilized as 
previously mentioned, blocked with 3% BSA for 15 min and then stained with 1:100 
diluted rabbit anti-nuclear factor-κB (NF-κB) p65 antibody (Santa Cruz Biotechnology, 
Santa Cruz, CA) for 1h at room temperature. After washing with a PBS + 0.05% Tween-
20 (Sigma Aldrich) solution, goat anti-rabbit 568 (Molecular Probes-Invitrogen) in a 1:400 
dilution was used as secondary antibody. The moDCs’ nuclei were stained with 4′,6-
diamidino-2-phenylindole (DAPI) (Molecular Probes-Invitrogen). Fluorescent images 
were obtained with a DMRA2 fluorescent microscope (Leica Microsystem) and merged 
with IMAGEJ software (National Institutes of Health). The percentage of cells with 
translocation of the NF-κB to the nucleus was determined through the analysis of a 
minimum of 600 cells in each condition. 
110 
 
3.9 Rho GTPases activation assay 
 
Human moDCs were FBS-starved for 24h, to set the basal state of the GTPase 
activation, and then treated under various conditions. Cell lysates (0.6 mg/mL of total 
protein) were prepared and the Rac1 and Cdc42 activation was determined using the G-
LISA Activation Assay Biochem Kit (Cytoskeleton), according to the manufacturer’s 
instructions. The principle behind the assay is, in brief, a classical ‘sandwich’ ELISA: a 
Cdc42- or Rac1-GTP-binding protein is immobilized (from manufacture) on the wells of 
a 96-well plate. Active, GTP-bound Cdc42 or Rac1 in moDCs cell lysates were 
recognized and bound by the immobilized protein on the wells. A secondary, Rac1- or 
Cdc42-specific antibody with horseradish peroxidase conjugate (HRP) conjugate closes 
the ‘sandwich’ and allows colorimetric detection after substrate addition. The final 
reaction was photometrically measured by absorbance at 490 nm. In parallel, positive 
(Rac1 or Cdc42 protein) and negative (no protein) controls were also assayed. The 
amounts of activated Rac1 or Cdc42 (arbitrary units) were based on the optical density 




3.10 Determination of α2,6-sialylated proteins 
 
3.10.1 SNA-affinity protein separation 
 
In order to isolate the α2,6-sialylated proteins, we performed lectin affinity 
chromatography assays. For that, 5 x 108 moDCs were lysed in 5 mL RIPA buffer (Sigma 
Aldrich Chemical Co.). The SNA-agarose column (EY Labs) column was then 
equilibrated with PBS, according with the manufacturer’s instructions and 3 mL of lysate 
was applied to the column to bind. The non-bound fraction was eluted with 6 mL PBS 
and the bound fraction was eluted with 3 mL of elution buffer (0.1 M lactose in PBS). All 
fractions (non-bound and bound) were collected. After sample elution, the column was 
extensively washed and regenerated with 20 mL of a 1.2M NaCl solution. 
The collected bound fraction was concentrated from a 3 mL suspension volume to a 
700 μL volume using an Amicon Ultracel 3K column and the separation efficiency was 
assessed by SDS-PAGE and western blot. 
 
3.10.2 SDS-PAGE and lectin western blot 
 
The SNA+ positive fraction was run on a 12.5% SDS-PAGE gel, using 25 μg of 
protein/lane (as quantified by the Bradford method). The gel was transferred to a PVDF 
membrane (Bio-Rad) using a semi-Dry transfer unit (General Electric), for 1h, according 
to the manufacturer’s instructions. The membrane was then blocked for 1h, at room 
temperature, with a 1x PBS + Tween 0.1% (PBS-T) + 1x Carbo-Free (Vector Labs) 
solution, washed and undergone a 2-step blotting: first, a 1h incubation with SNA-
digoxigenin (1:1000 dilution) in PBS-T 0.1% + 10 mg/mL BSA, with double washing; 
second, a 1h incubation with anti-digoxigenin-HRP (Roche Diagnostics) (1:20000) 
dilution) in PBS-T 0.3% + 10 mg/mL BSA, with double washing. The blotted membrane 
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was then incubated with Immobilon chemo-luminescent substrate (Millipore Co.) and as 
above described (section 3.7). 
3.10.3 MALDI TOF/TOF assay 
Glycoprotein samples were separated by SDS-PAGE on 12.5% polyacrylamide gels 
and the bands revealed by Coomassie. The bands of interest were manually excised 
and digested in-gel with trypsin. Briefly, they were washed three times with 25 mM 
ammonium bicarbonate/50% acetonitrile (ACN), one time with ACN and dried. Twenty-
five μl of 10 μg/mL sequence grade modified porcine trypsin (Promega) in 25 mM 
ammonium bicarbonate were added to the dried gel pieces and the samples were 
incubated overnight at 37 °C. Extraction of tryptic peptides was performed by adding 
10% formic acid (FA)/50% ACN (3×) being lyophilized in a SpeedVac (Thermo Fisher 
Scientific). Tryptic peptides were ressuspended in 15 μL of a 0,5% acetonitrile/1% TFA 
solution. 
3.10.4 Protein Identification and Data Mining 
Protein identification was performed as previously described by Vitorino et al (Vitorino 
et al., 2010). Tryptic digests were separated with a C18 Pepmap (Dionex) column on an 
Ultimate 3000 (Dionex/LC Packings) nano-HPLC and fractions were collected with a 
Probot (Dionex/LC Packings) directly onto a matrix-assisted laser desorption ionization 
(MALDI) plate. The MALDI-TOF/TOF (time-of-flight) mass spectrometry (MS) analysis 
was performed on a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems). The MS 
spectra acquired were processed and analyzed by the Global Protein Server Workstation 
(Applied Biosystems). Protein identification was achieved with a search performed 
against the Swiss-Prot protein database for Homo sapiens. N-Glycosylation in human 
proteins was predicted by use of the NetNglyc 1.0 server 
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(http://www.cbs.dtu.dk/services/NetNGlyc), an artificial neural network that examines the 
sequence context of Asn-Xaa-Ser/Thr (where Xaa is not Pro) sequences. O-
Glycosylation was predicted by use of the NetOglyc 3.1 server 
(http://www.cbs.dtu.dk/services/NetOGlyc) that produces neural network predictions of 
mucin-type GalNAc O-glycosylation sites in mammalian proteins (Julenius et al., 2005). 
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3.11 Statistical analysis 
When necessary, data were analyzed for statistical significance using the Student’s 
t-test and ANOVA One-way at 95% confidence level, as appropriate, using GraphPad
Prism versions 4.0, 5.0 and 6.0 (GraphPad Software, Inc., La Jolla, CA, U.S.A). 
Correlations between variables were tested using the Spearman correlation analysis. All 
data were expressed as means of standard errors of independent assays, i.e. using cells 









4.1 Sialylation profiling of DCs  
4.1.1 Characterization of sialylation in DCs  
There are increasing evidences that sialic acid plays a role in the innate and adaptive 
immune response. For instance, T cells depend on O-glycan α2,3-sialylation for 
migration to the periphery and mice from ST6Gal-1-/- mice present impaired humoral 
response (Hennet et al., 1998;Priatel et al., 2000a). Sialic acid usually terminates 
glycosidic structures and is, for that reason, a likely candidate to participate in the 
modulation of several biologic processes (Varki, 2008). As such, we hypothesized that 
terminal sialic acid influences the main DC immune functions. 
To understand this, we first analyzed the profile of cell surface sialylation during the 
in vitro moDC generation from monocytes. For this purpose, we have first examined the 
surface sialylation pattern in monocytes and respective derived immature DCs, at 2 days-
interval during differentiation, using the following specific glycan-recognizing proteins: 
- the Sambuccus nigra lectin (or agglutinin) (SNA) – which recognizes mainly sialic
acid α2,6-linked to lactosamine (6′ sialyl-Galβ1,4GlcNAc); 
- the Maackia amurensis lectin(or agglutinin) (MAA) lectin recognizes mainly sialic
acid α2,3-linked to lactosamine (3′ sialyl Galβ1,4GlcNAc) or, to a lesser extent, linked to 
Galβ1,3GalNAc; 
- the Arachis hypogaea lectin (PNA, from ‘peanut’ agglutinin), a lectin specific for the
Core 1 structure of the O-linked chains (Galβ1,3-GalNAc, also known as T antigen). 
SNA binding studies showed that monocyte surface had a low binding density of such 
a structure, which increased during differentiation into moDC, reaching a maximum at 
day 6 of differentiation (Fig. 4.1), suggesting a higher ɑ2,6-sialic content in moDCs N-
glycans. MAA binding increased dramatically during the beginning of the moDC 
differentiation (maximum at day 2), decreasing slightly until moDCs were fully 
differentiated (Fig. 4.1), suggesting that monocytes present a low density of α2,3-linked 
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sialic acid, when compared with moDC. On the other hand, the overall reactivity of PNA 
was much lower than shown by previous lectins and it increased slightly during the 
differentiation process (Fig. 4.1). PNA binding could be hindered by sialylation of the 
galactose or of the GalNAc residues in the T antigen. 
 
Fig. 4.1 - Lectin binding to the cell surface of monocytes (CD14) along its differentiation into DCs. Results are the mean 
fluorescence intensity (MFI) obtained by flow cytometry of at least four independent assays. SNA lectin results are 
represented in grey, MAA in white and PNA in black. 
 
4.1.1.1 Sialyltransferase expression alterations during moDC differentiation  
To investigate the molecular bases of the sialylation changes accompanying the 
moDC differentiation, we studied the mRNA expression of relevant sialyltransferases 
(STs). When a marked upregulation of the ST gene expression was observed, we also 
analyzed the enzyme activity level, using specific substrates. For the gene expression 
two parameters were considered: the relative mRNA levels (Fig. 4.2A, 4.2C) and, for 
differentiation experiments, the expression relative to the monocytes’ expression (Fig. 
4.2B, 4.2D).  
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4.1.1.1.1 STs involved in α2,6-sialylation of N-linked chains 
The most relevant enzyme involved in ɑ2,6-sialylation of lactosamine, giving rise to 6’ 
sialyllactosamine (6′ sialylGalβ1,4GlcNAc) is by far ST6Gal-1. Although a second 
ST6Gal has been cloned (Takashima et al., 2002;Krzewinski-Recchi et al., 2003), we 
didn’t find any level of expression in moDCs and ST6Gal-2 was not further considered.  
As revealed by real time PCR analysis, the level of ST6Gal-1 mRNA expression 
increased during moDC differentiation (p < 0.01), closely paralleling the increase of SNA 
reactivity (Fig. 4.2C and D). Nevertheless, the major correlation is found between the 
ST6Gal-1 expression and the ST activity (r=0.98, p=0.017), measured with the ST6Gal-
1-specific acceptor, asialotransferrin (Dall'Olio et al., 2006) (Fig. 4.2E). Altogether, these
results indicate that moDC differentiation is characterized by a marked increase of 
ST6Gal-1 gene expression, thus resulting in increased enzyme activity and increased 
α2,6-sialylation of cell surface lactosaminic termini.  
4.1.1.1.2 STs involved in α2,3 sialylation of N-linked chains 
The α2,3-sialylated lactosaminic chains can be sialylated by, at least, three different 
STs – namely ST3Gal-3, -4 and -6. MAA staining of DCs was positive, showing that 
these structures are expressed by DCs, with their expression increasing during moDC 
differentiation. 
The pattern of ST3Gal-4 expression by moDCs (Fig. 4.2B) resembles the changes of 
MAA reactivity, although this correlation is not statistically significant (p=0.360) and the 
ST3Gal-4 mRNA appears to be expressed at a low level (Fig. 4.2A). On the other hand, 
the expression of ST3Gal-3 and -6 mRNA is higher, but shows little changes during 
differentiation. This finding suggests that ST3Gal-4 contributes to the α2,3-sialylation of 
lactosaminic chains in differentiating monocytes, but the contribution of ST3Gal-3 and -
6 remains open.  
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4.1.1.1.3 STs involved in α2,3-sialylation of O-linked chains  
The ɑ2,3-sialylation of galactose residues present in core 1 O-glycans is mediated by 
ST3Gal-1, -2 and -4 sialyltransferases. According to the real time PCR analysis, besides 
the above mentioned ST3Gal-4 upregulation, both ST3Gal-1 and -2 genes are also 
upregulated during moDC differentiation with ST3Gal-1 showing a significant increased 
expression (p<0.05) (Fig. 4.2B). To corroborate the increased expression of the 
corresponding enzymes, we have tested the ST activity using Galβ1,3GalNAc-O-benzyl 
as an acceptor. The ST activity towards the core 1 structures increases during the moDC 
differentiation process (Fig. 4.2E). These observations could, in some way, justify the 
observed low reactivity of PNA, but not its slight increase. It is possible that, at that stage, 
cells are already saturated with sialylated Galβ1,3GalNAc O-glycans (sialyl-T antigens) 
and, in this context, any increase in α2,3-ST expression will have a negligible influence. 
In fact, we have observed that moDCs dramatically increased their reactivity with PNA 
lectin after sialidase treatment (Fig. 4.2F), evidencing a significant content of O-linked 
Galβ1,3GalNAc masked by sialic acid in these cells. 
4.1.1.1.4 ST involved in α2,6-sialylation of O-linked chains.  
As shown in Fig. 4.2C, amongst the genes coding for STs able to catalyze the α2,6-
sialylation of the GalNAc residues present on O-glycans (ST6GalNAc-1, -2, -3 and -4), 
ST6GalNAc-4 is the highest expressed, followed by ST6GalNAc-2 and 4. ST6GalNAc-1 
relative mRNA level was very low (<0.01‰ of β-actin/GAPDH) and was not considered 
further (Fig. 4.2C). ST6GalNAc-3 was fairly expressed in monocytes, but its level 
decreased during moDC differentiation. Given the ST6GalNAc-4 high mRNA expression 
(Fig. 4.2D) and its restricted substrate specificity, recognizing only sialylated 
Galβ1,3GalNAc O-glycans (sialyl T antigen) (Harduin-Lepers et al., 2000), it is likely that 
disialyl-T antigens are expressed by monocytes and moDC.  
123 
Fig. 5.2 – Alterations in sialylation profile during differentiation of monocytes into moDCs. (A, B, C and D) Relative mRNA 
level and relative expression of α2,3-sialyltransferases (A, B) and ɑ2,6-sialyltransferases (C, D) genes. The mRNA 
expression level of each gene relative to the endogenous controls, β-actin and GAPDH, expression (A, C) was measured 
from samples collected each 2 days during the differentiation of monocytes (CD14) into DCs (day 2, 4, 6 and 8) and during 
DC maturation with IFN-γ , IL-1β, TNF-α and LPS. The relative expression compares the expression of a given gene at 
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day 2, 4, 6 and 8 relative to the respective expression in monocytes and upon DC activation with IFN-γ, IL-1β, TNF-α and 
LPS, relative to control, immature DCs at day 8 (B, D). The results are the mean of 4 independent assays. *Data from 
ST3GalNAc-3 expression at minimum and omitted from the graphs; 
(E)- Level of sialyltransferase activity using asialotransferrin and Galβ1,3GalNAcα1-O-Benzyl glycoside as acceptor 
substrates. The activity was assessed in sample homogenates collected at two days intervals during the differentiation of 
monocytes (CD14, control) into DCs (day 2, 4, 6 and 8). The results represent the mean of, at least, 4 independent assays.  
Mice liver homogenates (M) were used as assay control; 
(F) PNA lectin staining of moDCs prior and after sialidase treatment, as assessed by flow cytometry. The results represent 
the mean of 11 independent assays. **** p < 0.0001 
 
 
4.1.1.2 Maturation induces changes in the sialylation profile of moDC 
To test the influence of maturation in the sialylation profile, we separately stimulated 
moDC with cytokines that act as diverse pro-inflammatory mediators, namely, TNF-α, IL-
1β, LPS or IFN-γ.  
LPS and IL-1β stimuli lead to an increased SNA reactivity, contrarily to IFN-γ and 
TNF-α, which promote a lower SNA reactivity, suggesting the additional expression of 
α2,6-sialylated lactosamines in the former (Fig. 4.3A). Nevertheless, the ST6Gal-1 gene 
expression (Fig. 4.3B) and ST activity towards asialotransferrin (Fig. 4.3F) decrease 
upon all the stimuli and both parameters are highly correlated (r=0.98, p=0.017). MAA 
reactivity is not significantly affected upon maturation (Fig. 4.3A), although the 
expression of ST3Gal-2 and -4, which are involved in the synthesis of MAA ligands, 
decreases with maturation (Fig. 4.3C). This apparent inconsistency can be explained 
considering that the glycosyltransferases-product relationship is not necessarily linear. 
In fact, the level of an oligosaccharide product can be regulated at multiple levels, 
including the action of glycosyltransferases competing for the same acceptor and the 
action of glycosidases. On the other hand, the ST3Gal-1 expression increases with all 
maturation stimuli, except TNF-α (Fig. 4.3C), and it is significantly correlated with ST 
activity for Galβ1,3GalNAc-O-benzyl acceptor (r=0.97, p=0.040). Accordingly, following 
IL-1β, LPS or IFN-γ stimulation, the PNA reactivity decreases slightly (Fig. 4.3A), 
suggesting moDC carry out de novo synthesis of sialylated T antigens. 
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Fig. 4.3 – Alterations in sialylation profile during maturation of moDCs (A) Lectin binding to cell surface of immature 
moDCs (Control) and DC maturated with IFN-γ, IL-1β, TNF-α and LPS. Results are the mean fluorescence intensity (MFI) 
obtained by flow cytometry of at least four independent assays. SNA lectin results are represented in grey, MAA in white 
and PNA in black. 
(B, C, D and E) Relative mRNA level and relative expression of α2,3-sialyltransferases (B and C) and α2,6-
sialyltransferases (C and D) genes. The mRNA expression level of each gene relative to the endogenous controls, β-actin 
and GAPDH, expression (B and D) was measured from samples collected during DC maturation with IFN-γ, IL-1β, TNF-
α and LPS. The relative expression compares the expression of a given gene upon DC activation with IFN-γ, IL-1β, TNF-
α and LPS, relative to control, immature DCs at day 8 (C and E). The results are the mean of, at least, 4 independent 
assays. *Data from ST3GalNAc-3 expression at minimum and omitted from the graphs.
(F)- Level of sialyltransferase activity, using asialotransferrin and Galβ1,3GalNAcα1-O-Benzyl glycoside as acceptor 
substrates. The activity was assessed in sample homogenates collected during DC maturation with IFN-γ, IL-1β, TNF-α 
and LPS, as described in the Materials and Methods section. As control (C) condition, fully differentiated, immature 
moDCs were used. The results represent the mean of, at least, 4 independent assays. Mice liver homogenates (M) were 
used as assay control. 
4.1.1.3 Discussion 
The importance of sialic acid in the innate and adaptive immune responses is 
becoming increasingly evident. It is known that the surface α2,6- and α2,3-sialylation of 
B and T cells is modulated according to the cell differentiation and maturation (Moody et 
al., 2003;Marino et al., 2004). DCs are essential to orchestrate the immune response 
mediated by lymphocytes. However, many DC features, such as the sialylation role, are 
still poorly understood.  
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In this subsection, we showed that DCs express significant amounts of sialylated 
structures during differentiation from monocyte precursors and that said 
expression correlates with the expression level of specific sialyltransferases 
during differentiation. 
The analysis of the ST gene expression demonstrated that all α2,3- and almost all 
α2,6-ST genes are expressed. Clearly, the α2,3- and α2,6-sialylation profile of 
monocytes and moDCs is a commitment of several STs encoded by different genes.  
We have observed an increased expression of α2,3-sialylated O-glycans and α2,6- 
and α2,3-sialylated N-glycans during the differentiation of monocytes into moDCs. It is 
known that during moDC generation the cell suffers profound mechanism changes, 
including the acquisition of specific features such as increased capacity of antigen uptake 
and the expression of antigen presenting molecules (MHC class I, MHC class II and CD1 
molecules), adhesion and co-stimulatory molecules (reviewed in (Banchereau and 
Steinman, 1998a)). It is, therefore, likely the observed sialylation changes are related 
with the mechanisms changing during moDC. 
The expression of sialylated molecules in some cases appears to be under the control 
of a single ST, whereas in other cases their biosynthesis appears to be more complex. 
For example, the increase of α2,6-sialylated lactosamines we detected using SNA lectin 
during the moDC differentiation clearly relates with the increased sialyltransferase 
activity on asialotransferrin and the increase of ST6Gal-1 transcript. ST6Gal-1 is highly 
expressed in B cells and one of its best known products is the counter receptor of CD22 
(Collins et al., 2002) but its specific substrates in DCs are still unidentified. It is possible 
that, similarly to B cells, this 6′ sialyl-lactosamines are ligands for inhibitory receptors on 
the surface of DCs or effector T cells, during the antigen presentation.  
The increased reactivity with MAA lectin, we observed during moDC differentiation, 
could be attributed to ST3Gal-3, ST3Gal-4 and/or ST3Gal-6. The transcripts of all these 
three enzymes show a tendency toward upregulation during differentiation, but ST3Gal-
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4 high expression at the beginning of moDC differentiation resembles more the level of 
MAA reactivity. It is reasonable to propose that, although ST3Gal-4 may have a higher 
contribution, all three enzymes contribute to the biosynthesis of MAA ligands in 
DCs. The low PNA lectin reactivity together with Galβ1,3GalNAc-O-benzyl acceptor 
enzymatic assays indicate that differentiating moDCs express the Core 1 structure of the 
O-linked chains (T antigen) masked by sialic acid. The T antigen can be sialylated in 
α2,3-linkage to Gal by at least three different sialyltransferases, namely ST3Gal-1, -2 
and -4, yielding the sialyl-T antigen which, in turns, can be further sialylated by 
ST6GalNAc-1, -2, -3 or -4, generating the disialyl T-antigen (reviewed in (Dall'Olio and 
Chiricolo, 2001)). According to the real time PCR analysis, all the genes coding for 
enzymes involved in the α2,3-sialylation of T antigen undergo upregulation during moDC 
differentiation, suggesting the expression of this structure. During moDC generation, the 
ST3Gal-1 expression variations are more similar to the ST activity towards 
Galβ1,3GalNAc-O-benzyl acceptor. This enzyme is known to exhibit a higher acceptor 
substrate selectivity towards O-linked oligosaccharides of glycoproteins (Kitagawa and 
Paulson, 1994) than ST3Gal-2 and ST3Gal-4, accepting preferentially glycolipids and N-
glycans, respectively (Kitagawa and Paulson, 1994;Kim et al., 1996). Therefore, it is 
likely that the ST3Gal-1 gene is the major responsible for the α2,3-sialylation of T 
antigens in moDC. In addition, the increased expression of ST3Gal-1 during the 
stimulation of moDCs is significantly correlated with the ST activity over the T antigen, 
indicating an enhanced content of these sialylated structures. Nevertheless, masking by 
sialylation does not appear to be the major mechanism of regulation of T antigen 
expression in differentiating moDC, as the PNA reactivity does not decrease (as one 
could expect) but, rather, slightly increases. This means that, in moDCs, the main 
regulation of the T antigen probably occurs at the level of peptide:GalNAc transferases 
and/or of β1,3-galactosyltransferase (Brockhausen, 1999).  
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The STs expressed in differentiating moDC, involved in the α2,6-sialylation of the 
GalNAc residue of the sialyl-T structure, ST6GalNAc-2, -3 and -4, show opposite 
behaviors, being the first two downregulated and poorly expressed, and the latter slightly 
upregulated during differentiation. Hence, it is expected that the moDC differentiation 
process poorly affects the expression of the disialyl-T antigen.  
The biosynthesis of sialyl-Lex, the functional motif of selectin ligands, requires the 
α2,3-sialylation of lactosamine, followed by the α1,3-fucosylation of 3′ sialyl-lactosamine. 
The sialylation reaction may be mediated by ST3Gal-4, -6 and, to a lesser degree, 
ST3Gal-3 (Okajima et al., 1999). The expression of selectin ligands has been 
demonstrated in DCs derived from bone marrow (Kieffer et al., 2001) and we have also 
observed sialyl-Lex antigens in moDCs (Silva et al., 2011). In neutrophils, ST3Gal-4 was 
found to play the major role (Ellies et al., 2002), although, in this work, ST3Gal-4 
exhibited a relative low mRNA level in monocytes and moDCs (Fig. 4.2a), whereas 
ST3Gal-6 is probably the main ST involved in the biosynthesis of sialyl Lex in these cells. 
Nevertheless, further studies are necessary to investigate this assumption.  
We have analyzed the influence of maturation stimuli in the sialylation pattern of 
moDC. We used several inflammatory stimuli, namely TNF-α, IL-1β, LPS and IFN-γ, 
known for activating DC to polarize T cells towards a Th1 profile, yet with only known 
slight phenotypical or functional differences (Ardavin et al., 2001). According with the 
lectin reaction patterns, the major moDC phenotype difference after maturation was 
found in the expression of α2,6-sialylated lactosamines, with each stimulus leading 
to distinct expression of these structures. Regarding the ST gene expression, all these 
stimuli lead to a downregulation of ST6Gal-1 and ST3Gal-4 while upregulating ST3Gal-
1. Another research group has recently reported that tolerogenic, immature DCs have a
high α2,6-linked sialic acid density, which decreases after stimulation with a cytokine 
cocktail (IL-6, IL-1β, TNF-α and PGE2) (Jenner et al., 2006). Concomitant with our 
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results, these authors have also found that ST6Gal-1 is downregulated after stimulation, 
indicating that this is probably a common pattern of the moDC maturation. It is known 
that the DC maturation leads, generally to the downregulation of the antigen-uptake 
machinery, upregulation of adhesion and co-stimulatory molecules and peptide-MHC 
complexes density on DC cell surface and ultimately the polarization of different T cell 
subsets (Banchereau and Steinman, 1998b). Based on these facts, it can be assumed 
that the observed expression changes of ST3Gal-1, -4 and ST6Gal-1 may be 




4.1.2 DC subtypes and tissue distribution in ST3Gal-1- and ST6Gal-1-deficient 
mice 
 
Given our previous observations relating DC differentiation and sialylation, namely, 
the modification of sialylation during monocyte to moDC differentiation and maturation, 
we sought to find its functional impact and, ultimately, why these alterations occurred.  
DCs are generated in bone marrow from a common myeloid progenitor and, in later 
stages of differentiation, they migrate to different peripheral tissues where they perform 
their functions (Shortman and Naik, 2007). Given the known influence of 
glycosylation/sialylation in DC migration (Le Marer and Skacel, 1999;Yakubenia et al., 
2008), we hypothesized that sialylation alterations may, thus, translate into 
alterations in DC function, and that one of the first observable alterations in vivo 
would be alterations in DC subtype’s tissue distribution. The chosen DC subset 
markers were, at the time of this work, the accepted standards for DC subset analysis. 
We first tested the distribution of lymphoid (CD8α+), plasmacytoid (CD45R/B220+) and 
conventional (CD11b+) within mouse DC (CD11c+ I-Ab +) subsets in blood, spleen and 
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lymph nodes of ST3Gal-1-/- and ST6Gal-1-/- mice. Interestingly, we found differences in 
the ST3Gal-1-/- mice, which presented not only an increased percentage of total DCs, 
but also a significant inferior percentage of CD8α+ DCs and, conversely, increased 
number of B220+ DCs in the three analyzed sources (Table 4.1). With the exception of 
B220+ DCs in the spleen of ST6Gal-1-/- mice, DC from these mice didn’t show any 
significant alteration in tissue distribution and subset quantity, compared with wild type 
mice.  
Table 4.1. Distribution of dendritic cell subsets in ST3Gal-1-/- and ST6Gal.-1-/- mice compared with wild-type control 
mice. The values of statistical significance were obtained by comparison of the knocked-out mouse strains with the wild-
type mice in the same tissue. DCs, dendritic cells; WT, wild-type; DCs were considered CD11c and MHC II positive 
cells. N indicates the number of mice used for each determination. * p < 0.05, ** p < 0.01, *** p < 0.005 
Tissue N % DCs1 
% Lymphoid DCs 
(CD8α+)2 
% Plasmacytoid DCs 
(CD45/B220+)2 
% Conventional DCs 
(CD11b+)2 
Blood 
WT 8 0.938 ± 0.08 4.400 ± 0.88 23.94 ± 2.16 7.353 ± 0.79 
ST3Gal-1-/- 6 
1.208 ± 0.09 
*p = 0.044
0.7183 ± 0.32 
** p = 0.002 
43.03 ± 3.62 
** p = 0.002 
8.500 ± 2.26 
ST6Gal-1-/- 10 0.797 ± 0.06 4.435 ± 0.51 17.98 ± 1.20 5.535 ± 0.69 
Spleen 
WT 6 6.426 ± 0.89 11.12 ± 1.09 25.19 ± 2.13 25.65 ± 4.94 
ST3Gal-1-/- 7 
11.82 ± 1.04 
** p = 0.004 
7.300 ± 1.30 
* p = 0.048
40.56 ± 5.56 
* p = 0.048
36.44 ± 2.28 
ST6Gal-1-/- 11 5.074 ± 0.72 8.071 ± 0.89 
32.10 ± 1.52 
* p = 0.025
30.13 ± 3.66 
Lymph 
nodes 
WT 7 3.042 ± 0.47 10.19 ± 1.61 35.79 ± 3.45 28.18 ± 6.82 
ST3Gal-1-/- 6 
7.220 ± 0.44 
*** p = 0.0002 
3.720 ± 1.81 
* p = 0.032
54.80 ± 5.10 
* p = 0.015
42.09 ± 6.65 
ST6Gal-1-/- 9 3.690 ± 0.75 9.929 ± 1.98 41.11 ± 1.97 34.16 ± 6.24 
1 Percentage related to total leucocytes; 2 Percentage related to total DCs. 
4.1.2.1 Discussion 
Lymphocytes, granulocytes and neutrophils from ST3Gal-1-/- and ST6Gal-1-/- mice 
have been the object of several studies (Hennet et al., 1998;Priatel et al., 
2000a;Nasirikenari et al., 2006;Nasirikenari et al., 2010) but, as far as we know this is 
the first reported characterization of their DCs. By studying the distribution of lymphoid, 
132 
plasmacytoid and conventional DC subsets in blood, lymph nodes and spleen, based on 
the expression of specific markers, we have found significant differences in DC 
population. ST3Gal-1-/- mice presented a significantly lower percentage of CD8α+ 
DCs. In contrast, both ST3Gal-1-/- and ST6Gal-1-/- show increased number of B220+ 
DCs in the periphery (Table 4.1).  
The results here presented corroborate our hypothesis that sialic acid content may 
influence DC tissue distribution. Deficiencies in ST3Gal-1 and ST6Gal-1 result in 
significant altered DC subtype populations, underlying the relevance of these 
sialyltransferases in the distribution of specific subsets. The underlying causes of the 
observed alterations can occur in two sequential phases of DC lifecycle: differentiation 
and migration (Lund-Johansen and Terstappen, 1993;Le Marer et al., 1997;Le Marer 
and Skacel, 1999;Alvarez et al., 2008;Winkler et al., 2012).  
Our results show a more relevant role for the ST3Gal-1, which may be justified by its 
role in the synthesis of a prominent selectin ligand - sialyl-Lewis x (sLex). Among the 
three selectins, E-selectin has been described to be a key player both in hematopoiesis 
and migration, by regulating the stem cell balance between quiescence to differentiation 
(Winkler et al., 2012) and the stem cell migration from the BM to the blood and from here 
to the peripheral tissues, especially to the lymph nodes (Alvarez et al., 2008), which could 
explain the differences found in DC populations. In addition, it is relevant to note that 
ST3Gal-1-/- CD8+ lymphocytes have been described as having a similar CD8/B220 
disproportion (as assessed by the Consortium for Functional Glycomics - 
http://www.functionalglycomics.org/glycomics/ImmunologySummaryServlet?pageType
=view&sideMenu=no&summaryId=imm_summary_4_06202003) with a significant 
reduction of the CD8+ T cell population and increase of B220+ population, due to defects 
in T cells maturation (Priatel et al., 2000a). The observed alterations in different DC 
(CD8+ and B220+) population numbers suggests a higher content of plasmacytoid 
(B220+) DCs. From the therapeutic point of view alterations in DC subsets may prove 
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useful in several dysfunctional immune disorders. However, further analysis are required 
to validate the relationship of ST3Gal-1 expression and plasmacytoid DC abundance.  
As for ST6Gal-1, regarding the observed B220+ increase in spleen and lymph node, 
it has been described as influencing the hematopoietic cell precursors detachment from 
the bone marrow during DC differentiation (Le Marer and Skacel, 1999). In line with the 
available literature, the absence of ST6Gal-1 may, thus, also inhibit DC precursor 
detachment from the BM matrix, lowering circulating DC levels and hampering blood to 
peripheral tissue DC transition. This, for the same adhesion properties and over time, 
would lead to DC accumulation in the spleen and other SLOs. 
In this context, our results contribute to existing evidence, further enlightening the 
role of ST3Gal-1 (more relevant) in these stages of differentiation, specifically as 
a regulator of DC population homeostasis and tissue distribution. Using the KO 
model, the absence of these STs in our assays is similar to the downregulation of these 
STs upon maturation, but taken to an extreme. Since, as we’ve presented in section 
4.1.1, after inflammation induction we observe a downregulation of STs, the KO model 
could, biologically, could be organically interpreted as permanent state of inflammation, 
inducing the release of a higher number of DCs to migrate towards an insult site. This 
may be of particular relevance regarding exogenously induced hematopoietic stem cell 
ablation, as during chemotherapy, where immune cell repopulation is required. 
4.1.3 Sialylation-induced DC maturation 
DC maturation is a natural process arising from the encounter of DC with extracellular 
stimuli (antigenic or not), for instance, during endocytosis/phagocytosis. Curiously, both 
endocytosis and maturation seem to be co-dependent, since an increase of 
maturation is accompanied by a decrease in endocytic activity in moDCs. Knowing 
the overwhelming majority of the stimuli interacts with DCs via cell surface receptors, we 
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questioned if a change in the sialylation content of DCs would alter their 
maturation status, thus impacting their endocytosis performance. To confirm this 
suppositions, we also analyzed the maturation levels of sialidase-treated and non-
treated moDCs, submitted to endocytosis or not, via the expression of maturation 
markers, namely, MHC class II, CD80 and CD86. We also tested moDCs which had not 
undergone endocytosis (assays performed at 4°C in the presence of ovalbumin) or were 
not treated (assays performed at 37ºC in the presence of “mock” (heat-inactivated) 
sialidase) (Fig. 4.4). DC maturation was unlikely to be the result of heat-stable factors in 
the sialidase preparation, such as bacterial endotoxins, because the control DCs 
treated with heat-inactivated sialidase did not show decreased endocytosis. 
According to our results, the expression level of these markers was significantly elevated 
in the cells treated with sialidase, although, except for MHC I, with less extent (Fig. 4.4A). 
The sialidase treatment alone (4°C condition) caused a significant increase of MHC I and 
MHC II expression in moDCs, as well as the expression of co-stimulatory molecules, 
CD80 and CD86 (Fig. 4.4B) – a change even more pronounced when followed by 
endocytosis (37°C condition). We also observed the same cumulative effect of the 
sialidase treatment and phagocytosis on moDCs maturation, as represented in Fig. 4.4C, 
translated in higher expression of MHC II expression. Besides MHC molecules, human 
moDCs prominently express other antigen-presenting molecules, the CD1 family (CD1a, 
-b and -c) that mediate the presentation of lipid and glycolipid antigens to T cells (Porcelli 
et al., 1998). However, the trafficking of such molecules to the plasma membrane is 
generally independent of the DC maturation stage (van der Wel et al., 2003), except in 
the case of strict stimulus (Martino et al., 2006;Rigano et al., 2007), so we haven’t 






Fig. 4.4 – Maturation levels in sialidase-treated and mock-treated human moDCs, following endocytosis and phagocytosis. 
(A and B) Sialidase treatment increases expression of major histocompatibility complex class II (MHC II) and class I (MHC 
I) (A), CD80 and CD86 (B) in human moDCs after sialidase treatment and endocytosis. Sialidase treated (T) or mock-
treated (i.e. inactivated sialidase) (MT) moDCs were pulsed with the endocytic agent ovalbumin and incubated for 1h at 
37°C or 4°C (control). After the endocytosis assay, the expression of MHC II (HLA DR), MHC I (HLA ABC) and the co-
stimulatory molecules CD80 and CD86 were evaluated by flow cytometry. The results are the mean of the mean 
fluorescence intensity (MFI) values of at least 3 individual experiments ± SEM. Significantly different values (* p<0.05 or 
** p<0.01 paired Student’s t-test) were observed for all the maturation markers employed, comparing sialidase-treated 
with mock-treated human moDCs, either in cells that had internalized ovalbumin (assay at 37°C) or in the control cells 
(assay at 4°C). (C) moDCs were treated with sialidase or left untreated, and then incubated or not (control) with E. coli. 
The expression of MHC was evaluated by flow cytometry after staining moDCs with anti-human APC-MHC-II (HLA-DR) 
antibodies. Values represent the means of the MFI values from, at least, 6 independent assays. 
 
In the previous section (section 4.1.1), we studied the sialyltransferases involved in 
human moDC sialylation and highlighted the significant contribution of ST3Gal-1 and 
ST6Gal-1 (Videira et al., 2008). Now, having observed that sialidase treatment induced 
DC maturation, we wished to further inspect the type(s) of sialylation whose 
shortage was (or were) involved in this maturation process by focusing on ST3Gal-
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1-deficient and ST6Gal-1-deficient DCs. To address that question, we assayed ex vivo 
DCs from mice deficient in either these sialyltransferases for a more mature phenotype. 
For that, we quantified the expression of MHC II and CD86 in DCs present in blood, 
lymph nodes and spleens of ST3Gal-1-/- and ST6Gal-1-/- mice. The MHC II expression 
was higher in ST6Gal-1-/- DCs when compared with WT mice, but no apparent 
differences were observed regarding CD86 expression (Table 4.2).  ST3Gal-1-/- mice 
presented insignificant variation of the MHC II and CD86 expression (Table 4.2).  
To determine whether the increased expression of MHC II in ST6Gal-1-/- DCs could 
be linked to one particular DC subset, we focused our analysis on the lymphoid, 
plasmacytoid, and conventional DC subsets, based on the DC expression of CD8α, 
B220/CD45RA and CD11b markers, respectively (Table 4.2). Upon examination of each 
of these subsets for the expression of MHC II and CD86, we noted that the increased 
MHC II expression – detected in the total ST6Gal-1-/- DCs – was mainly present in the 
plasmacytoid (B220+) DC subset (Table 4.2). Moreover, no specific sialylation absence 
showed an impact on the expression levels of the co-stimulatory marker CD86 in all the 
analyzed tissues’ DCs. These results suggest that the more mature phenotype found in 
DCs from ST6Gal-1-/- mice, was mainly related – but not limited – to the plasmacytoid 
DC subset. 
These last observations and the observations initially described on this section on 
sialidase-treated human moDCs after endocytosis, led us to clarify the contribution of 
ST3Gal-1- and ST6Gal-1-mediated sialylation on those previous observations. In 
practical terms, we wished to confirm the increased intensity of MHC II in bone marrow-
derived DCs (BMDCs) from ST3Gal-1-/- or ST6Gal-1-/- mice before and after endocytosis. 
Bone marrow cells were used due to its higher generation yield, when compared to an 
ex vivo isolation from mice, as previously mentioned (subsection 1.1.1.2.1). Generally, 
as expected from the ex vivo DC analysis, ST6Gal-1-/- BMDCs showed a higher 
expression of MHC II than WT (Fig. 4.5A). However, contrasting with the analysis patent 
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in table 4.2, ST3Gal-1-/- BMDCs showed a significant and even higher expression of MHC 
II (Fig. 4.5A). 
Table 4.2 – Maturation analysis through expression of major histocompatibility complex class II (MHC II) and CD86 in 
ST3Gal-1-/- and ST6Gal-1-/- mouse dendritic cells, compared with wild-type control, in blood, spleen and lymph nodes. 
The values are expressed in mean ± SEM of mean fluorescent intensity (MFI) units, as defined by the flow cytometer. 
DCs were considered CD11c+ and MHC II+ cells. N indicates the number of mice used for each determination. 1Values 
are related to total DCs. 2Values related to plasmacytoid (B220+) DC subset. 
N MHC II1 MHC II (B220+ DCs)2 CD861 
Blood 
WT 8 157.0 ± 40.7 117.3 ± 20.6 22.78 ± 0.55 
ST3Gal-1-/- 6 236.0 ± 59.5 166.0 ± 60.2 20.19 ± 1.79 
ST6Gal-1-/- 10 
280.4 ± 37.9 
* p = 0.046
272.2 ± 26.9 
*** p = 0.0005 
26.55 ± 2.01 
Spleen 
WT 6 575.9 ± 61.4 784.8 ± 94.0 66.55 ± 5.37 
ST3Gal-1-/- 7 554.0 ± 140.5  654.2 ± 92.5 65.65 ± 5.23 
ST6Gal-1-/- 11 
903.1 ± 91.0 
** p = 0.009 
1047.0 ± 93.8 62.75 ± 7.28 
Lymph 
nodes 
WT 7 975.6 ± 105.8 864.3 ± 153.0 209.4 ± 47.60 
ST3Gal-1-/- 6 1465.0 ± 366.8 1197.0 ± 171.0 198.0 ± 14.40 
ST6Gal-1-/- 9 
1498 ± 74.5 
** p = 0.007 
1810.0 ± 177.0 
** p = 0.003 
245.0 ± 44.50 
To investigate whether the increased MHC II expression was exclusively derived from 
the endocytosis or if it was present, originally, in the ST6Gal-1-/- and ST3Gal-1-/- BMDCs, 
we have analyzed the MHC II expression in the control BMDCs which had not undergone 
endocytosis. The intensity of MHC II fluorescence also tended to be higher in both control 
ST6Gal-1-/- and ST3Gal-1-/- BMDCs than control WT BMDCs (Fig. 4.5A, 4°C condition). 
After endocytosis (Fig. 4.5A, 37°C condition), either WT, ST3Gal-1-/- or ST6Gal-1-/- 
BMDCs presented two distinguishable BMDC subpopulations based on the mean 
fluorescence intensity of MHC II (MHC IImedium and MHC IIhigh) (Fig. 4.5B). When gating 
both subpopulations and comparing the intensity of MHC II fluorescence, the MHC IImedium 
subpopulation was approximately identical, in the three analyzed BMDCs. However, the 
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MHC IIhigh population of both ST6Gal-1-/- and ST3Gal-1-/- BMDCs presented a slightly 
increased intensity of MHC II fluorescence (Fig. 4.5B and C). The percentage of MHC 
IIhigh subpopulation of BMDCs compared to the MHC IImedium subpopulation was about 
10% and 5% higher in ST6Gal-1-/- and ST3Gal-1-/- BMDCs than in their WT homologues, 
respectively, but the differences were not statistically significant (Fig 4.5D and E)). 
Regarding the corresponding endocytosis values of these populations, the MFI of FITC-
labelled ovalbumin of the MHC IImedium subpopulation was approximately identical, in the 
three analyzed BMDC types, whereas the one from the MHC IIhigh population of both 
ST3Gal-1-/- and ST6Gal-1-/- BMDCs presented a decreased intensity [49% (p = 0.0075) 
and 78% of fluorescence intensity relative to WT, respectively] (Fig 4.5F and G). 
Collectively, these data indicate that BMDCs deficient for ST6Gal-1 or ST3Gal-1, 
upon endocytosis, show an augmented number of fully mature BMDCs 




Fig. 4.5 - Major histocompatibility complex (MHC) expression is increased in ST3Gal-1-/- and ST6Gal-1-/- bone marrow-
derived dendritic cells (BMDCs). The MHC II expression of ST3Gal-1-/- (ST) and ST6Gal-1-/- (SG) BMDCs was analyzed 
by staining with PE-anti I-Ab, after exposure to FITC-conjugated ovalbumin and incubation at 37°C or 4°C, as described 
in the Materials and methods. Control assays were performed in parallel with wild-type (WT) BMDCs. (A) The results are 
expressed as the mean fluorescence intensity (MFI) ± SEM of ST3Gal-1-/- BMDCs (six mice) and ST6Gal-1-/- BMDCs 
(seven mice). Significantly different values, related to WT BMDC, were observed at 37°C for the ST3Gal-1-/- BMDCs (* 
p<0.05). (B) Scatter plot showing that, after endocytosis (at 37°C), BMDCs express different levels of MHC II, defining a 
MHC IImedium and a MHC IIhigh subpopulation. The data shown correspond to analysis of one representative population of 
BMDCs (either from WT, ST3Gal-1-/- or ST6Gal-1-/- mice) acquired by flow cytometry. (C) MHC IImedium subpopulations of 
ST3Gal-1-/- and ST6Gal-1-/- BMDCs are no different from WT BMDCs in terms of MHC II expression, while MHC IIhigh 
subpopulations showed increased MHC II expression. The results are the means ± SEM of the MFI for MHC II for the 
MHC IImedium and MHC IIhigh subpopulations, gated as described in (B). The left axis corresponds to the MHC IImedium 
subpopulation and the right axis corresponds to the MHC IIhigh population. (D and E) After ovalbumin endocytosis, the 
MHC IIhigh BMDC subpopulation from ST6Gal-1-/- (ST) (D) mice or ST3Gal-1-/- (SG) (E) mice is larger than its WT 
counterpart. The results are expressed as the mean of the percentage of the different BMDCs subpopulations relatively 
to the total BMDCs ± SEM of ST3Gal-1-/- BMDCs (N≥5), ST6Gal-1-/- BMDCs (N≥5) and WT BMDCs (N≥5). (F and G) The 
amount of ovalbumin endocytosed by the MHC IIhigh subpopulations is also lower than the one from its WT homologues. 









































































results are expressed as the mean fluorescence intensity (MFI) ± SEM of ST3Gal-1-/- BMDCs (N≥5), ST6Gal-1-/- BMDCs 
(N≥5) and WT BMDCs (N≥5). 
 
4.1.3.1 Discussion 
With the recent progress of glycobiology it is becoming evident that sialic acid is 
relevant to the immune responses and the evaluation of sialylation-modification at the 
leucocyte surface contributes to a better understanding of the immune functions. We 
have previously demonstrated that the expression of surface sialylated structures was 
modulated during moDC differentiation and maturation, and we suggested that changes 
in sialylation are related to specific DC functions (Videira et al., 2008). Nevertheless, 
because of the characteristic complexity of DCs, the identification of the specific nature 
and role of these structures is still difficult to predict.  
Here we show that the sialylation shortage, generated by sialidase treatment, induces 
an increased expression of MHC molecules and co-stimulatory molecules at the cell 
surface of human moDCs. To obtain a better insight, we studied DCs that were deficient 
for ST3Gal-1 and ST6Gal-1. As mentioned before, these two sialyltransferases are 
probably the most relevant for moDCs sialylation, they are significantly expressed by 
human moDCs and have a good correlation between their mRNA expression levels and 
the α2,3- and α2,6-sialylation profile during differentiation and maturation process of 
human DCs (Videira et al., 2008). In addition, the data derived from these mouse 
models with ST6Gal-1 or ST3Gal-1 deficiencies suggest that the overall extent of 
cell surface sialylation, and not of specific sialylated glycoprotein entities, may be 
the important contributing factor, hinting at a possible synergy of several cell 
surface receptors.  
In this study, as part of this possible synergistic effect, specific differences in DC 
maturation and physiological distribution were noted between ST6Gal-1-/- compared to 
ST3Gal-1-/- and WT animals (see Table 4.2). These differences may indicate functional 
specializations for sialic acid linkages specified by the two sialyltransferases, which, in 
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their turn, may be dependent on the presence of several cell surface molecules as 
targets for sialylation or as recognizants of sialylated structures. Indeed, human moDCs 
express several receptors, such as Siglecs (see section 1.3.1), that recognize sialic-acid-
containing glycans, and may have preferences for either the Sia(α2,3) linked to 
Galβ1,3GalNAc or the Siaα2,6 to Gal(β1,4)GlcNAc structures synthesized by ST3Gal-1 
or ST6Gal-1, respectively (Varki and Angata, 2006;Varki and Gagneux, 2012). Siglecs 
have the potential to interact not only in trans with sialylated ligands found in other cells, 
but also in cis with ligands found at the same cell surface (Varki and Angata, 2006;Varki 
and Gagneux, 2012). The physiological functions of the majority of Siglecs are still 
unknown. However, because they contain immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs), they are expected to have a major role in controlling immunity. 
Furthermore, additional glycan-recognizing receptors exist, and removal of the sialic acid 
residues, normally residing as the outermost residue of glycans, may uncover ligands for 
other immunologically relevant carbohydrate-binding molecules such as galectins. Some 
members of galectins, a family of lectins that recognize β-galactosyl-containing 
glycoconjugates, have been implicated in both innate and adaptive immune responses 
(Stowell et al., 2008). The biological functions of the galectins expressed by DCs are 
probably complex and are not well understood. Interestingly, it was found that galectins 
(namely galectin-1 and -9) could, indeed, induce DC to mature, with important adhesion 
properties modulated in the case of galectin-1 (Dai et al., 2005;Fulcher et al., 2006;Zhuo 
and Bellis, 2011). In this scenario, it is difficult to anticipate the extent of molecules and 
mechanisms that are engaged when DCs are treated with sialidase.  
One point that should be addressed is the possibility that the observed DC maturation 
could be the result of the engagement of the innate receptors because the sialidase, 
used throughout this study, was of bacterial origin and could be contaminated with 
microbial products, particularly endotoxins. Nevertheless, to rule out that possibility, 
control assays were performed with a sialidase, whose activity was inactivated by heat, 
preserving eventual endotoxins present. 
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Considering the fact that differential sialylation can influence the accessibility of MHC 
epitopes to antibodies that recognize them (Liberti et al., 1979;Boog et al., 1989), it would 
be possible that the increased antibody binding to MHC molecules, observed in 
sialidase-treated DCs, was the result of an enhanced antibody affinity rather than of 
augmentation of the number of binding sites of such molecules. However, it should be 
noted that the increased immunogenicity of sialidase-treated DCs is confirmed not only 
by the increased binding of anti-MHC antibodies, as shown by flow cytometry, but also 
at functional level (transcription of specific cytokines and T cell priming proficiency) as it 
will be shown in the following section 4.4. In addition, qualitative differences in the extent 
of antibody binding to MHC II molecules were also observed among ST6Gal-1-/- and 
ST3Gal-1-/- DC subsets, corroborating the idea that clearance of cell surface sialic acids 
is indeed involved in an elevated expression of MHC II at the cell surface. 
Our findings strongly suggest that sialic acid linkages mediated by different 
sialyltransferases have distinct influence on diverse, fundamental DC functions, 
such as DC maturation. More specifically, sialic acid deficiency, either in ST3Gal-
1-/- and ST6Gal-1-/- BMDCs or in human sialidase-treated moDCs, triggers DC 
maturation.  
 
4.1.4 Intracellular activation pathways of DCs and potentially involved 
sialylated receptors 
 
Whether desialylation is naturally present (due to sialyltransferases deficiencies in 
gene expression, deletion or glycan moiety shedding) or artificially induced (by sialidase-
mediated cleavage), we have previously observed (in subsection 4.1.3) that it induces 
mechanisms of maturation in DCs. We then asked whether induced DC maturation 
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was a consequence of the signaling transduction induced by cell membrane, 
sialylated receptors.  
In mammalian species, the Mitogen Activated Protein Kinases (MAPKs) signaling 
transduction pathway is involved in all aspects of the immune response, and cell death 
when immune function is complete (Dong et al., 2002;Nakahara et al., 2006). The MAPK 
signaling pathway is a highly conserved pathway that is involved in diverse 
cellular functions, including cell proliferation, cell differentiation and apoptosis. 
After recognition of PAMPS by PRRs, it transmits activating or inhibitory signals via 
phosphorylation from the cell surface down to their cytoplasmic substrates, being also 
translocated into the cell nucleus, where many MAPK targets, such as transcription 
factors, are found. This pathway comprises three major signaling pathways: the 
Extracellular signal-Regulated Kinases 1 and 2 (ERK 1/2) or p44 pathway, the p38 
pathway and the c-Jun kinase (JNK) pathway (Chang and Karin, 2001;Johnson and 
Lapadat, 2002), all of them known to be involved in the maturation and allostimulation 
mechanisms. 
Particularly, MAPKs have been shown to be involved in DC maturation (Sato et 
al., 1999;Arrighi et al., 2001;Agrawal et al., 2003;Nakahara et al., 2004). Thus, given the 
importance of this signalling pathway, we used a two-step approach: first, we sought to 
clarify which of the intracellular signalling pathways was activated following sialic acid 
removal by performing western blots of the major MAPK; second, we determined the 
potentially involved cell-surface receptors using the data obtained in the previous step 
and crossing it with MALDI-TOF/TOF mass spectrometry of SNA lectin binding (α2,6-
sialylated) receptors. This α2,6-sialylation linkage was chosen given the Clostridium 
perfringens sialidase (used throughout out studies) preference for the Siaα2,6Gal 
substrate (Bouwstra et al., 1987). Other sialidases with other substrate preferences 
(such as the Siaα2,3Gal linkage) could be used, such as sialidase from Salmonella 
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typhimurium. However, given our interest in the receptors affected by the C. perfringens 
sialidase action, we purified and analyzed the α2,6-sialylated ones. 
We focused our study on the activation of ERK 1/2 signalling pathways. The MAPK 
respond to a wide range of stimuli (including regular cell handling), thus care was taken 
to reduce the activation level of these enzymes (as described in the Materials and 
Methods section of this dissertation). Western blotting techniques, using antibodies with 
specificities for phosphorylated (active form) and native ERK 1/2, were used to determine 
the amount of activated and total MAPKs. Using the soluble fraction of lysates of 
immature, sialidase-treated human moDCs, we consistently observed a higher level 
of ERK 1/2 activation in sialidase treated moDCs, when compared with the positive 
and negative controls or the inactivated sialidase (‘mock’)-treated moDCs (Fig. 
4.6). Interestingly, even in the presence of the inactivated enzyme with no assessable 
sialylation reduction, the activation level was higher than the negative control (untreated 
cells) (Fig. 4.6B). These results confirm that sialic acid absence induces MAPK 
signalling pathway, namely, the ERK pathway, although the induction of other 
pathways should not be discarded. 
After confirmation of the receptor-mediated induction of maturation, we sought to find 
the receptors potentially affected by sialidase treatment and subsequently involved in the 
maturation induction. For this purpose, we performed mass spectrometry analysis of 
α2,6-sialylated proteins isolated by SNA lectin affinity chromatography from immature 
moDCs lysates. After successful separation by SNA lectin affinity chromatography, the 
samples were analyzed by MALDI-TOF/TOF, with posterior data mining of the obtained 
results. The resulting list of α2,6-sialylated glycoproteins, presented in the Annex I 
(section 7), shows a variety of cell surface targets of sialidase action, both cytoplasmic 
and membranar, and it includes proteins involved in metabolism, gene expression, 
signalling, antigen presentation and actin organization. But, most interestingly, are the 
presence of sialylated proteins that are described as triggering intracellular signalling 
145 
mechanisms, such as αM-integrin (CD11b) and β2-integrin (CD18), commonly integrated 
in macrophage-1 antigen (Mac-1) (also known as complement receptor 3 (CR3)). The 
next step in the determination should be, hence, the isolation of these integrins, confirm 
its sialylation status and functional relation, in DCs, with the ERK signalling pathway or 
others. 
Fig. 4.6 – Expression of ERK 1/2 and phosphorylated-ERK 1/2 MAPK in moDCs. A) The ERK 1/2 activation level of 
moDCs was determined by Western blot analysis of soluble phase of lysates of moDCs of different conditions: C – control 
(untreated) (negative control); I – inactivated sialidase-treated (‘mock’-treated); T – sialidase treated; L – LPS-stimulated 
moDCs (positive control). The left blot image is obtained by incubation of the membrane with the separated, transferred 
proteins with anti-phosphorylated-ERK 1/2 (pErk) antibody, whereas the right blot image is the same membrane, after 
pErk antibody removal, incubated with anti-total ERK 1/2 antibody, thus giving the total intracellularly available amount of 
ERK 1/2. This image is representative of, at least, four (4) assays. B) Using the image acquisition software, the blot 
density could be translated into a numeric value, which was used to calculate the presented activation ratio given by the 
reason between the ‘pErk’ and the corresponding ‘Erk’ blot density values, for each of the conditions tested. 
4.1.4.1 Discussion 
The maturation mechanisms are a key feature of the DC immunobiology. As 
previously mentioned, maturation marks a new phase in the DC lifecycle: from a 
“passive”, information collecting phase characterized by high endocytic potential and 
constant environment screening, to an “active”, stimulatory phase. This new phase is 
mainly characterized by upregulation of the antigen presenting and co-stimulatory 
molecules, inflammatory cytokines’ secretion and homing to the lymph nodes. 
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Simultaneously, the obtained antigenic information is processed and the cytoplasm and 
cell membrane is rearranged (adopting its hallmark dendrites). Maturation is normally 
initiated after recognition of PAMPs or other “foreign”/“non-self” antigens by PRRs or 
other immune receptors such as Fc receptors or complement receptors. Recognition of 
antigens includes the intracellular translation of this recognition by a cascade of signals, 
such as the MAPK pathways. These pathways affect many processes in DC 
immunobiology: for instance, on mature DCs, p38 and JNK are involved in increased 
surface antigen expression, inflammatory cytokine production and allostimulatory 
capacity; the ERK signaling pathway positively regulates inflammatory cytokine 
production and shows a tendency to negatively regulate IL-12 production and the 
phenotypic maturation of moDCs. (Puig-Kroger et al., 2001;Nakahara et al., 2006). 
Observations have previously been made regarding on the impact of desialylation in 
monocytes’ intracellular signaling. Desialylation of glycoconjugates on the surface of 
purified monocytes led to activation of ERK 1/2 (Stamatos et al., 2004a). The results 
here obtained, regarding MAPK activation on moDCs, follow the same trend and clearly 
point to the activation of signal translation after change of the glycosidic charge of DC 
surface proteins. After exogenous sialic acid removal by an α2,6-selective sialidase, the 
observed maturation is associated with a clear increase of the phosphorylated (activated) 
form of ERK 1/2. This increase may justify some of the changes induced by sialidase 
action given the functional impact ERK has in DC immunobiology, namely the increase 
in IL-6 and slight increase of TNF-α and IL-1β. In DCs, evidence has also been produced 
showing that the various signalling pathways are differently elicited in a stimuli-
dependent way (Karakhanova et al., 2010) inducing different effects. This also raises the 
hypothesis that sialidase-treatment may specifically induce maturation mechanisms via 
other MAPK signalling pathways other than ERK 1/2. In order to confirm these 
hypothesis, studies of sialidase treatment-induced maturation in the remainder MAPK 
pathways (namely, p38 and JNK) in the presence of selective MAPK inhibitors should be 
performed. A hypothetical p38 and JNK activation may account for the remainder 
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maturation features, namely, for the marked mature phenotype changes observed. 
Considering that p38 has a higher impact in DC immune functions (Nakahara et al., 
2006), one might speculate that even a small variation in p38 activation could be 
nonetheless sufficient to override the slightly negative influence caused by ERK 
activation, or even being synergistically needed. Such cases have been observed in 
other contexts: given two apparently opposed signals transmitted via ERK 1/2 and p38, 
the latter only prevailed in the presence of the apparently antagonistic ERK signal 
(Karakhanova et al., 2010). 
The most amazing feature of the MAPK signalling pathways is the fact that, knowing 
the vast variety of receptors that potentially induce the signalling pathways, all the signals 
elegantly converge to one MAPK, and from that point onwards, are divergently translated 
in a large variety of translocated nuclear transcription factors (Fig. 4.7). Still, knowing the 
type of induced signalling pathway may valuably hint at the number and type of receptors 
involved in the studied phenomenon.  
Using an overlapping/complementary reasoning, we decided to determine the 
potential targets of sialidase by mass spectrometry, using state-of-the-art MALDI-
TOF/TOF after lectin affinity separation. Crossing the results represented in Annex I 
(section 6) with the receptor families described as inducing ERK and p38 signalling 
pathways lead us to focus our attention on the αM- (CD11b) and β2- (CD18) integrins. It 
is well established that integrins depend on a conformational change in order to change 
to their active form, leading, among other effects, to intracellular signalling cascades. 
CD11b and CD18 integrins dimerize to form the complement receptor CR3, known to be 
expressed on DCs (Reis et al., 2007;Li et al., 2011), being the dominant phagocytotic 
complement receptor (Sandor et al., 2013). αMβ2 integrins bind an array of ligands that 
do not share canonical binding sequences and are expressed exclusively in leukocytes 
with functions in adhesion, especially during the formation of the immunological synapse, 
transendothelial migration of immune cells and interaction with the extracellular matrix 




Fig. 4.7 – ERK 1/2 MAPK intracellular signalling pathway, from a G-Protein Coupled Receptor starting point. The figure 
depicts the major signalling cascades featuring direct/indirect (full line/dotted line, respectively) stimulation or inhibition 
(full-line, arrow point or blunt point, respectively). In Cell Signalling Technology, Inc. website 
(http://www.cellsignal.com/common/content/content.jsp?id=pathways-mapk-g). 
 
Integrins need to be activated by intracellular signals derived from the activation of 
other ITAM-bearing cell surface receptors or chemokine receptors, in what is known by 
“inside-out” mode, thus acquiring the correct conformation for functional binding 
(Kellermann et al., 2002;Takagi and Springer, 2002). However, in a not totally clear 
mechanism, known to require the Syk tyrosine kinase (Abram and Lowell, 2009), 
integrin binding to ligand also induces an “outside-in” activation, triggering 
intracellular signalling cascades leading to ERK activation (Whitlock et al., 
2000;Streuli, 2009). Hence, it is reasonable to suppose that CD11b and CD18 integrins 
can be likely candidates through which sialic acid absence/removal may have a 
crucial impact in DC immune functions. Nevertheless, future studies should be carried 
out to confirm this hypothesis, and consolidate sialic acid’s position as an important 
immune modulator.  
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4.2 Sialylation influence in DC endocytosis and phagocytosis 
4.2.1 Endocytosis 
DCs use several pathways to capture antigens including macropinocytosis, receptor 
mediated endocytosis and phagocytosis. The former is described as being exclusive of 
DCs and activated macrophages but is not present in monocytes (Sallusto et al., 1995). 
The latter two require cell-surface receptors such as C-type lectins, mannose receptors, 
Fc receptors or integrins, with phagocytosis also uptaking large molecules or cells 
(Banchereau et al., 2000;Norbury, 2006). In order to verify whether the presence of sialic 
acid was critical for the endocytosis performed by monocytes and moDCs, we have 
tested the uptake capacity for three endocytic agents after treating both types of cells 
with sialidase. Ovalbumin, Lucifer Yellow and dextran are all described, in DCs, as being 
uptaken by macropinocytosis, although a number of receptors have also been identified 
as involved in the internalization of ovalbumin (Kikuchi et al., 2005), whereas dextran is 
uptaken mainly through mannose receptor (Sallusto et al., 1995). In this work, we 
observed that monocytes treated with sialidase present an increased capacity to 
uptake ovalbumin and dextran, when compared with non-treated monocytes, as 
determined by a higher mean fluorescence intensity (MFI), (1.3- and 2-fold, respectively) 
when analyzed by flow cytometry (Fig. 4.8 and Table 4.4). The uptake of Lucifer Yellow 
by monocytes was almost negligible and unaffected after sialidase treatment. By 
contrast, when compared with the controls, sialidase-treated moDCs showed a decrease 
in the capacity to uptake all the endocytic tracers tested (Fig. 4.8). According to the MFI 
analysis, after sialidase treatment, the uptake of ovalbumin, Lucifer Yellow and dextran 
is significantly decreased by 0.76, 0.75 and 0.85-fold, respectively (Table 4.4). We have 
also determined the cell percentage which underwent endocytosis in the assays 
performed with the different endocytic tracers and found no significant differences after 




Fig. 4.8 - Effect of sialidase treatment on the uptake capacity of immature moDC (upper panels) and monocytes (lower 
panels). Cells were incubated for 1 h with ovalbumin (a, d), dextran (b, e) and Lucifer Yellow (d, f), as described in Materials 
and methods and analyzed by flow cytometry. Bold and solid lines represent, respectively, sialidase treated and non-
treated cells incubated at 37°C. Grey histograms represent control cells incubated at 0°C. Data shown are a representative 
of one of different experiments, whose statistical analysis is represented in Table 4.4. 
 
Table 4.4. Statistical analysis of the effect of sialidase treatment on the endocytosis capacity of moDC and monocytes. 
Values are the mean fluorescence intensity (MFI) and percentage (%) of fluorescent cells and represent the mean  SD 
of at least 4 independent assays. The values from the corresponding control cells incubated at 0°C were subtracted. 
 Sialidase-treated  Non treated  Ratio§ 
MFI % MFI % MFI % 
MoDC 
Ovalbumin 1239.3  150.4 68.1  8.4 1638.0  231.1 70.1  5.2 0.76** 0,98 
Lucifer Yellow 203.3  34.0 32.4  7.1 285.9  45.2 37.6  7.6 0.75* 0,86 
Dextran 319.7  45.2 35.4  3.8 372.1  46.2 35.6  5.9 0.85*** 0,99 
Monocyte 
Ovalbumin 134.3  20.5 79.0  1.7 98.9  18.5  80.0  2.7 1.35* 0,98 
Lucifer Yellow 11.0  1.9 87.0  2.1 10.1  1.8 90.0  1.2 1.10  0,96 
Dextran 94.7  1.9  80.0  6.2 46.5  1.6 86.5  3.3 2.00*** 0,92 
§The ratio corresponds to the values from sialidase treated cells divided by the values of non-treated cells. *p< 0.05; 
**p< 0,01;***p< 0,005. 
 
A possible explanation for this observation is that, as we’ve previously seen, sialidase 
treatment triggered DC maturation, a process known to be accompanied by diminished 
antigen uptake. The results supporting this hypothesis were previously mentioned in 
section 4.1.3, where we explored the relation between sialidase treatment and 
maturation. 
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Since we demonstrated that, at least, ex vivo ST6Gal-1-/- DCs presented increased 
expression of MHC II (as patent in section 4.1.3), we then asked whether ST6Gal-1-/- or 
ST3Gal-1-/- DCs also had impaired endocytic capacity. To answer this, similar to the 
described in subsection 4.1.3, we used DCs differentiated in vitro from bone marrow 
collected from mice deficient for these STs. 
We performed FITC-conjugated ovalbumin endocytosis assays with ST3Gal-1-/- and 
ST6Gal-1-/- BMDCs. As a control condition, similar assays with WT BMDCs were always 
run in parallel. The percentage of BMDCs that endocytosed ovalbumin was roughly 
identical to that of WT BMDCs (± 62%). However, and most notably, the fluorescence 
intensity of FITC-labelled ovalbumin was reduced in BMDCs from ST3Gal-1-/- and 
ST6Gal-1-/- mice [61% (P = 0.0078) and 76% of fluorescence intensity relative to WT, 
respectively] (Fig. 4.9). These observations demonstrate that ST3Gal-1-/- and, to a lesser 
extent, ST6Gal-1-/- BMDCs endocytose less ovalbumin than WT BMDCs. 
The observations here presented confirm the previously obtained data using 
sialidase-treated moDCs. However, we did not check the endocytosis performance of 
ST3Gal-1-/- and ST6Gal-1-/- monocytes. The data would have allowed us to give a deeper 
insight on the specific sialylation influence on the different endocytic processes on 
monocytes. 
Fig. 4.9 - Endocytic ability of ST3Gal-1-/- and ST6Gal-1-/- 
bone marrow-derived dendritic cells (BMDCs). The 
ST3Gal-1-/- or ST6Gal-1-/- BMDCs were incubated, for 30 
min, with 0.05 mg/ml FITC-conjugated ovalbumin, as described 
in the Materials and methods. Control assays were performed 
in parallel with wild-type (WT) BMDCs. The mean 
fluorescence intensity (MFI) values obtained at 4°C were 
subtracted from the 37°C values. The results are expressed as the 
ratio of the MFI ± SEM of ST3Gal-1-/- BMDCs (N = 6) or 
ST6Gal-1-/- BMDCs (N = 7) related to WT BMDC. 
Significantly different values were observed for the endocytic 
capacity of ST3Gal-1-/- BMDC (**P < 0.01) 
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4.2.2 Phagocytosis 
4.2.2.1 Desialylated moDCs and mature moDCs (m-moDCs) exhibit an improved 
phagocytic capacity for E. coli 
Phagocytosis is a major form of endocytosis, dedicated to the elimination of whole 
bacteria and/or viruses and, thus, with greater visibility and impact upon the clearance 
of pathogens. Although DCs are not professional phagocytic cells, like macrophages, 
they are still able to phagocytose, with this endocytosis type being a major antigen 
source to process and present them to T cells. As such, to complete the study of the 
aforementioned endocytic processes, we sought to study the implications of sialic 
acid mediating phagocytosis. 
As previously performed with endocytosis, in order to better investigate whether 
removal of cell surface sialic acids affected phagocytosis, we analyzed the capacity of 
sialidase-treated moDCs to internalize a K12-derived strain of E. coli. After confirmation 
of successful α2,6- and α2,3-desialylation of moDCs (by SNA and MAA staining, 
respectively) (fig. 4.10C), flow cytometry analysis revealed that desialylated moDCs 
phagocytosed significantly more E. coli (MFI = 499.90 ± 66.92) than fully sialylated 
moDCs (MFI = 382.80 ± 38.94) (Fig. 4.10A) – a fact contrasting with the previously 
found reduction in DC endocytic levels. Sialidase intervention also resulted in an 
increase in the number of moDCs that internalized bacteria (73-74% ± 3.9 as 
compared with 58-92% ± 3.8 in the control assays) (Fig. 4.10D).  
An established hallmark of DC maturation is the loss of internalization capacity 
(Sallusto et al., 1995;Garrett et al., 2000), so, as expected, pre-stimulation of moDCs 
with LPS decreased phagocytosis in ~60% (Fig. 4.10A). To assess the effect of sialidase 
treatment in already mature moDCs (m-moDCs), we desialylated LPS-stimulated m-
moDCs. However, sialidase treatment significantly lowered the typical decrease in 
phagocytic capacity of LPS- or TNF-α-matured moDCs (Fig. 4.10A and 4.10E). The 
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observed differences in phagocytosis were exclusively the result of antigen 
internalization and could not be attributed to differences in adhesion of the antigen to the 
cell surface, based on quenching experiments with trypan blue and negative control 
assays performed at 4°C. Analysis of phagocytosis by confocal microscopy further 
confirmed the intracellular localization of the fluorescent bacteria (Fig. 4.10B and 4.10F). 
Taken together, these observations, therefore, suggest that phagocytosis can be 
altered by the removal of sialic acids regardless of the maturation state of the DCs. 
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Fig. 4.10. Sialidase treatment improves phagocytosis by human monocyte-derived dendritic cells (moDCs) and mature 
moDCs (m-moDCs). Immature moDCs and lipopolysaccharide-matured (LPS) m-moDCs were treated with sialidase (dark 
gray bars on A, B, C and D) or left untreated (light gray bars on A, B, C and D), following incubation with fluorescent 
Escherichia coli, for 1h at 4°C or 37°C. (A) moDCs were stained with Sambucus nigra lectin (SNA; recognizing ɑ2,6-sialic 
acids) and Maackia amurensis lectin (MAA; recognizing ɑ2,3-sialic acids) lectins following sialidase treatment and 
analyzed by flow cytometry. Values represent the means of the MFI of at least three independent assays. Statistical 
significance (*p < 0.05) refers to the difference between untreated and sialidase-treated moDCs. (B) The phagocytic 
capacity by moDCs and m-moDCs was evaluated by flow cytometry as the mean fluorescence intensity (MFI) and values 
obtained at 4°C were subtracted. Values represent the means of at least 20 independent assays. Statistical significance 
(**p < 0.001 or ***p < 0.0001) refers to the difference between untreated and sialidase-treated moDCs or m-moDCs (C) 
Sialidase treatment improves the % of human moDCs that phagocytosed E. coli.  moDCs were treated with sialidase or 
left untreated, following incubation with fluorescent E. coli, for 1 h at 37ºC. The phagocytic capacity by moDCs was 
evaluated by flow cytometry as the % of DCs that phagocytosed E. coli. Values represent the means of at least 10 
independent assays. Statistical significance (***P<0.001) refers to the difference between untreated and sialidase treated 
moDCs. (D) Sialidase treatment improves phagocytosis by human TNF-α-mature moDCs. TNF-α-matured m-moDCs 
were treated with sialidase or left untreated, following incubation with fluorescent E. coli, for 1h at 37°C. The phagocytic 
capacity by moDCs was evaluated by flow cytometry as the fluorescence (MFI). Values represent the means of at least 4 
independent assays. (E) Representative confocal microscopy images showing moDCs with internalized E. coli (green). 
Actin filaments of the moDCs’ cytoskeleton were stained with Phalloidin Alexa Fluor 633 (red). (F) Representative confocal 
microscopy images of detailed Z-staking series of a moDC with their cytoskeleton stained with Phalloidin Alexa Fluor 633 
(red) showing internalized E. coli (green). moDCs were previously incubated with fluorescent E. coli, for 1 h at 37ºC.
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4.2.2.2 Desialylation, moDC cytoskeleton organization and the activation of Rho 
GTPases upon E. coli stimulation 
Depending on the receptors involved, phagocytosis often requires significant 
remodeling of the actin cytoskeleton and the activation of small GTPases of the Rho 
family, namely Cdc42 and Rac1 (Garrett et al., 2000;Shurin et al., 2005). After observing 
that desialylation improves phagocytosis, we asked whether desialylation could affect 
the cytoskeleton organization or increase the level of Cdc42 and Rac1 GTPases 
activation. As shown in Fig. 4.11A, desialylation did not affect the cytoskeleton 
organization of moDCs. However, in the presence of E. coli, these visibly desialylated 
moDCs showed a disorganization of actin filaments with a tendency to aggregate and 
form clusters (Fig. 4.11A). Sialidase treatment did not affect the basal level of active 
Cdc42 and Rac1 GTPases in moDCs (Fig. 4.11B). However, no increase in the activation 
of Cdc42 and Rac1 upon E. coli phagocytosis was observed when the moDCs were 
sialidase-treated (Fig. 4.11B). Together these data indicate that increased 
phagocytosis upon removal of cell surface sialic acids by sialidase was not the 
result of improved moDC cytoskeleton dynamics. 
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Fig. 4.11. Sialidase affects the cytoskeleton organization and the activation of Rho GTPases. Monocyte-derived dendritic 
cells (moDCs) were treated with sialidase or left untreated, and then incubated or not (control) with Escherichia coli for 
15 min at 37°. (A) The moDC cytoskeleton was stained with Phalloidin Alexa Fluor 633 (red) and analyzed by confocal 
microscopy. (B) The Rho GTPase activation level was measured in moDC lysates, as described in the Materials and 
methods section. The level of active Rac1 or Cdc42 (in arbitrary units) is based in optical density values obtained at 490 
nm after subtracting negative control values. Values represent the means of at least four independent assays. Statistical 
significance (*P < 0.05) refers to the difference between control moDCs and moDCs incubated with E. coli.
4.2.2.3 Enhanced phagocytosis mediation by sialic acid moieties 
To further understand how moDCs cell surface sialic acids influence phagocytic 
activity, we started by examining the capacity of desialylated moDCs to internalize E. 
coli in the presence of structural blockers. After hindering α2,6-linked and α2,3-linked 
sialic acids with SNA and MAA lectins, respectively (as an alternative to cleavage of sialic 
acids moieties by sialidase), the E. coli phagocytosis showed a slight tendency towards 
inhibition (Fig. 4.12B). These results suggest that the improved phagocytosis requires 
the removal of sialic acid rather than the simple masking of cell surface sialic acid 
by lectins. As such, if covalently linked cell surface sialic acids are, indeed, involved in 
modulation of phagocytic activity, we predicted that restoration of sialic acids should 
undermine the sialidase activation of phagocytosis. For that matter, we studied how 
moDCs phagocytosed E. coli in the presence of free sialic acid. Interestingly, the 
enhanced phagocytosis observed in sialidase-treated moDCs was completely 
abolished in the presence of the unbound sialic acid (Fig. 4.12A). This result was 
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largely reminiscent of previous observations reported by our group regarding the 
presence of a moDC cell surface sialyltransferase activity (Cabral et al., 2010). The 
presence of such a re-sialylation mechanism could, thus, mediate the reconstruction of 
cell surface sialic acid linkages in the presence of the donor substrate cytidine 5′-
monophospho-N-acetylneuraminic acid (CMP-5-NeuAc). Accordingly, we tested if, in the 
presence of CMP-5-NeuAc, the phagocytosis enhancement in desialylated moDCs 
would revert to physiological levels. As expected, the presence of CMP-5-NeuAc 
abolished the improvement of E. coli phagocytosis by desialylated moDCs (Fig. 
12C) through the observed restoration of moDC surface sialylation, thus substantiating 
the idea that sialic acids act as phagocytic modulators.  
A sialic acid-dependent mechanism for the binding of sialylated bacteria to 
desialylated immune cells has been reported (Avril et al., 2006;Carlin et al., 2009;Khatua 
et al., 2010). As the K12-derived E. coli strain used in the present work contains sialic 
acids, we then wished to determine if improved phagocytosis was dependent on the E. 
coli surface sialic acids. As shown in Fig. 4.12D, desialylation of E. coli re-established 
the phagocytosis to levels similar to the control ones suggesting a mechanism of 
phagocytosis requiring the presence of sialic acids in both moDC and E. coli. 
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Fig. 4.12 - Escherichia coli phagocytosis is influenced by sialic acid moieties. Monocyte-derived dendritic cells (moDCs) 
were treated with sialidase or left untreated, and then incubated or not (control) with E. coli for 1 h at 4°C or 37°C. (A) The 
effect of hiding surface a2,6-linked and a2,3-linked sialic acids in phagocytosis was determined by incubating untreated 
moDCs in the absence (control) or in the presence of Sambucus nigra lectin (SNA) or Maackia amurensis lectin (MAA) 
blocking lectins. Values represent the means of MFI of at least three independent assays. (B) The influence of free sialic 
acid on phagocytosis was determined by evaluating the phagocytic capacity of moDCs in the presence (+) or absence (-
) of this sugar. Values, representing phagocytosis, calculated as the percentage (%) of the mean fluorescence intensity 
(MFI; obtained by flow cytometry) normalized with respect to untreated moDCs incubated without free sialic acid. Values 
represent the means of at least five independent assays. Statistical significance (**P < 0.001) refers to the difference 
between sialidase-treated and untreated moDCs. (C) The influence of ectosialyltransferase activity in phagocytosis was 
assessed by conducting the assay in the presence (+) or absence (-) of the sialyltransferase substrate, cytidine 5′-
monophospho-N-acetylneuraminic acid (CMP-5-NeuAc). Values represent the means of MFI of at least five independent 
assays. Statistical significance (**P < 0.001) refers to the difference between sialidase-treated and untreated moDCs. (D) 
The participation of sialic acids from E. coli surface on phagocytosis was determined by comparing the capacity of moDCs 
to internalize E. coli when sialidase-treated (+) or left untreated (-). Values represent the means of MFI of, at least, three 
independent assays. Statistical significance (**P < 0.001) refers to the difference between sialidase-treated and untreated 
moDCs. 
4.2.2.4 Phagocytosis of pathogenic E. coli isolates 
We then asked whether moDC desialylation could improve the internalization of 
pathogenic strains of E. coli. We used different pathogenic E. coli isolates (designated 
here as I, II, III, IV) obtained from urine cultures and hemocultures of patients either with 
a urinary infection or septicemia. As with their non-pathogenic homologues, after 
treating moDC with sialidase, the phagocytosis of all four pathogenic isolates was 
enhanced. In fact, as in the case of the K12-derived strain, an improvement of 29%, 
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29%, 17% and 30% in the phagocytosis of pathogenic isolates I, II, III and IV, 
respectively, was observed when moDCs were treated with sialidase (Fig. 4.13). These 
results suggest not only a role for sialic acid as a modulator of phagocytosis by 
moDCs, but also a potential therapeutic utility against pathogenic E. coli 
infections. 
Fig. 4.13 – Sialidase treatment improves the capacity of monocyte derived dendritic cells (moDCs) to phagocytose 
pathogenic Escherichia coli isolates. moDCs were sialidase-treated or left untreated and incubated for 1h, at 4°C or 37°C, 
with pathogenic E. coli isolates (I, II, III, IV). The phagocytic capacity was evaluated by flow cytometry as the MFI and 
values obtained at 4° were subtracted. Values represent the means of, at least, 10 independent assays. Statistical 
significance (**p < 0.001 or ***p < 0.0001) refers to the difference between sialidase-treated and untreated moDCs. 
4.2.2.5 Improved phagocytic capacity for E. coli of ST6Gal-1-/--mouse BMDCs 
To further document the correlation between cell surface sialic acid and the 
phagocytic capacity of DCs without using sialidases, we used BMDCs harvested from 
sialyltransferase ST6Gal-1-/- mice. As shown in Fig. 4.14, ST6Gal-1-/- BMDCs showed an 
approximately twofold improvement in their capacity to phagocytose E. coli versus 
BMDCs from the WT mice (Fig. 4.14A). An increase of almost twofold on the percentage 
of DCs was also observed (Fig. 4.14B). These results corroborate the data from human 
desialylated moDCs, linking phagocytic capacity with cell surface sialylation status. 
Furthermore, the data suggest a specific contribution of α2,6-sialic acids to this 
process. 
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Fig. 4.14 – BMDC phagocytosis of E. coli. After incubation of BMDCs with FITC-labelled E. coli, as described in Material 
and Methods, the phagocytosis performance of BMDCs from ST6Gal-1-/- (KO) and wild-type (WT) mice was evaluated by 
flow cytometry and compared. Two parameters were quantified and are above represented: (A) the percentage of the 
BMDC population (FITC+ CD11b+ CD11c+ I-Ab+ cells) that effectively phagocytosed E. coli; and (B) the efficiency of DCs 
in E. coli phagocytosis, given by the MFI of the FITC+ DC population. Values represent the means of four (4) experiments. 
Significantly different values were observed regarding the phagocytic capacity of KO BMDC (* p < 0.05) and the fraction 
of phagocytosing KO BMDCs (** p < 0.01).
4.2.3 Discussion 
In our experiments, the endocytic capacity of both monocytes and moDCs was 
affected when the surface sialic acid was removed by sialidase treatment. In the case of 
monocytes, the treatment gives rise to an increased fluorescence intensity of the cells, 
suggesting an increased amount of endocytosed particles by cell; contrarily to the 
moDCs, whose treatment decreases slightly the amount of endocytosed particles. Either 
monocytes or moDCs are able to endocytose dextran and ovalbumin through several 
mechanisms, which include phagocytosis and endocytosis via different groups of 
receptor families, such as Fc receptors, Toll-like receptors and C-type lectin receptors 
(Geijtenbeek et al., 2004). Nevertheless, both cells present distinct distribution of 
endocytic receptors, with DCs presenting a higher content and also specific receptors 
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such as DC-SIGN and DEC-205 (Jiang et al., 1995;Bleijs et al., 2001). In DCs, there is 
also the additional contribution of macropinocytosis, the actin-dependent formation of 
large vesicles for fluid-phase solutes uptake. Macropinocytosis is absent in monocytes, 
which is in accordance with the negligible Lucifer Yellow endocytosis, observed in the 
monocyte endocytosis assays (Fig. 4.8). Since the sialic acid removal affects the uptake 
capacity in an opposite manner in monocytes and moDCs, it could be suggested that 
the reduction in sialylation affects negatively an uptake mechanism exclusive of 
moDC, such as the macropinocytosis, but on the other hand, it promotes a further 
uptake mechanism probably shared by monocytes and moDCs. Considering three 
facts, namely: 1) the results obtained using sialidase-treated human moDCs and the 
ones obtained using ST-deficient mice; 2) that during the maturation of DCs its endocytic 
capacity decreases; and 3) that ST6Gal-1 and ST3Gal-4 enzymes are significantly 
downregulated during maturation (see section 4.1.1.2, Fig 4.3C and E), suggests these 
enzymes may be involved in the DC endocytosis. The downregulation of these STs 
could be associated with the decreased expression of sialylated molecules involved in 
the endocytosis, or, in case of equivalent expression, to the decreased sialylation of such 
molecules leading to its lower activity and, ultimately, to poor DC endocytosis. 
Nevertheless, the information regarding the glycosylation of molecules involved in the 
antigen uptake is still scarce and further studies remain to be performed to better 
understand the role of sialic acid in signaling a specific endocytosis mechanism. 
Antibiotic resistance among Gram-negative pathogens has been on the rise and the 
current gold-standard for the treatment of bacterial infections – the use of antibiotics – is 
under serious threat (Slama, 2008). Pathogenic variants of E. coli are known to easily 
acquire resistance, especially for antimicrobial agents that have long been in use in 
humans. Hence, while the search for new antibiotics continues, there is an urgent need 
for effective combat strategies against risk-associated Gram-negative bacteria. 
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Reinforcement of the immune system through a synergy of cellular stimulation, anti-
microbial action, and long-lasting antibacterial protection is considered an interesting 
choice. Through their potent immunoregulatory capacities, DCs are promising 
therapeutic targets to boost sufficiently robust and long-lasting immunity against 
pathogenic bacteria. Therefore, understanding the mechanisms that modulate the 
pivotal DC–pathogens interaction is, nowadays, a fundamental goal. 
Our results, patent on this thesis, and other recent reports show that human moDCs 
are highly sialylated (Julien et al., 2006;Bax et al., 2007;Trottein et al., 2009), and a 
growing body of evidence has implicated a role for their sialylated structures in the 
modulation of moDC functions (Silva et al., 2012), including endocytosis mechanisms. 
Here, we addressed the question of whether moDC sialic acids are particularly 
relevant for phagocytosis. Physiologically, it is already accepted that cell surface sialic 
acid content can be modulated by endogenous sialidases such as Neu1 (Amith et al., 
2010) and by sialidases from exogenous sources released by pathogenic bacteria or 
viruses during the course of an infection. Regarding phagocytosis, it was reported that 
mouse cell surface Neu1 activates phagocytosis by macrophages and DCs through 
desialylation of cell surface receptors (Seyrantepe et al., 2010). In addition, surface 
desialylation by influenza virus sialidase stimulates the internalization of target virus 
infected cells by mouse macrophages (Watanabe et al., 2004).  
In this section, we reported for the first time that the phagocytosis by human 
moDCs could also be modulated by cell surface sialic acids. We demonstrated that 
sialidase treatment significantly improved E. coli phagocytosis regardless of the 
state of DC maturation. As sialidase treatment led to actin cytoskeleton disorganization 
and did not lead to increased activation of the Rho family of GTPases, we inferred that 
desialylation influenced phagocytosis through an actin-independent mechanism. 
However, further investigations are necessary to fully understand the supportive 
mechanisms.  
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We showed that the enhanced phagocytosis induced by desialylation was 
inhibited by free sialic acid and was dependent on E. coli sialic acids. Moreover, 
this phenomenon was not observed by simply hiding cell surface sialic acid by the use 
of lectins, hinting that actual removal of cell surface sialic acid residues was needed for 
phagocytosis improvement. Concordantly, phagocytosis improvement could be 
reversed by regeneration of cell surface sialic acid linkages by means of an 
ectosialyltransferase activity present on DC surfaces. Of note, we also found that 
desialylation also improved the capacity of moDCs to internalize pathogenic E. 
coli isolates, suggesting the sialidase mechanism to be ubiquitous regarding other E. 
coli. According to the data shown above, this mechanism should be restricted, at 
least, to bacteria that express cell surface sialylated structures. However, further 
studies are necessary to elucidate if this mechanism is E. coli restricted or could be 
extended to other sialylated Gram-negative bacteria. 
One possible hypothesis to explain the sialidase phenomenon is the engagement of 
receptors that become more accessible after sialidase treatment. This mechanism 
hypothesis is supported by previous suggestions that sialylation content, modulated by 
Neu1 sialidase, is a new important parameter controlling interactions between 
macrophage receptors, their ligands and signaling proteins (Seyrantepe et al., 2010). 
Bacterial pathogen-associated molecular patterns (PAMPs) are recognized by a 
variety of pathogen-recognition receptors (PRRs), which include several sialylated 
receptors and receptors that recognize sialylated structures. Toll-like receptors (TLRs) 
recognize several microbial ligands, leading to the activation of intracellular signaling 
cascades. Interestingly, endogenous or exogenous sialidases have an essential role in 
LPS-induced TLR4 activation by cleaving specific sialic acid residues thus making 
PAMPs recognizable (Stamatos et al., 2004b;Amith et al., 2010;Stamatos et al., 2010). 
Sialic acid binding immunoglobulin-like lectins (Siglecs) are receptors that specifically 
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recognize sialic acids and are involved both in endocytosis and cellular signaling 
functions (Lock et al., 2004). Siglecs are usually masked by cis interactions with sialic 
acids expressed on the same cell membrane, which can be unmasked following 
exposure to sialidase or, in some cases, by cellular activation (Crocker et al., 2007). Most 
Siglecs possess cytoplasmic tails harboring immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs) with an important immunoregulatory role. Indeed, some Siglecs from the 
CD33-related family can suppress the TLR dependent production of TNF-α and IL-6 pro-
inflammatory cytokines and enhance the production of the anti-inflammatory cytokine IL-
10 (Ando et al., 2008). On a related note, many pathogens are known to possess, or 
acquire, sialic acid to interact with Siglec-expressing leucocytes thus advantageously 
modulating the immune response (Avril et al., 2006;Carlin et al., 2009;Khatua et al., 
2010). 
Taking these characteristics into account, and considering that E. coli exhibit some 
ligands for some TLRs and/or Siglecs receptors, these are candidate receptors 
involved in the observed improvement of E. coli phagocytosis by desialylated 
moDCs. Nevertheless, it is probable that a complex combination of receptors is 
simultaneously engaged following moDC desialylation resulting in the observed up-
regulation of phagocytosis. Connecting with previous observations of this work, it has 
been reported that integrin αMβ2-mediated phagocytosis is Cdc42- and Rac-dependent 
(Caron and Hall, 1998). Considering this and also the fact that sialidase treatment of DCs 
involves the activation of Cdc 42 and Rac, which correlate with increased E. coli 
phagocytosis, the results described in section 4.1.4 (activation of moDCs’ ERK 1/2 
MAPK following sialidase treatment of these cells) lead us to add to the Siglec 
hypothesis, a functional model that includes sialic acid as a novel modulator for αMβ2 
integrins function. On this model, sialic acid removal would influence these integrins 
conformation/stability to a more avid conformation, leading to activation of Rac 
and Cdc42 and enhanced phagocytosis, and, downstream the signalling pathway, 
165 
activation of ERK 1/2 accounting for the previously mentioned effects mediated 
by this MAPK. 
Our studies with BMDCs deficient for ST6Gal-1, which mediates the synthesis of the 
α2,6-sialyl linkages, strongly implicates the influence of specifically α2,6-sialic acids in 
this process and further suggests a role for the expression of the ST6Gal-1 enzyme in 
regulating DC phagocytic activity. ST6Gal-1 is one of the most highly expressed 
sialyltransferases in human moDCs (see section 4.1.1.1 of this thesis). One of the best 
known products of ST6Gal-1 is the counter-receptor of CD22 Siglec on B cells (Ghosh 
et al., 2006). Besides the humoral responses, the maintenance of myeloid homeostatic 
balance (Nasirikenari et al., 2006;Jones et al., 2010b;Nasirikenari et al., 2010), T cell 
functionality (Amano et al., 2003), and integrin signaling (Woodard-Grice et al., 2008) 
are just a few of the physiological processes that also implicate ST6Gal-1 participation. 
The complete set of specific ST6Gal-1 acceptor substrates is still not identified in DCs 
but it is most likely to involve key α2,6-sialylated receptors or α2,6-sialylated ligands 
engaged in cis interactions with endogenous receptors.  
There is a possibility of E. coli receptors or components actively participating and 
interacting with desialylated moDCs. This possibility is irrelevant because, in this work, 
we adopted an experimental design that involved exclusively heat-killed rather than live 
bacteria.  
Summarizing, in contrast to classical maturation stimuli such as LPS, TNF-α or IL-1β 
(Sallusto et al., 1995), desialylation-triggered maturation does not dramatically abrogate 
endocytosis mechanisms such as macropinocytosis or receptor-mediated endocytosis: 
human or mouse DCs with reduced sialic acid content retain around 70% of their 
endocytic capacity. In terms of phagocytosis, the data from the present study indicates 
that desialylation, and in particular depletion of α2,6-sialic acids, improves the 
capacity of human moDCs to internalize E. coli, independently of their maturation 
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stage. Further studies are still required to illuminate the details of the involved 
mechanisms, but the present work lays the foundation insight for the importance of cell 
surface sialic acids of DC at the critical interface between bacterial challenges and the 
mobilization of host adaptive immune responses.  
We believe that these findings are relevant in adding to the knowledge required for 
the establishment of efficient antibiotic substitutes and immunotherapies, which are 
particularly important in fighting antibiotic-resistant Gram-negative pathogens. 
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4.3 α2,6-sialylation is involved in DC homing to lymph nodes 
DC homing could be described as a multi-step process, including (1) mobilization, (2) 
detachment, (3) interstitial migration, (4) entry into the afferent lymphatics, and (5) transit 
via lymph (Alvarez et al., 2008) (figure 4.15). Most of these steps have continuously 
being found to be strongly influenced by leukocyte glycosylation and the tissue 
glycocalyx. Glycan-mediated processes in leukocyte migration are well described in 
literature and found to be essential in this process. In the case of DCs, this aspect has 
recently started to be studied, with many glycan-mediated interactions being described, 
such as: the Lewis Y antigen-mediated interaction between DC-SIGN and ICAM-2 on 
endothelial walls (Garcia-Vallejo et al., 2008); the binding of the macrophage Mannose 
Receptor to CD44 via chondroitin sulfate side chains in this antigen or to sulfated 
oligosaccharides of blood group Lewis a and Lewis x and sulfated N-glycans of lutropin 
(Leteux et al., 2000;Salmi et al., 2013); and, most notably and common to most innate 
immunity leukocytes, the sialyl Lewis X (sLex) mediated interaction between PSGL-1 and 
P-/E-selectins (Robert et al., 1999a;Bonasio et al., 2006;Silva et al., 2011), a paramount 
interaction in the rolling and tethering stages of the initial homing/migration process in 
high endothelial venules in several tissues. 
However, the role of α2,6-sialylated N-glycans in the migration and/or homing of 
DCs is still unclear. In order to clarify this, end-point DC homing in vivo assays using 
the murine model were performed. In the first group of assays we generally assessed 
DC homing to regional draining lymph nodes, after inflammatory stimulus. Secondly, we 




Fig. 4.15 – DC Trafficking in Peripheral Tissues. This schematic illustrates a proposed model for the interstitial migration 
for skin DCs from the cutaneous microenvironment to the afferent lymphatics en route to the LN. The migratory cascade 
is divided into five discrete steps (clockwise from top left), starting with recognition of a mobilizing signal (inset 1), 
detachment from structural tissue elements (inset 2), trafficking through interstitial space (inset 3), transit through the 
afferent lymphatic endothelium (inset 4), and transit through the afferent lymph vessels (inset 5). Major chemokine-
chemokine receptor (CKRs) pathways and other trafficking molecules controlling DC migration are highlighted. In Alvarez 
D. et al., Mechanisms and Consequences of Dendritic Cell Migration, Immunity, 29, 2008. 
 
In order to evaluate the α2,6-sialylation of N-glycans influence in DC migration on an 
inflammatory context, an Alexa 625-Ovalbumin + alum solution was intracutaneously 
injected in both WT and ST6Gal-1-/- mice scruff region in order to promote inflammation. 
Given that ovalbumin is essentially uptaken by DCs via endocytosis, the migrating 
(mature) DCs present in the draining lymph nodes will be, by this reason, fluorescently 
distinct. After 48h, the regional draining lymph nodes were collected and their resident 
cell population was analyzed by flow cytometry. The results, patent in figure 4.16A, 
clearly show a reduced number of inflammatory DCs present in the lymph nodes of 
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ST6Gal-1-/- mice when compared with their WT counterparts and hinted to a relevant 
role of α2,6-sialylation in DC homing. 
Next, we wanted to evaluate if this functionality is dependent on the N-glycan’s α2,6-
sialylation of DCs or if it is a result of the presence of this type of glycosylation in adhesion 
molecules in the surrounding tissues to which DCs may bind. Our hypothesis was that 
BMDCs derived from ST6Gal-1-/- mice would show impaired homing towards the 
lymph nodes. To test this, LPS-stimulated and fluorescently-labelled BMDCs from WT 
and ST6Gal-1-/- mice were adoptively transferred to other mice, according to the 
conditions described in figure 4.16B.  
The percentage of migrating DCs when there is a sialylation deficiency (ST6Gal-1 -/- 
deficient mice as donor, k/w and k/k conditions) is significantly lower (approximately 
50%) than the percentage of WT BMDC (Fig. 4.16C). But, surprisingly, the same 
significant reduction was also observed when there was α2,6-linked sialic acid 
absence in the recipient mice, being even more statistically significant (p = 0.0049 (w/k 
condition) and p = 0.0051 (k/k condition), Fig. 4.16C). A synergistic effect on the 
sialylation absence in both donor cells and recipient was not observed. As a control, 
labelled, immature BMDCs were also adoptively transferred, in parallel. Comparing the 
ratio of LPS-stimulated migrating BMDCs and unstimulated ones (Fig. 4.16D), 
(maturation control), the total number of DCs present in the regional draining lymph 
nodes in the former condition is higher. 
Together, these results point to a clear role of DCs’ α2,6-sialylation of N-glycans 
in DC homing but it also suggests an equally importance of this sialylation type in 
adhesion ligands exogenous to DCs for functionally effective DC homing. 
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Fig. 4.16 – Migration assays of BMDCs. (A) In situ stimulation of inflammation-driven DC migration. After administration 
of an AlexaFluor 625-Ovalbumin + Alum suspension, the draining lymph nodes of the neck and thorax region were 
removed and the contained leukocytes collected, as described in Materials and Methods. The collected cells were then 
sorted by flow cytometry in order to evaluate the fraction of endocytosing DCs. The results are depicted as the wild-type 
(WT) or ST6Gal-1-/- (KO) DC percentage of total leukocytes collected and analyzed. (B) BMDC homing assay. Adoptive 
transfer of exogenously cultivated, stimulated and fluorescently labelled (PKH 67+) BMDCs was performed as described 
in Material and Methods. represents the ratio of migrating BMDCs to total cDCs (CD11c+ CD11b+ I-Ab+), based on the data 
represented in B), present in the collected regional draining lymph nodes of the tested subjects, normalized to the same 
ratio in the control conditions. These conditions are given as the phenotype of the adoptively transferred BMDCs (donor) 
and the phenotype of the subject receiving the exogenously differentiated BMDCs (receptor): w/w (control condition, not 
represented, equal to 100%) – WT BMDCs transferred to WT receptor; w/k – WT BMDCs transferred to KO receptor; k/w 
– KO BMDCs transferred to WT receptor; k/k – KO BMDCs transferred to KO receptor. C) Immature to mature ratio of
migrating BMDCs. The ratios were calculated between homologue conditions, viz. immature w/w to mature w/w, immature 
w/k to mature w/k, immature k/w to mature k/w and immature k/k to mature k/k.  
Figures represent mean ± SEM of values corresponding to, at least, 5 independent experiments, except in C), which 
correspond to a minimum of 3 individual experiments. Significantly different values were observed in A) the migrated WT 




While glycans have been implied in different aspects of DC migration, the relevance 
of α2,6-sialylated N-glycans in DC homing is still poorly understood. Here, we present 
evidence regarding the importance of this specific type of glycosylation in the DC 
adhesion and migration processes. By showing a clear impairment of DC migration 
wherever an ɑ2,6-sialylation defect is present, either on DCs or in the surrounding 
tissues, our results clearly show that α2,6-sialylation is relevant for DC homing to 
draining lymph nodes. Thus, we suggest that N-glycan α2,6-sialylation is a 
requirement for DC homing during inflammation.  
The natural question at this point is, hence, what are the N-glycosylated, α2,6-
sialylated adhesion molecules and ligands involved in this mechanism, accounting for 
the observed approximate 50% reduction in DC homing.  
Some of the previously mentioned α2,6-sialylated moDC receptors, as determined by 
mass spectrometry (see subsection 4.1.4 and section 6 for results) are also known to be 
involved in the ligation to extracellular matrix proteins or adhesion molecules, such as 
the αMβ2 integrin or the CD44 glycoprotein, and are known to be relevant players in DC 
homing mechanisms (Diacovo et al., 2005). Therefore, sialylation of these receptors may 
also be mediating DC adhesion to endothelium and homing. 
In the terminal phase of myeloid cell differentiation, an increase of cell surface α2,6-
sialylation that correlated with decreased adhesion to the bone marrow stroma was 
reported, in a mechanism thought to be mediated via αMβ2 integrin (Le Marer and Skacel, 
1999). This principle of “high sialylation, high mobility; low sialylation, high 
adhesiveness” is also seen in other blood cell types and involving other receptors. For 
instance, removal of senescent erythrocytes seems to be dependent of a reduced sialic 
acid content of membranar proteins, namely CD44, leading to enhanced hyaluronan 
binding on the endothelium of tissues presenting high content of this glycan, namely liver 
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or spleen (Kerfoot et al., 2008). Lymphocytes, erythrocytes and platelets are also 
captured by endothelial galectins recognizing low sialic acid content in liver and spleen 
tissues (Schauer, 2009). As previously seen, α2,6-sialylated N-glycan content increases 
during monocyte to moDC differentiation conferring immature moDCs a high sialylation 
content. Once the maturation process begins, we observed a downregulation of ST6Gal-
1 expression and activity.  
It is known that sialidase-treated monocytes present enhanced adhesion to hyaluronic 
acid (Katoh et al., 1995;Katoh et al., 1999) and that sialylation loss, mediated by sialidase 
action or glycosylation shedding, is a requirement for integrin or CD44 mediated-
leukocyte homing (Katoh et al., 1995;Katoh et al., 1999;Weber et al., 2004). Successful 
homing also depends on the firm arrest of leukocytes prior to transmigration via binding 
of adhesion molecules, such as β2 integrins (LFA-1, CD11a,c,d/CD18) to ICAM-1, -2 or 
VCAM-1 (Butcher et al., 1999;Smith, 2008) (Fig. 4.15). Regarding these integrins, it is 
interesting to find that CD18-/- mice present a degree of DC migration impairment towards 
the lung tissue (approximately, 68%) (Schneeberger et al., 2000) similar to the one 
here presented by us.  
A high sialic acid content in adhesion molecules may prevent DCs transmigration 
through lymphatic endothelium, with compromised homing towards the lymph nodes. 
Oppositely, excessive low sialylation levels (such as in the case of ST6Gal-1-/- 
BMDCs) could lead to excessive firm adhesion to extracellular matrix, reducing 
migration towards the lymph nodes. The sialic acid removal would lead to increased 
integrin avidity, significantly slowing down posterior cell detachment after transmigration, 
thus disturbing the normal transmigration under physiological flow conditions. This 
hypothesis needs to be tested by other techniques, such as in vivo microscopy, in order 




The reduced WT BMDC migration observed when these BMDCs were transferred into 
ST6Gal-1-/- KO host may be due to the asialylated nature of the ECM. In addition, the 
endothelial glycocalyx, has been described as being tendentiously anti-adherent mainly 
due to the presence of terminal, negative-charged sialic acid residues in the glycan 
structure (Simionescu and Simionescu, 1986;Silvestro et al., 1994;Constantinescu et al., 
2003). Activation of endothelia was proven to induce a glycocalyx modulation in order to 
become more adherent (Sabri et al., 2000). The leukocyte-endothelium firm arrest, 
mediated by integrins and their ligands seem also to be influenced by sialylation in some 
of the adhesion molecules. For instance, Van Kooyk and collaborators have shown that 
a sialylation increase of ICAM-2 was translated in poor adhesion to all its DC counter-
receptors, namely, LFA-1 and DC-SIGN (Weber et al., 2004). VCAM-1, another relevant 
integrin ligand expressed in endothelial wall, indirectly depends on the presence of 
lysossomal Neu1 for its expression (Yogalingam et al., 2008). It has also been described 
that endothelial cells up-regulate ST6Gal-1 expression and N-glycan α2,6-sialylation of 
the expressed ICAM-1 and VCAM-1 upon inflammatory stimulation, suggesting a 
structural preparation of these adhesion molecules for firm arrest (Hanasaki et al., 1994). 
The effect of both these observations are somewhat equivalent: a fine balance of 
sialidases and sialyltransferases are, therefore, paramount for proper function of 
these adhesion molecules, with the removal of any of these enzymes seeming to 
disturb normal leukocyte homing, either by lack of adhesion or by excessive one. 
Another hypothesis may be the functional impact of sialylation removal on chemokine 
receptor expression, namely on DC homing-associated chemokine receptors such as 
CCR7, CCR5, CXCR4 and CCR8 (Diacovo et al., 2005). Of these, CCR7 is of paramount 
importance for successful DC homing. Two of its corresponding ligands, CCL21 and 
CCL19, are expressed by the lymphatic endothelium, forming the main chemotactical 
gradient responsible for homing DCs towards the lymph nodes (Fig. 4.15). The sialylation 
of CCL21 has a known impact in moDC homing: ST8Sia-4 polisialylation of neuropilin-2 
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was shown to promote chemotactic migration of human moDCs toward the chemokine 
CCL21, but not to CCL19 (Bax et al., 2009;Rey-Gallardo et al., 2010;Rey-Gallardo et al., 
2011;Rollenhagen et al., 2013). Although, this is not a case of N-glycosylation 
(Rollenhagen et al., 2013), little has been explored regarding the glycosylation (and 
sialylation) of chemotactical mediators, leaving an open door for a possible role of 
ST6Gal-1 in lymph node chemotaxis. 
The knockout of ST6Gal-1 stops the glycosidic chain extension at a terminal 
Galβ1,6GlcNAc or N-acetyl-lactosamine (LacNAc) glycan on an N-glycan chain, the 
preferential acceptor substrate for this enzyme. The exposed LacNAc residues thus 
become potential ligand for lectins specifically recognizing this carbohydrate, 
such as galectins. Their recognition and binding are inhibited by α2,6-sialylation of 
recognizable LacNAc residues of N-glycans (Amano et al., 2003;Cummings and Liu, 
2009;Zhuo and Bellis, 2011). It is described that galectins-1, -3, -8 and -9 show selectivity 
for cell surface ligands as well as extracellular matrix (ECM) protein ones (Ozeki et al., 
1995;Levy et al., 2001;Nishi et al., 2003;Fulcher et al., 2006;Cummings and Liu, 
2009;Fulcher et al., 2009). Galectin-1 is mainly present in the ECM and lymphoid 
endothelium (Ahmed et al., 1996;He and Baum, 2004), two crucial substrates in the 
migration process. Triggering DC maturation via inflammatory cytokine stimulus leads to 
an upregulation and enhanced expression of galectin-1 by endothelial cells (Baum et al., 
1995;Dietz et al., 2000;Pereira et al., 2005). Thus, our previously observed enhanced 
maturation of sialic acid-deficient DCs could plausibly stimulate the local production of 
galectin-1 by DCs themselves and by surrounding tissues, with concomitant autocrine 
and paracrine action. In addition, given the highly availability of LacNAc ligands for these 
lectins in ST6Gal-1-/- BMDCs or recipients, it is logical to assume that galectin-1 may 
bind DCs in excess numbers or avidity, sterically hindering integrins or other 
adhesion molecules thus possibly impairing DC homing thus delaying their 
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homing to the lymph nodes, similar to the proposed by Avni and collaborators (Avni et 
al., 1998). In fact, data regarding in vitro migration of monocytes in the presence of 
galectin-1, -2, -3 and -4 has shown that these galectins are, in fact, inhibitors of migration 
(Paclik et al., 2011), with galectin-1 presenting clear anti-adherent properties on already 
galectin-adhered cells (Cooper et al., 1991;Elola et al., 2005). The known anti-
inflammatory effect of galectin-1 (La et al., 2003;He and Baum, 2006;Norling et al., 
2008;Ilarregui et al., 2009) clearly contributes to these anti-adhesion mechanisms by, 
among other effects, downregulating endothelial adhesion molecules. Additional assays 
regarding the galectin involvement in this process are, naturally, needed to enlighten this 
question. 
ST6Gal-1 can also be expressed by the liver as a soluble form with catalytic properties 
as part of the acute phase response in an inflammation context (Lance et al., 
1989;Appenheimer et al., 2003), and, given the presence of glycoforms that could act as 
targets for the action of this enzyme, it would be expected a possible sialylation of these 
N-glycans on sialic acid deficient BMDCs by soluble ST6Gal-1 from the WT hosts (the
K/W assay condition on fig. 4.16) thus reverting to the control conditions, translatable in 
a normalization of the migrating DCs percentage. Nevertheless, if the sialylation 
occurred, it didn’t translate in the restoration of a normal migration patterns. Given that 
a high systemic level of pro-inflammatory cytokines for a sustained period of time is 
needed in order to initiate soluble ST6Gal-1 secretion by the liver, it is likely that threshold 
level wasn’t reached causing the external sialylation to not occur. As such, the 
administration of DCs in the presence of an inflammatory stimulus could be a condition 
that may be explored in future developments in order to clarify this issue. 
Altogether, it is clear that these results provide new insight on the homing processes, 
especially concerning N-glycans’ α2,6-sialylation. As standing on the cell interface with 
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the exterior, it doesn’t come as a surprise the multiplicity of players mediating the 
interaction of this type of sialylation with adhesion molecules, endothelial tissue and 
ECM. In fact, illustrating (and adding) to this problem is the fact that different DC subtypes 
adhere with different affinities to the different ECM components (Kohl et al., 2007). The 
facts here presented raise several questions that will complete the general model (viz. 
adhesion molecules modulation by sialylation, galectin and Siglec involvement) and 
contributing to advances in the use of DCs as immunotherapy. Furthermore, the data 
here presented further stresses that prior to a practical, clinical use of moDCs in DC 
immunotherapy, migration/homing assays should be performed in order for optimization 
of function and ultimate therapy success in what it is, of late, the Achilles’ heel of this 
form of therapy. 
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4.4 Sialylation role in triggering the adaptive response 
 
4.4.1 Altered expression of cytokines in sialidase-treated DCs 
 
The most important function of DCs is their unparalleled capacity for eliciting 
an adaptive immune response. This is accomplished by antigen presentation to T cells 
via MHC and CD1 molecules, together with co-stimulatory and a “cytokinic” signal, the 
latter with important consequences in skewing the T cell polarization. 
Following our endocytosis/phagocytosis and maturation studies (see sections 4.1.3 
and 4.2), we asked whether the immunological function of moDCs following 
phagocytosis would change by removing sialic acids. To investigate the functional 
consequence of the exposure of human moDCs to sialidase, the gene expression of IL-
6, IL-12ɑ, IL-1β, TNF-ɑ and IL-10 cytokines was analyzed by quantitative real-time PCR. 
Although there was some sample-to-sample variation, at the end of endocytosis, all 
sialidase-treated moDC samples had increased levels of IL-6 (around 2 to 50-fold) 
compared with the corresponding mock-treated moDCs (Fig. 4.17). The mRNAs for 
IL-12α, IL-1β and TNF-α were also augmented by the sialidase treatment in the 
majority of the samples, although in one out of five samples this increase was almost 
insignificant (Fig. 4.17). Regarding the IL-10 expression, even though a number of moDC 
samples presented ± twofold increased expression, after endocytosis and sialidase 
treatment, two out of five samples showed a slight IL-10 down-regulation (Fig. 4.17).  
As in previous assays, we also investigated the effect of sialidase itself, by analyzing 
the expression of these cytokines in the moDCs which had not undergone endocytosis. 
Our results showed that the sialidase treatment per se led to a similar increased 
expression of IL-12α and IL-6 (Fig. 4.17). For the IL-10, IL-1β and TNF-α, there was an 
up-regulation slightly higher than the sialidase-treated moDCs which had undergone 
endocytosis (Fig. 4.17). Therefore, removing the sialic acid in moDCs led to an 
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increased expression of IL-6, IL-1β, IL-12α and TNF-α genes. However, the range of 
up-regulation seemed to depend upon the individual donor and to be slightly lessened 
during endocytosis.  
 
Fig. 4.17 - Expression of cytokines is altered in sialidase treated human moDCs. Sialidase treated and mock-treated (i.e., 
inactivated sialidase) moDCs were pulsed with ovalbumin, as described in Materials and Methods. After endocytosis, 
total RNA was used to generate cDNA that was analysed by Real Time PCR. Boxes represent minimum and maximum 
of the mean relative expression, RQ, (± SEM) of IL-6, IL-12α, IL-1β, TNF-α and IL-10 genes. Values above or below 1 
indicate, respectively, overexpression or downregulation of a specific gene after moDCs sialidase treatment, either in cells 
that have internalized ovalbumin (assay at 37ºC) or in the control cells (assay at 4ºC). The values represent the expression 
of a given gene in 5 different sialidase-treated moDCs compared with the expression in the respective mock-treated 
moDCs, at 4°C (dark gray) and 37°C (light gray). 
 
Interestingly, we observed that desialylation and E. coli phagocytosis have an additive 
effect in the expression of cytokines by moDCs (Fig. 4.18A). As expected, the 
expression of IL-10, IL-12, TNF-ɑ and IL-6 increased after phagocytosis (Fig. 4.18A) 
but, by adding desialylation to this condition (phagocytosis + desialylation), moDCs 
expressed cytokines at their highest level (Fig. 4.18A). This remarkable observation 
suggests that removal of cell surface sialic acids, besides improving E. coli 
phagocytosis (as previously described in section 4.2.2), also promotes the 
concomitant moDC cytokine expression. 
The Nuclear translocation Factor kappa B (NF-κB) is a key transcription factor directly 
associated with DC maturation (Ghosh and Hayden, 2008;Patil et al., 2010). Accordingly, 
we wanted to see how the sialidase treatment might influence the activation of NF-
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κB. For that, we followed the sub-cellular distribution of p65 (RelA), a component of the 
NF-κB transcription complex detectable in the cytoplasm of moDCs that translocates to 
the nucleus upon DC maturation (May and Ghosh, 1998). Upon sialidase treatment, NF-
κB nuclear translocation was limited to ~30% of the cells (Fig. 4.18B). Following 
phagocytosis, nuclear translocation of NF-κB was observed in in ~80% of 
untreated moDCs vs. ~89% of sialidase-treated moDCs. The percentage of moDCs 
with NF-κB translocated to the nucleus was comparable with the cytokine levels 
mentioned above, suggesting the involvement of NF-κB transcription factor in the 
increase of cytokine gene expression of desialylated moDCs in the tested conditions. 
Fig. 4.18 - Sialidase treatment improves the immunological function of monocyte-derived dendritic cells (moDCs). moDCs 
were treated with sialidase or left untreated, and then incubated or not (control) with Escherichia coli. (A) The expression 
of IL-10, IL-12, tumor necrosis factor-ɑ (TNF-ɑ) and IL-6 cytokine genes was evaluated by quantitative real-time PCR in 
total RNA extracted moDCs (following sialidase and 1h incubation with E. coli). The mRNA levels of each cytokine are 
expressed as the permillage (‰) of the expression of the endogenous positive control, β-actin. Values represent the 
means of, at least, six independent assays. Statistical significance (* p < 0.05) refers to the difference between untreated 
and sialidase-treated moDCs following E. coli phagocytosis. (B) Representative images of the nuclear factor-κB (NF-κB) 
transcription factor nuclear translocation. Translocation was assessed by labelling moDCs (following sialidase and a 15-
min incubation with E. coli) with anti-NF-B p65 (red) and staining the cell nucleus with DAPI (blue). Cells were then fixed 
and analyzed by combining colors through microscopy. At least 600 cells in each condition were analyzed. 
180 
4.4.2 Increased T cell priming induced by sialidase-treated human DCs 
To further investigate the functional effect of sialidase treatment on human DCs, we 
evaluated the ability of either sialidase-treated or mock-treated moDC to induce 
autologous T cell proliferation. We have performed mixed lymphocyte cultures with 
moDCs loaded with tetanus toxoid (TT) from Clostridium tetani, treated or mock-treated 
with sialidase, and autologous CFSE-labelled T cells. The choice of TT as an endocytic 
stimulus holds up to the fact that donors had previously been immunized against this 
pathogen and, thus, guaranteed a strong and specific T cell response when moDCs 
presented TT-derived antigens. Oppositely, ovalbumin (used throughout the endocytosis 
studies) is a poor immunogen and, therefore, was excluded as a likely candidate for this 
assay. According to our results, the number of proliferating T cells is significantly 
increased when antigen-loaded moDCs lose their surface sialic acid (Fig. 4.19), as 
the mean value for mixed lymphocyte cultures with moDCs loaded with TT, treated or 
mock-treated with sialidase were 51% and 39% of CD3+ cells, respectively (p = 0.003). 
Fig. 4.19 - Increased T cell proliferation in mixed leukocyte reactions with sialidase treated DCs. Human moDCs were 
stimulated with TT (5 g/ml), inactivated with mitomycin-C and treated [T DC(TT)] or mock treated (i.e., inactivated 
sialidase) [MT DC(TT)] with sialidase, as described in Materials and Methods. Control assays with unstimulated moDCs, 
treated (T DC) or mock treated (MT DC) with sialidase, were also performed in parallel. MoDCs were then cultured with 
autologous, CFSE labelled CD14– PBMCs (1:8 ratio), for 7 days. As controls (gray bars), CD14– PBMCs were cultured 
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alone, in the absence or presence of PHA. Cells were stained with APC-labelled anti-CD3 antibodies and analyzed by 
flow cytometry. Graph represents the percentage of proliferating T cells, of five individual experiments ± SEM, estimated 
by the percentage of CFSE diluted, CD3+ cells. Significantly different values were observed for the percentage of T cell 
proliferation induced by T DC(TT) (* p < 0,05), when compared with the one induced by MT DC(TT). 
To assess how desialylation in the context of phagocytosis might influence the ability 
of moDCs to stimulate a T cell response, we measured IFN-γ mRNA levels in co-
cultures of moDCs and autologous T cells (Fig. 4.20C). In all controls, namely, 
unstimulated T cells, moDCs cultured alone (irrespective of them being challenged or 
not with E. coli) and co-cultures of T cells with untreated moDCs that did not experience 
phagocytosis, none or very low expressed IFN-γ mRNA was detected. However, the 
levels of IFN-γ mRNA expressed by T cells stimulated by moDCs experiencing E. coli 
internalization, or pre-treated with sialidase, or both, was dramatically increased. 
Specifically, desialylated moDCs in response to E. coli exposure stimulate T cells 
to produce 70% more IFN-γ mRNA than fully sialylated moDCs. These results 
associate well with the expected downstream events accompanying maturation, 
including the increased cytokine and MHC expression observed in desialylated moDCs 
following phagocytosis. 
Fig. 4.20 - Sialidase treatment improves the immunological function of human moDCs. moDCs were treated with sialidase 
or left untreated, and then incubated or not (control) with Escherichia coli. (A) Interferon-γ (IFN-γ) gene expression was 
evaluated by quantitative real-time PCR in total RNA extracted from a 48 hr co-culture of moDCs, (following sialidase and 
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a 1h incubation with E. coli) and autologous T cells, in a DC:T cell ratio of 1:4. The IFN-γ mRNA levels are expressed as 
the permillage (‰) of the expression of the endogenous positive control, β-actin. Values represent the means of at least 
seven independent assays. Statistical significance (* p < 0.05) refers to the difference between untreated and sialidase-
treated moDCs following E. coli phagocytosis.  
4.4.3 Discussion 
Cytokines produced by DCs are known to be important in regulating the adaptive 
immune response, directing it to either a pro-inflammatory immune response or to an 
anti-inflammatory immune response. According to our experiments investigating the 
functional consequences of sialic acid loss in DCs, sialidase-mediated cleavage of 
sialic acid residues remarkably potentiates DC maturation and cytokine 
production via NF-κB translocation, resulting in an increased ability to activate T 
cells. Notably, sialic acid shortage induces an up-regulation of IL-1α, IL-6 and TNF-α 
pro-inflammatory cytokines (Kopf et al., 1994;Dinarello, 1997) and IL-12, which drives 
Th1 lymphocyte differentiation and the cell-mediated immune response (Gately et al., 
1998). In contrast, the expression of IL-10, which plays a major role inducing tolerance 
in naïve T cells (Enk et al., 1993) and in biasing their development into Th2 cells (Liu et 
al., 1998), remained basically unchanged. Increased expression of signals, such as 
antigen presentation and co-stimulatory molecules and IL-12, driving the development 
of naive precursors into Th1 cells (Trinchieri, 1995) are key determinants for DC 
immunogenicity. To evaluate the cytokine profile, the expression of mRNA, but not of 
protein, was analyzed and it is relevant to note that a discrepancy between mRNA and 
protein expression is possible. Notwithstanding, our strategy is well suited to elucidate 
the Th1- or Th2-skewed DC activation profile. Our results suggest that sialidase creates 
an overall proinflammatory effect on moDCs, increasing their immunogenicity.  
It has been reported that Gram-negative bacteria induce moDCs towards a pro-
inflammatory response, with secretion of IL-12, TNF-α, IL-6 and IL-10 (Karlsson et al., 
2004). In fact, here we observed that desialylation of moDCs followed by E. coli 
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phagocytosis not only significantly improves the expression of IL-12, IL-6 and 
TNF-α, which are potent pro-inflammatory cytokines able to stimulate cytotoxic T cells, 
but also improves the expression of IL-10, which helps the production of B cell’ 
immunoglobulin (Karlsson et al., 2004). This cytokine profile recalls the idea that 
sialidase triggers distinct intracellular signals, with relevant functional impact on the anti-
pathogenic response. We further confirm the high immunological potency of 
sialidase-treated moDCs following phagocytosis by demonstrating the high ability 
of these cells in priming T cells. In agreement with previously produced evidence 
(Stamatos et al., 2004a), the matured phenotype of moDCs, acquired through 
desialylation per se, activate the NF-κB pathway, which explains the increased 
cytokine gene expression. 
The idea of using sialidase treatment to alter DC immunogenicity, namely, to skew T 
cells towards Th1 profile, needs further clarification. Sialidase treatment removes non-
specifically α2,3-linked and α2,6-linked sialic acid from all cell surface sialylated 
constituents. 
Mechanistically, so far, it is known that Gal-3 expression in DCs is pivotal to control 
the magnitude of T cell priming (Breuilh et al., 2007). There is evidence correlating 
reduced sialylated structures with the activation of other leucocytes such as neutrophils 
and T cells (Razi and Varki, 1999;Sadighi Akha et al., 2006). In the case of DCs, there 
is one report describing how murine DCs treated with sialidase induced specific T cell 
responses more efficiently (Boog et al., 1989). Interestingly, some sialyltransferases, like 
ST6Gal-1, are known to be down-regulated after DC maturation (see section 4.1.1) 
(Jenner et al., 2006), suggesting that maturation, on its own, leads to the reduction of 
specific sialylation.  
Further functional studies are still required to further understand the competence and 
immune modulatory capacities of desialylated DCs. Nevertheless, because surface 
sialylation influences the immunogenicity of DCs upon antigen loading, our findings may 
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have a particular relevance to DC-based therapies and they propose that sialylation is 









Dendritic cells (DCs) are important coordinators of the immune system and have a 
potential application as cellular vaccines in order to elicit an immune response against 
pathogens and tumor antigens. 
Our original findings highlight that sialic acids containing-cell surface glycans 
broadly influence many DC functions. The modulation of these cells key functions – 
such as antigen uptake, maturation, migration and T cell stimulation – by sialic acid is 
reassuring towards the use of sialic acid for immunomodulation and suggesting its use 
as therapeutic tool. 
It can be concluded from this work that sialic acid removal enhances DC 
maturation while its capacity for endocytosis is compromised. In case of 
phagocytosis capacity, even after the maturation process is elicited, the sialic acid-
deficient DCs not only maintain their phagocytotic potential but the loss of sialic acid is 
also translated by an enhanced immune potency of DCs, showed by an increase 
of the ability of DCs to stimulate T cells, favoring a Th1 profile. 
In the future, it is important to clarify or to confirm the involved receptors that are 
affected by sialic acid. In endocytosis, Siglecs, TLRs and integrins are important 
candidates, of which sialic acids modification have been reported (Crocker and Varki, 
2001;Feng et al., 2012;Bassaganas et al., 2014). However, it remains to be clarified 
whether sialic acid modifications also affect the function of these receptors in DCs. 
Furthermore, it is necessary to confirm whether the decreased sialylation also enhanced 
phagocytosis properties with other pathogens. The means to improve phagocytosis may 
have potential therapeutic applications in case of phagocytosis deficiency. Similar work 
is needed regarding T cell stimulation, where it is necessary to determine the full 
immunomodulating properties of desialylated DCs. The identification of the involved cell 
surface receptors and/or the mechanisms responsible for the observed higher ability of 
desialylated DCs to activate T cell response is paramount to better fine tune DC:T cell 
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interactions. The MHC class I and II, are important candidates, which were identified 
among the sialylated proteins expressed by moDCs. However, it remains to be clarified 
how sialic acid modifications affect the antigen presentation process. Also to be 
determined is the sialic acid-driven involvement of receptors involved in the formation of 
the immunological cleft (i.e., the contact area between DCs and T cells) such as galectins 
and integrins or even if the classic maturation markers are functionally altered when 
asialylated. These mechanisms may result from the absence of sialylation, at the 
moment of antigen presentation, but may also result from the same mechanisms that 
upregulated pro-inflammatory cytokine expression. 
 
It was already established that sialic acid is a crucial component in DC adhesion. 
Nevertheless, this importance was limited to selectin ligands, and in particular to O-
glycans containing α2,3-bound sialic acid, sLeX in PSGL-1 protein (Silva et al., 2011). 
Here, we added information to that body of evidence by clearly demonstrating that DC 
homing also depends on α2,6-sialylated N-glycans. 
The homing/migration question is the most prominent issue, concerning DC-based 
therapies. In spite of successful patient-derived DCs ability to elicit the desired adaptive 
response, these functions are compromised by the weak ability of DCs to migrate to 
lymph nodes. Knowing that a considerable part of the adhesion processes depends on 
glycosylated proteins, where the glycan moiety is functionally crucial, we expect that a 
better understanding of the α2,6-sialic acid-mediated migration can contribute towards 
the establishment of effective DC-based immunotherapies. 
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Fig. 6.1 – Overall impact of sialic acid on principal DC functions. 
The study of intracellular signaling pathways has suggested that the ERK 1/2 MAPK 
signalling pathway is activated upon sialic acid removal. Activation of this pathway 
may explain the altered functions observed in desialylated DCs, such as altered cytokine 
expression. Besides, this pathway is known to be activated by integrins, as well as other 
receptors. Thus, considering our analysis of sialylated DC receptors, one can suggest 
the β2 integrin family as a likely candidate to be sialylated in human moDCs. β2 
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integrins are important for DC migration and therefore this could explain the observed 
reduction of homing of desialylated DCs. Nevertheless, further investigations are still 
necessary to be performed and other molecular effectors should not be discarded.  
Probing for α2,6-sialylated N-glycan molecules in the ECM and lymphatic tissues can 
provide, similar to the invaluable contribution of mass spectrometry for our results with 
DCs, new leads to clarify the intervenients. Moreover, other secreted molecules, such as 
the previously referred galectins, should also be functionally studied as potential 
modulators of DC homing, in particular its expression by – and functional impact on – 
sialidase-treated or α2,6-sialic acid deficient DCs. 
At this stage, our understanding of the underlying mechanisms linking a certain sialic 
acid structure and function is still limited and the interpretation of the available data 
assumes a considerable difficulty when evoking the diversity of receptors and the 
multiple signaling pathways used by DCs. The original work here presented can be a 
significant contribution in the growing field of glyco-immunology, especially regarding 
DCs, where no clear piece of evidence relating DC function and sialylation was available. 
However, the information regarding the sialic acid content of several receptors known to 
mediate functions such as endocytosis, migration and T cell priming is limited and 
hinders the development of important tools to manipulate DCs and to guarantee its 
applicability from bench to bedside. The question of whether the modulation of DC’s sialic 
acid content can improve DC-base immunotherapy, by dictating the type of response 
that is triggered by DCs, remains open for now. 
In the future, should the open questions be answered, solid ground for applications in 
DC immunotherapy can be attained. Understanding the binomial endocytosis-maturation 
on a perspective of Glycobiology, and studying it in the context of infection, we could 
unleash the mechanism of DC’s antigen presenting capabilities, thus providing powerful, 
tailor-made new therapeutic tools. The full determination of the proteins whose glycans 
are sialylated and understanding the role of such modification would unravel many 
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therapeutic targets, and understanding how these targets may modulate the many 
aspects of DC functionality is relevant for immunomodulation purposes. For instance, 
using in vitro and in vivo models and mapping the glycome in adhesion molecules and 
glycome-mediated signalling potential, could become the turning point to already existing 
forms of therapy that still find its ‘Achilles heel’ in adhesion. Modulating all these 
processes, intracellularly – and not just using exogenous, coarser methods –, by 
performing true Glycoengineering is, thus, the way to which we hope to have contributed 









7.1 Annex I – Results of MALDI TOF/TOF determination of N-α2,6-
sialylated proteins, in human moDCs. 
Entry name Protein name Mw (Da) 
ITAM_HUMAN Integrin alpha-M  127179 
MA2B1_HUMAN Lysosomal alpha-mannosidase  113744 
ECE2_HUMAN Endothelin-converting enzyme  99773 
GELS_HUMAN Gelsolin 85698 
ITB2_HUMAN Integrin beta-2  84782 
PERM_HUMAN Myeloperoxidase 83869 
CD44_HUMAN CD44 antigen  81538 
TRFL_HUMAN Lactotransferrin 78182 
BGAL_HUMAN Beta-galactosidase 76075 
KNG1_HUMAN Kininogen-1 71957 
EST1_HUMAN Liver carboxylesterase 1 62521 
DHE4_HUMAN Glutamate dehydrogenase 2, mitochondrial 61434 
DHE3_HUMAN Glutamate dehydrogenase 1, mitochondrial 61398 
TPP1_HUMAN Tripeptidyl-peptidase 1 61248 
STK39_HUMAN STE20/SPS1-related proline-alanine-rich protein kinase 59474 
OXSR1_HUMAN Serine/threonine-protein kinase OSR1 58022 
KPYM_HUMAN Pyruvate kinase isozymes M1/M2 57937 
ATPB_HUMAN ATP synthase subunit beta, mitochondrial 56560 
VATB2_HUMAN V-type proton ATPase subunit B, brain isoform 56501 
PCP_HUMAN Lysosomal Pro-X carboxypeptidase 55800 
6PGD_HUMAN 6-phosphogluconate dehydrogenase, decarboxylating 53140 
CISY_HUMAN Citrate synthase, mitochondrial 51713 
IDHP_HUMAN Isocitrate dehydrogenase [NADP], mitochondrial 50909 
GDIB_HUMAN Rab GDP dissociation inhibitor beta 50663 
GDIA_HUMAN Rab GDP dissociation inhibitor alpha 50583 
CBPM_HUMAN Carboxypeptidase M 50514 
EFTU_HUMAN Elongation factor Tu, mitochondrial 49542 
CALR_HUMAN Calreticulin 48142 
IF4A3_HUMAN Eukaryotic initiation factor 4A-III 46871 
IDHC_HUMAN Isocitrate dehydrogenase [NADP] cytoplasmic 46656 
IF4A2_HUMAN Eukaryotic initiation factor 4A-II 46402 
IF4A1_HUMAN Eukaryotic initiation factor 4A-I 46154 
PGK2_HUMAN Phosphoglycerate kinase 2 44796 
PGK1_HUMAN Phosphoglycerate kinase 1 44615 
IGHG3_HUMAN Ig gamma-3 chain C region 41287 
1C17_HUMAN HLA class I histocompatibility antigen, Cw-17 alpha chain 41238 
1A25_HUMAN HLA class I histocompatibility antigen, A-25 alpha chain 41218 
1A26_HUMAN HLA class I histocompatibility antigen, A-25 alpha chain 41218 
200 
 
1C02_HUMAN HLA class I histocompatibility antigen, Cw-2 alpha chain 41095 
1A66_HUMAN HLA class I histocompatibility antigen, A-66 alpha chain 41082 
1A34_HUMAN HLA class I histocompatibility antigen, A-34 alpha chain 41055 
1A32_HUMAN HLA class I histocompatibility antigen, A-32 alpha chain 41048 
1A43_HUMAN HLA class I histocompatibility antigen, A-43 alpha chain 41033 
1A31_HUMAN HLA class I histocompatibility antigen, A-31 alpha chain 41004 
1C04_HUMAN HLA class I histocompatibility antigen, Cw-4 alpha chain 40995 
1A69_HUMAN HLA class I histocompatibility antigen, A-69 alpha chain 40977 
1C06_HUMAN HLA class I histocompatibility antigen, Cw-6 alpha chain 40969 
1C01_HUMAN HLA class I histocompatibility antigen, Cw-1 alpha chain 40965 
1A11_HUMAN HLA class I histocompatibility antigen, A-11 alpha chain 40937 
1A36_HUMAN HLA class I histocompatibility antigen, A-36 alpha chain 40934 
1C18_HUMAN HLA class I histocompatibility antigen, Cw-18 alpha chain 40933 
1A02_HUMAN HLA class I histocompatibility antigen, A-2 alpha chain 40922 
1C05_HUMAN HLA class I histocompatibility antigen, Cw-5 alpha chain  40912 
1A68_HUMAN HLA class I histocompatibility antigen, A-68 alpha chain 40909 
1A30_HUMAN HLA class I histocompatibility antigen, A-30 alpha chain 40905 
1A33_HUMAN HLA class I histocompatibility antigen, A-33 alpha chain 40892 
HLAH_HUMAN 
Putative HLA class I histocompatibility antigen,  
alpha chain H 
40892 
1A74_HUMAN HLA class I histocompatibility antigen, A-74 alpha chain 40891 
1C12_HUMAN HLA class I histocompatibility antigen, Cw-12 alpha chain 40886 
1C15_HUMAN HLA class I histocompatibility antigen, Cw-15 alpha chain 40863 
1A29_HUMAN HLA class I histocompatibility antigen, A-29 alpha chain 40863 
1C03_HUMAN HLA class I histocompatibility antigen, Cw-3 alpha chain 40861 
1A01_HUMAN HLA class I histocompatibility antigen, A-1 alpha chain 40846 
1A03_HUMAN HLA class I histocompatibility antigen, A-3 alpha chain 40841 
1C14_HUMAN HLA class I histocompatibility antigen, Cw-14 alpha chain 40838 
1A80_HUMAN HLA class I histocompatibility antigen, A-80 alpha chain 40792 
1C08_HUMAN HLA class I histocompatibility antigen, Cw-8 alpha chain 40773 
1C16_HUMAN HLA class I histocompatibility antigen, Cw-16 alpha chain 40753 
1A23_HUMAN HLA class I histocompatibility antigen, A-23 alpha chain  40733 
1A24_HUMAN HLA class I histocompatibility antigen, A-24 alpha chain 40689 
1C07_HUMAN HLA class I histocompatibility antigen, Cw-7 alpha chain  40649 
1B59_HUMAN HLA class I histocompatibility antigen, B-59 alpha chain  40584 
1B49_HUMAN HLA class I histocompatibility antigen, B-49 alpha chain 40581 
1B47_HUMAN HLA class I histocompatibility antigen, B-47 alpha chain 40571 
1B51_HUMAN HLA class I histocompatibility antigen, B-51 alpha chain 40566 
1B50_HUMAN HLA class I histocompatibility antigen, B-50 alpha chain  40541 
1B41_HUMAN HLA class I histocompatibility antigen, B-41 alpha chain 40539 
1B52_HUMAN HLA class I histocompatibility antigen, B-52 alpha chain 40521 
1B40_HUMAN HLA class I histocompatibility antigen, B-40 alpha chain 40505 
1B55_HUMAN HLA class I histocompatibility antigen, B-55 alpha chain 40496 
1B53_HUMAN HLA class I histocompatibility antigen, B-53 alpha chain 40495 
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1B44_HUMAN HLA class I histocompatibility antigen, B-44 alpha chain 40481 
1B56_HUMAN HLA class I histocompatibility antigen, B-56 alpha chain 40478 
1B78_HUMAN HLA class I histocompatibility antigen, B-78 alpha chain 40478 
1B13_HUMAN HLA class I histocompatibility antigen, B-13 alpha chain 40474 
1B07_HUMAN HLA class I histocompatibility antigen, B-7 alpha chain  40460 
1B37_HUMAN HLA class I histocompatibility antigen, B-37 alpha chain 40456 
1B35_HUMAN HLA class I histocompatibility antigen, B-35 alpha chain 40455 
1B46_HUMAN HLA class I histocompatibility antigen, B-46 alpha chain 40440 
1B73_HUMAN HLA class I histocompatibility antigen, B-73 alpha chain 40435 
1B27_HUMAN HLA class I histocompatibility antigen, B-27 alpha chain 40428 
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1B48_HUMAN HLA class I histocompatibility antigen, B-48 alpha chain 40362 
1B14_HUMAN HLA class I histocompatibility antigen, B-14 alpha chain 40358 
1B67_HUMAN HLA class I histocompatibility antigen, B-67 alpha chain 40342 
1B58_HUMAN HLA class I histocompatibility antigen, B-58 alpha chain 40337 
1B42_HUMAN HLA class I histocompatibility antigen, B-42 alpha chain 40333 
1B08_HUMAN HLA class I histocompatibility antigen, B-8 alpha chain 40331 
1B39_HUMAN HLA class I histocompatibility antigen 40328 
1B18_HUMAN HLA class I histocompatibility antigen, B-18 alpha chain 40275 
1B57_HUMAN HLA class I histocompatibility antigen, B-57 alpha chain 40224 
HLAE_HUMAN HLA class I histocompatibility antigen, alpha chain E  40157 
ALDOA_HUMAN Fructose-bisphosphate aldolase A 39420 
HLAF_HUMAN HLA class I histocompatibility antigen, alpha chain F  39062 
CAPG_HUMAN Macrophage-capping protein 38499 
HLAG_HUMAN HLA class I histocompatibility antigen, alpha chain G 38224 
CD1C_HUMAN T-cell surface glycoprotein CD1c 37654 
LSP1_HUMAN Lymphocyte-specific protein 1 37192 
CD1A_HUMAN T-cell surface glycoprotein CD1a 37077 
CD1B_HUMAN T-cell surface glycoprotein CD1b 36939 
IGHG2_HUMAN Ig gamma-2 chain C region 36901 
IGHG1_HUMAN Ig gamma-1 chain C region 36106 
MPRD_HUMAN Cation-dependent mannose-6-phosphate receptor 30993 
2B1B_HUMAN HLA class II histocompatibility antigen, DRB1-11 beta chain 30160 
2B14_HUMAN HLA class II histocompatibility antigen, DRB1-4 beta chain 30112 
DRB5_HUMAN HLA class II histocompatibility antigen, DR beta 5 chain 30056 
2B1G_HUMAN HLA class II histocompatibility antigen, DRB1-16 beta chain 30030 
2B18_HUMAN HLA class II histocompatibility antigen, DRB1-8 beta chain 30004 
2B1A_HUMAN HLA class II histocompatibility antigen, DRB1-10 beta chain 30002 
DRB3_HUMAN HLA class II histocompatibility antigen, DR beta 3 chain 29962 
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2B11_HUMAN HLA class II histocompatibility antigen, DRB1-1 beta chain 29914 
2B19_HUMAN HLA class II histocompatibility antigen, DRB1-9 beta chain 29826 
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